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ABSTRACT
Survival rates for ovarian cancer haven't meaningfully improved in thirty years. Ovarian cancer is
particularly difficult to treat because it is usually discovered after it has metastasized and it quickly
develops resistance to the few drugs that are initially effective at controlling it. Nanomedicine has
the potential to change the paradigm for ovarian cancer treatment by delivering complex combi-
nations of conventional drugs plus next-generation therapies like small interfering RNA (siRNA)
and immunotherapy. However, nanoparticles must be tailored to the particular drug-delivery chal-
lenges and opportunities posed by ovarian cancer. In this thesis, we designed layer-by-layer
(LbL) nanoparticles (NPs) to target ovarian cancer using library-based approaches. Using this
approach, we identified promising formulations for developing an advanced nanotheranostic that
both treats and detects ovarian cancer. In order to develop LbL NPs for treating ovarian cancer,
we identified and overcame process engineering and fundamental materials challenges, thereby
improving synthesis robustness, throughput and scale. Chapter 2 describes how modern tan-
gential flow filtration significantly improves throughput and scalability in colloidal LbL assembly.
Chapter 3 implements this improved synthetic approach to generate a small library of LbL NPs
that screen for tumor-targeting properties on ovarian cancer cells, both in vitro and in vivo. Our
results demonstrate that ovarian cancer cells have a high affinity to carboxylated LbL NPs, and
we report several tumor-targeting formulations with distinct subcellular trafficking patterns. Chap-
ter 4 explores the role of salt in LbL colloidal assembly, and we develop strategies for robustly
synthesizing LbL-modified liposomes with high loading of siRNA. Chapter 5 advances a promis-
ing formulation identified by our surface chemistry screen, which we developed into an advanced
nanotheranostic device that delivers siRNA and mediates urinary-based tumor detection. Future
work that continues to improve the synthesis of LbL NPs will be essential to generate larger and
more ambitious LbL NP libraries. In turn, these libraries will facilitate systematic studies that fur-
ther tailor the LbL platform to specific diseases and biomedical applications.
Thesis Supervisor: Paula T. Hammond
Title: David H. Koch Professor of Engineering and Department Head of Chemical Engineering
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Chapter 1. Introduction
This chapter is in part adapted from:
Correa, S.; Dreaden, E. C.; Gu, L.; Hammond, P. T., Engineering nanolayered particles for modular drug
delivery. J Control Release 2016, 240, 364-386.
The National Cancer Act of 1971 marked the beginning of a concerted effort by American sci-
entists and engineers to develop a cure for cancer. As we approach fifty years of America's war
on cancer, significant challenges remain to be conquered even as we learn more about this for-
midable foe. We now properly recognize that cancer is a multi-faceted disease with tremendous
heterogeneity that complicates the search for curative treatments1 -2. Focus has shifted away from
a universal cure and instead towards personalized treatment38. This strategy is enabled by pow-
erful - but highly specific - new technologies like monoclonal antibodies9, small molecule inhibi-
tors10 and genetically-modified immune cells" that have begun to be deployed to the front lines.
Nanotechnology is a major advancement in improving the sophistication of the anti-cancer ar-
senal 12. Like a battleship, nanoparticles ferry potent drugs and therapeutics directly to enemy
territory. Therapeutic payloads can be encapsulated within nanoparticle drug delivery vehicles,
or nanocarriers, which in turn help to navigate those payloads through the body. The nanocarrier
protects its payload from premature release into healthy tissue, where the payload can cause
toxic side effects or degrade before reaching the target. By harnessing emerging biological and
chemical engineering approaches, nanocarriers can mediate complex interactions with biological
barriers - avoiding immune recognition clearance, negotiating passage through endothelial barri-
ers, and finally docking and entering cancer cells to unleash their payloads.
The potential for nanoparticle-based medicine, or nanomedicine, in the clinic is significant. Major
advances have already been made in improving the safety of encapsulated drugs13. And recent
efforts showed that nanocarriers that deliver combination chemotherapy can achieve superior
results over free drugs alone14 . The potential of nanomedicine is now being aimed at enduring
challenges such as glioblastoma, pancreatic and ovarian cancer. This thesis focuses on the de-
velopment of nanotherapeutics for the treatment of ovarian cancer, where survival rates haven't
improved in over thirty years.
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The main target, high-grade serous ovarian cancer (HGSOC), accounts for 70% of all epithelial
ovarian cancers and kills roughly two-thirds of women who develop ovarian cancer15 -17. Drug
resistance is the modus operandi of this disease, because while up to 85% of patients respond
favorably to frontline platinum-based therapies like cisplatin, this initial response is only a short
reprieve for the majority of patients. Within a year, roughly 75% of HGSOCs recur with a plat-
inum-resistant phenotype that renders chemotherapy ineffective18-19. If nanomedicines can be
engineered to deliver cisplatin alongside next-generation therapeutics like small interfering RNA
(siRNA) or small molecule inhibitors that specifically disable key biological pathways that medi-
ate resistance, then perhaps meaningful improvements can be made in treating ovarian cancer.
Because siRNA can target genes that are otherwise undruggable, it is a particularly promising
approach towards shutting down mechanisms of resistance. And because of their relative fragil-
ity and inability to cross cellular membranes, siRNA treatments require a nanoparticle delivery
vehicle in order to be used effectively.
This dissertation describes the systematic development of layer-by-layer (LbL) nanoparticles
optimized to specifically target therapeutics and diagnostics to HGSOC. This strategy expands
on traditional nanoparticle formulations of small molecule drugs by utilizing the LbL technique
to add further functionality to liposomal drug carriers, namely siRNA delivery capabilities and
tumor-targeting properties. Chapter 2 documents innovation in the synthesis and preparation of
LbL nanoparticles that provided the necessary throughput, scalability, and yield needed to carry
out the studies described in Chapters 3. This improvement in throughput led to the development
of a small library of LbL nanoparticles that facilitated a systematic study of the role of surface
chemistry in mediating specific interactions with ovarian cancer cells both in vitro and in vivo,
as described in Chapter 3. The identification of tumor-targeting LbL films in Chapter 3 and the
improvements in siRNA encapsulation in Chapter 4 lay the groundwork for Chapter 5, which docu-
ments the development of a theranostic LbL nanoparticle that delivers therapeutic siRNA while
simultaneously providing a urinary biomarker diagnostic utility. Together, this work establishes a
basis for the fabrication and development of a number of therapeutic and diagnostic nanoparticles
for interventions in ovarian cancer.
This work rests squarely on decades of foundational materials, biological, and chemical research
that is discussed at length in the following sections. Section 1.1 briefly reviews the impact and
11
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role of nanomedicine in medical oncology, as well as its current shortcomings and path forward.
Section 1.2 discusses the fundamentals of the layer-by-layer method and its advantages for
nanomedicine. Sections 1.3.1 and 1.3.2 offer a more comprehensive review of specific facets of
LbL technology that motivate Chapter 3. Likewise, Sections 1.3.3 and 1.3.4 are the foundation
for Chapter 5. Section 1.4, which motivates the work described in Chapter 2 and Chapter 4,
discusses potential obstacles for clinical translation and offers logistical insight into commercial-
ization of this technology.
12
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1.1. Nanomedicine and the era of targeted drug delivery
Until recently, medicine has largely consisted of enteral (absorption via the gastrointestinal tract,
e.g., oral or sublingual dosing) and parenteral (not absorbed via the GI tract, e.g., intravenous
or intramuscular injection) administration of free drugs. Clinicians optimize these administration
methods to carefully balance the pharmacokinetics of a drug to achieve a therapeutic concentra-
tion while minimizing toxic side effects, a range termed the therapeutic window. This approach
has yielded successful pharmaceuticals for managing a myriad of chronic health issues ranging
from epilepsy to heart disease. However, within the realm of medical oncology the balancing act
becomes untenable due to the very nature of chemotherapy - drugs used precisely for their toxic-
ity to proliferating cells. In this scenario, clinicians must moderate the dosage of chemotherapy
to limit severe side effects, such as thrombocytopenia, neutropenia, anemia, neurotoxicity, neph-
rotoxicity, cardiotoxicity, and severe digestive side effects. Administering chemotherapeutic regi-
mens at tolerable dosages provides limited anticancer activity and ample opportunity for cancer
to adapt and evolve new resistance mechanisms. Sadly, the cancer adapts while our healthy
tissues cannot, eventually closing the therapeutic window and rendering the drugs useless.
Chemotherapy suffers from an extremely tight therapeutic window because traditional drug ad-
ministration leads to comparable (and sometimes greater) concentrations of the drug in off-target
tissues. This is an inevitable consequence of the delivery of small molecules, which eventually find
their way to the blood compartment and are spread efficiently throughout the body. Fortunately,
this paradigm has been disrupted by the development of nanoscale drug-delivery vehicles that
can help to steer therapeutics towards target tissues, thereby limiting side effects. With nanotech-
nology, therapeutics are encapsulated within delivery vehicles ranging from 10-200 nanometers,
roughly the scale of a virus. Like viruses, these carriers navigate the body in a unique, way - their
large size, relative to their cargo, prevents them from escaping the bloodstream through capillary
beds or through the kidneys. In healthy individuals, nanocarriers are eventually removed from
circulation through the action of the mononuclear phagocytic system (MPS)a, composed largely of
professional phagocytic cells of the liver and the spleen. However, in organisms bearing tumors,
a phenomenon known as the enhanced permeability and retention (EPR) effect leads to leaky
vasculature and sluggish lymphatic drainage within the tumor that allows nanoparticles to perfuse
a Also known as the reticuloendothelial system, or RES. 13
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and reside within neoplastic tissue. With the ability to preferentially accumulate within tumor
tissue, nanotherapeutics have the potential to significantly contribute towards solving the drug
delivery problem inherent to chemotherapy.
In the 1990s, the chemotherapeutic doxorubicin was the first drug to benefit from encapsulation
into a nanocarrier known as Doxil@20. Doxil is a liposomal formulation decorated with the polymer
poly(ethylene glycol) (PEG), which is actively loaded with doxorubicin via a pH gradient method to
achieve high (ca. 10 weight percent) loading. The PEG brush provides a very hydrophilic surface
that helps prevent protein adsorption and clearance of the nanoparticle via the MPS, and thereby
significantly extends the circulation time of the nanoparticle. Doxil@ is just as effective as doxoru-
bicin in treating cancer, but significantly reduces risk of a fatal side effect of doxorubicin - cardio-
myopathy13. Interestingly, Doxil@ presented a new dose-limiting toxicity, a rash of the hands and
feet termed palmar-plantar erythrodysthesias. However, a non-PEGylated liposomal formulation
approved in the European Union avoids this side effect without impacting effectiveness and still
reduces overall cardiotoxicity21 .
Subsequent work aimed to reformulate a variety of chemotherapeutics into nanotherapeutics with
reduced toxicity, and with the hope of improved efficacy. Because nanocarriers have the potential
to preferentially increase drug concentrations in neoplastic tissues, there is the possibility that
much higher doses can be achieved than could be possible with free-drug administration. This
would naturally translate towards greater anti-cancer effects and improved therapeutic efficacy.
Work in the EU developing PEGylated liposomal cisplatin (Lipoplatin@) presented results that
supported this concept of improved accumulation in humans. Notably, Boulikas et al. reported
a 10-200 fold increase in platinum concentration in tumor tissue relative to surrounding healthy
tissue 22 . But in spite of this preferential accumulation within tumors, phase 11 and Ill clinical trials
of Lipoplatin did not find increased efficacy over free cisplatin, though the improvement in safety
b Initially, it was thought that the EPR effect was a universal cancer trait, and would be sufficient for nanocarriers to
accumulate to a great extent in malignant tissues. We now know that the EPR effect is highly heterogenous, varying
between cancer types and even patients bearing the same disease. The EPR effect also appears to be exaggerated
in the most common animal models for cancer, exacerbating the field's reliance on passive targeting. Fortunately, new
research that incorporates active transport through endothelial barriers is ongoing and leading to promising new strate-
14 gies to improve nanoparticle accumulation in tumor tissue.
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was dramatic 23-24. Liposomal cisplatin significantly reduced nephrotoxicity , neuropathy, nausea
and vomiting in clinical trials relative to free cisplatin, both in single-drug regimens and combina-
tion therapy22-23
This overall trend has continued for monotherapy nanoparticles, wherein nanoparticle encapsula-
tion of single agents have generally improved the safety profile of the cargo drug but not the thera-
peutic efficacy2 -30. This may be due in part to an overreliance on passive targeting mechanisms
such as the EPR effect, or it may be a limitation of the drug itself. In the case of the latter, the field
of nanomedicine may be poised to benefit from a renaissance similar to that of chemotherapy
in the 1960s, when the first combined chemotherapy regimens came about. These regimens
combined some of the most potent chemotherapeutic agents at the time (vincristine, amethop-
terin, 6-mercapto-purine, and prednisone in childhood acute leukemia and nitrogen mustard,
vincristine, and methotrexate or procarbazine, and prednisone in adult Hodgkin's Disease). Both
of these treatment plans showed immense benefits, improving the remission rate for Hodgkin's
disease from less than 5% to nearly 80%31. Remarkably, 60% of patients never relapsed over the
course of the 40-year study. The impressive clinical impact of these therapies helped to eliminate
the negative view of chemotherapy treatments and combination therapies in oncology at the time.
Ultimately, these breakthroughs allowed for new research in rational combination treatments us-
ing the extensive catalog of anti-cancer therapies already in the clinic3 2.
Since the 1960s there have been many new combinations successfully tested in the clinic show-
ing superior outcomes compared to standard treatment33-3 7. In a recent example, Conroy et al.
reported the effective use of a combination therapy including oxaliplatin, irinotecan, and fluo-
rouracil-leucovorin (FOLFIRINOX) against single agent gemcitabine for the treatment of meta-
static pancreatic cancer. This regimen presented the first major improvement in this disease in
decades, extending median overall survival to 11.1 months compared to 6.8 months seen with
gemcitabine monotherapy 34-35 . Similarly, Grothey et al. showed that FOLFIROINOX is more effec-
tive than dual combinations of Fluorouracil-leucovorin with a single agent across multiple clinical
trials in colorectal cancer, providing a 3.5 month increase in median overall survival when used
as a first-line treatment 36 . Despite the significant benefits in efficacy, FOLFIRINOX also showed
much higher occurrence of adverse events when compared to standard treatment, limiting its
use to patients with good performance status 34 -35 . The FOLFIRINOX combination treatment is an
15
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excellent example of the possibilities for these combination therapies in the clinic, and how their
implementation can be limited by toxicity.
Nanomedicine provides significant advantages for the delivery of potent combination chemo-
therapy that extends beyond the reduction of toxic side effects. While multi-drug nanoparticles
likely will provide significant safety benefits, they will also provide unparalleled control over the
presentation of the combination therapy to cancer cells. Free-drug combination therapies are
challenged by the disparate pharmacokinetic and pharmacodynamics profiles of the individual
drugs, which often possess wildly different physiochemical properties. Smorenburg et al. illustrate
this point with a comprehensive study of multiple antimetabolite/taxane combination therapies,
showing that drug combinations must be considered in terms of their activity and pharmacokinet-
ics to avoid toxicity and achieve the highest efficacy. This work further showed that whether or not
a treatment is effective can be strongly schedule dependent, with improper scheduling leading to
an antagonistic effect in some cases such as 5-fluorouracil followed by paclitaxe3 .
On the other hand, nanocarriers can be engineered to co-encapsulate precise ratios of different
drugs to provide a dual benefit. First, co-encapsulation simplifies the scheduling issue of adminis-
tering drugs with different pharmacokinetics and biodistributions by forcing the drugs to share the
pharmacokinetics of the carrier39. Second, the ability to encapsulate exact ratios of drugs allow
researchers to guarantee that cancer cells that interact with the nanomedicine will be exposed
to a synergistic drug ratio. This approach has met with great success with the FDA approval of
the liposomal co-encapsulation of cytarabine and daunorubicin (Vyxeos@). Vyxeos demonstrated
highly successful results in a recent phase Ill clinical trial, enhancing overall survival in high-risk
acute myeloid leukemia patients to 9.56 months over the free-drug combination regimen which
had an overall survival of only 5.95 months14. The suspected mechanism behind the success of
Vyxeos is the precise 5:1 molar ratio between cytarabine and daunorubicin, supporting the notion
that nanocarriers can be used to deliver regimens in a tightly controlled stoichiometry to improve
efficacy over free-drug administration. The success of this approach should highlight the value of
revisiting currently approved drugs to build new and improved treatments.
Multi-drug nanocarriers may enhance the efficacy of their cargo, but the benefits of improving
the safety profile of combination therapies cannot be understated. This is because nanoparticle
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formulations of a single FDA-approved drug already possess a somewhat reasonable therapeutic
window, otherwise they wouldn't have any clinical utility. On the other hand, there are numerous
combination therapies (composed of drugs that are individually FDA-approved) that have shown
improved efficacy but unacceptable toxicity. These combination therapies represent lost potential
in the clinic, a regimen that could be effective but lacks a practical therapeutic window. In this
way, previously undeliverable regimens may become viable as a nanoparticle formulation that
adequately manages toxic side effects. The clinical impact of mitigating toxicity using multi-drug
nanocarriers may be significant, because combinations of free chemotherapy drugs often show
synergistic toxicities and require careful management40 -43 . Recent efforts to develop combination
regimens that involve next-generation small molecule inhibitors are also facing major obstacles
with regards to unexpected toxicity44 -4 7. For example, Liu et al. recently showed that combining
small molecule inhibitors of PARP and VEGF led to dramatically increased toxicity, with 70% of
combination therapy patients experiencing grade 3 or higher adverse events compared to just
10% in PARP inhibitor monotherapy 47. However, the combination therapy also increased progres-
sion free survival by 8.7 months over monotherapy. Results such as these suggest that promising
combination therapies are being stymied by toxicity issues. Fortunately, nanoparticles may offer
a means to revisit promising combination therapies that are otherwise too toxic to administer as
free drugs.
Nanomedicine may also hold the key to delivering next-generation therapeutics that have struggled
to be implemented in the clinic - such as gene therapies and immuno-modulating cytokines48 -50 51-
2 . Gene therapy in particular has promising applications for addressing genetic disease, cancer,
and even for the development of vaccines. These approaches offer new avenues for anticancer
therapies, where the ability to silence or restore specific genes could provide ways to prevent or
reverse drug resistance mechanisms in neoplastic tissue. But gene delivery is highly challeng-
ing due to the ubiquitous presence of nucleases in the body and the inability for nucleic acids
to penetrate cell membranes. Nanoparticles provide the means to protect encapsulated nucleic
acids from premature degradation while simultaneously guiding them into target cells to medi-
ate transfection, with numerous encouraging examples reported in the literatures3 -0 . Promisingly,
several nanoparticle formulations for siRNA are now in clinical trias6 1-6 2.
The rise of nanoscale drug carriers is creating new opportunities in medicine, and the current
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achievements in the field of nanomedicine have highlighted both its potential and enduring chal-
lenges. Clear progress has been made in improving the safety profiles of encapsulated drugs,
but significant work remains in order to improve the efficacy of nanoparticle formulations beyond
that of the free-drug. Using nanotechnology to deliver combination therapies may provide major
improvements in efficacy, especially as nanoparticles begin to leverage potent therapeutics such
as siRNA alongside traditional chemotherapeutics. But simultaneous efforts must be made to
systematically engineer nanocarriers that can actively bypass the biological barriers that limit
accumulation in tumors and other tissues of interest. In the following sections, we will explore
how the layer-by-layer platform offers the means to actively explore all of these avenues towards
improved nanomedicines.
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1.2. Modular nanotechnology through layer-by-layer self-assembly
In this Section, we will discuss the application of Layer-by-layer (LbL) nanotechnology towards
anti-cancer drug delivery. We will focus on the numerous distinct and novel formulations that have
been developed to tackle a variety of biomedical challenges to demonstrate the variety of direc-
tions the field has moved towards. But we also aim to show that considerable parameter space
available to LbL nanoparticles has led to a dispersion of efforts in the field, which makes it difficult
to connect the lessons from the different studies. Consequently, it is challenging to develop a
thorough understanding of the importance of different parameters in LbL nanoparticles and how
they impact drug delivery. So while these studies form an important basis for the field, the next
steps to advance LbL technology will benefit greatly from systematic studies that begin to define
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Figure 1.1. The layer-by-layer self-assembly technique can be applied to colloidal templates to build hier-
archically organized nanoparticle composites. Generally mediated via electrostatic interactions, the process
involves the sequential deposition of polyelectrolytes, or other charged macromolecules, onto a charged colloid.
The resulting nanomaterials can contain therapeutics and stimuli-responsive elements that provide biomedical
functionalities ranging from targeted drug delivery to diagnostics.
how important parameters like surface chemistry, polyelectrolyte identity, substrate and synthetic
conditions impact critical nanoparticle functions like tumor targeting, transfection efficiency, bio-
distribution and industrial scalability. This section therefore surveys the state of the field, and sets
up the reader for a better understanding of the systematic studies discussed in later chapters.
LbL self-assembly of nanoparticles is an emerging and powerful method to develop multifunctional
and tissue-responsive nanomedicines for a broad range of diseases. This unique assembly tech-
nique is able to confer a high degree of modularity, versatility, and compositional heterogeneity to
nanoparticles via the sequential deposition of alternately charged polyelectrolytes onto a colloidal
template (Figure 1.1). LbL assembly can provide added functionality by directly incorporating a
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range of functional materials within the multilayers including nucleic acids, synthetic polymers,
polypeptides, polysaccharides, and functional proteins. These materials can be used to generate
heterogeneous, but hierarchically ordered, thin films on an extensive range of both traditional and
novel nanoscale colloidal templates, providing the opportunity to engineer precise nanocompos-
ites capable of performing the numerous tasks required for systemic drug delivery.
The LbL technique, beginning with the fundamental concept of alternating electrostatic assembly,
was first described by ler in 196663-69. Since then, LbL assembly has become a well-established
technique for the solution-phase synthesis of hierarchical and multifunctional nanoscale thera-
peutics70 -72 . LbL nanoparticles can possess a range of desirable properties for drug and gene
delivery due to the versatility granted by the technique. In its most frequently employed form, LbL
assembly is driven by the electrostatic interaction between oppositely charged polyelectrolytes
and a charged substrate. Possible substrates include colloids such as gold, polymer, silica, and
liposomal nanoparticles, amongst others 73-78. Along with the flexibility in the choice of a core sub-
strate, any polyelectrolyte with a multivalent charge can be incorporated into an LbL construct,
including native polysaccharides, nucleic acids, linear polypeptides, and synthetic polymers7 3,-79-81
In addition to electrostatics, LbL assembly can be driven by a multitude of intermolecular interac-
tions that include hydrogen bonding, covalent bonding, and biologically specific interactions 2.
More recently, research into LbL nanomaterials has yielded important developments for a variety
of fields including chemical sensing, catalysis, energy storage, optics, and drug delivery78, 83-87.
There are several advantages that LbL nanoparticles provide in developing sophisticated drug
delivery vehicles. First, deposition of polyelectrolytes of alternating charge generates an ionically
crosslinked thin film that acts as a gate for regulating drug release from the core nanoparticle tem-
plate. This film can also be engineered to possess a characteristic isoelectric point that responds
to pH at the target tissue, such as the acidic tumor microenvironment or the interior of a lysosome,
to accelerate drug release or to mediate other critical functionalities for successful drug delivery.
Extensive discussion of this capability is provided in Section 1.3.2.
Another advantage is that LbL nanoparticles can incorporate diverse materials into the multi-
layered film, including charged polypeptides, polysaccharides, synthetic polymers and nucleic
acids. Because the incorporation of these materials occurs under aqueous conditions, a number
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of sensitive biologic drugs like peptides, siRNA, mRNA and plasmid DNA can be readily incorpo-
rated into the film itself. This capability enables the intermediate LbL bilayers to serve not only
as regulators of drug release, but as drug carriers that can contain high loads of drug - ranging
from 10 to 20% by weight of the LbL film, to potentially as high as 50% or more based on the
assembly process, which enables one to approach near-stoichiometric amounts of material for
charge compensation. These loadings contrast significantly with the more typical 1-3% weight
loadings observed in many solid polymer films and coatings, and thus enables an ultrathin film
coating that is only a few tens of nanometers thick to contain significant amounts of therapeutic
wrapped around the nanoparticle core.
Finally, the outer bilayers of the nanoparticle system play a critical role in the interactions of the
nanoparticle with cells, and ultimately in the routing of nanoparticles within the body. The layer-
by-layer approach involves the adsorption of polyelectrolyte chains onto an oppositely charged
polyion layer, and it is known that depending on the degree of ionization of the polyion adsorbed
and the underlying polymer, one can achieve dense, brush-like layers that can present relatively
high charge density. These dense, brush-like or loopy chain conformations can yield hydrated
and highly charged particle systems that regulate protein opsonization and monocyte uptake
in the bloodstream, providing key "stealth" properties for systemic delivery in the blood stream.
Furthermore, the free functional groups on the polyelectrolyte outer layer provide opportunities
for further chemical functionalization, and the attachment of ligands including small molecules,
peptides, glycans, and antibodies, all of which may be used for molecular targeting of specific
organs and cell types. Alternatively, the use of polycations as the final layer of a nanoparticle may
be used to engage a number of non-specific mechanisms of cell uptake.
The parameter space available to LbL nanoparticles is large, as each element - the core and
individual layers within the LbL film - can be swapped out for another similarly charged material.
As a result, films can be developed with unique properties and then applied to disparate colloidal
templates to study the role of size and shape of nanoparticles while maintaining the same surface
chemistry 88. Alternatively, elements of the film can be varied to study the role each constituent
plays in the nanocomposite. Overall, the platform offers researchers the ability to systematically
alter one component of a nanoparticle formulation to fully optimize it for a particular application.
The ability to change both the core and the inner and outer layers of the multilayered system en-
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ables incorporation of additional functionality such as imaging or light-activated therapies, which
can enable the development of theranostic nanocarriers. The broad range of new therapies that
can be introduced using this nanoparticle technology provides an exciting route to next-generation
tumor targeting cancer therapies.
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1.3. Developing cancer therapies using LbL nanotechnology
The following sections describe the engineering of LbL nanoparticle systems toward specific
cancer therapies, including some of the in vitro research that forms the underpinnings of under-
standing of how these nanoparticle systems interact with cells. It will not attempt to cover the
large body of work involving layer-by-layer hollow microcapsule systems, which are well captured
elsewhere9-96. Instead, it will focus mainly on LbL formulations using nanoparticle cores within the
range of 10 to 200 nm, typically thought to be relevant for targeted nanoparticles in systemic de-
livery applications. The work in LbL nanoparticles thus far will illustrate how this modular system
can be adapted or utilized for systemic drug delivery of nanoparticles for therapeutic, diagnostic,
and theranostic applications, as well as potential additional routes for targeted delivery. Finally,
we investigate the translational potential of this technology, and advances toward bringing these
highly promising nanoparticle systems to the clinic. This background will ultimately form the foun-
dation from which the work described in this thesis emerges.
1.3.1. LbL films as biofunctional nanoparticle surfaces
The modular nature of LbL nanoparticles 97-106 allows their cellular and physiological interactions
to be chemically tuned for a range of diagnostic and therapeutic applications. Following admin-
istration, these biological interactions occur first with the outermost layers of the particles; thus,
rationally engineering the interactions of these terminal LbL layers (or the lack thereof) is of critical
importance. In the following section, we review how the various physiochemical properties of LbL
nanoparticles (e.g. size, charge, compressibility, etc.) dictate their interactions with cells in the
body and, in Section 2.2, how these surface properties can be chemically modulated to direct
outcomes and achieve targeting to specific tissues or cell types in vivo.
Size, surface charge, and structure
A key issue that may be considered in the design of LbL nanoparticle systems is the effect
of an additive process on particle size. In applications where prolonged circulation is desired, for
example in tissue-targeting or drug delivery, LbL nanoparticles should be somewhat larger than
the renal clearance threshold (<6 nm), but smaller than 200-250 nm in hydrodynamic diameter
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(HD) in order to avoid efficient splenic clearance. Particles are able to maintain longer plasma
half-lives and more effectively accumulate in tumors when they are under 100 nm 107, which fits
the NCI definition of a nanoparticle 108. Once extravasated from circulation, optimal sizes can
range widely depending on anatomical site and application, however smaller particles are often
preferred in tumor-targeting applications where desmoplasia (stromal compaction) is often a sig-
nificant barrier to efficient transport. Other important size-dependent barriers, reviewed elsewhere
109-111, include the blood-brain-barrier (ca.15 nm), the nuclear pore complex (ca. 20-40 nm), the
lung periciliary layer (20-40 nm), and transmucosal mesh size (ca. 340 nm).
LbL assembly onto nanoparticles can be achieved using a range of approaches (refer
to Section 1.4) with subsequent sizes largely dictated by the nanoparticle core itself and the
thickness of the surrounding polymer layers. For centrifugal-based LbL colloidal assembly with
polymers lacking significant secondary structure, individual layers typically add 4-5 nm to the total
particle hydrodynamic diamter1 0 1 12-113. Spray-based methods'14 often yield nominally thicker shell
layers, adding 5-8 nm to particle diameter per adsorbed layer. Biopolymers such as hyaluronic
acid (HA), which present complex secondary structure, can often adsorb with layer thicknesses
106, 115-116 many times greater than polyelectrolytes such as poly(L-lysine) (PLK) or dextran sulfate
(DXS) 117-118. Charge density on the initial particle core can further dictate subsequent layer thick-
ness, with denser adsorbed layers required for efficient charge reversal. Thus, depending on the
end-application, LbL systems with multiple layers can be utilized without compromising function.
In applications such as imaging in which much smaller nanoparticles are coated, much can be
achieved with just 2 to 4 layers in an LbL coating, as will be discussed in upcoming sections.
Surface charge is another key design parameter for LbL nanoparticles used in biomedical
applications. As with other nanoscale diagnostics and therapeutics, positively charged constructs
should be avoided due to attraction to the negatively charged luminal surface of blood vessels 119,
the kidney globular basement membrane 120, and epithelial cell membrane surface 121, as well as
their tendency for erythrolysis of sialic acid-rich red blood cell surfaces 122. Electrostatically stabi-
lized (polyanionic) LbL nanoparticles, while capable of relatively long circulation, can also interact
with various extracellular matrix (ECM) components including collagen type 1. Wilson et al. for
example, found that polyanion-terminated gold nanoparticles could reduce the lag (nucleation)
phase of collagen self-assembly and increase the dynamic shear modulus of polymerized colla-
gen gels (Figure 1.2a). In contrast, polycation-terminated LbL nanoparticles had no effect on the
mechanical properties of the collagen. Interestingly, both polyanion- and polycation-terminated
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a. Charge
control
Chemical modification of the final LbL nanoparticle can provide added control over important
parameters including steric stability and introduce new functionalities like affinity-targeting. More
specifically, steric stability - from both synthetic and native biopolymers - can greatly improve
the in vivo stability of nanoparticles. This phenomena is attributed, in part, to decreased serum
protein adsorption (i.e., protein corona formation131-1 32 ) and opsonin binding, the latter of which
can contribute to efficient clearance by the mononuclear phagocyte system. For this reason, LbL
nanoparticles allow the advantageous use of highly negatively charged polyelectrolytes as the
final outer layer of nanoparticles designed for systemic delivery. A dense negative charge yields
significant repulsion between the nanoparticle and many of the negatively charged serum pro-
teins, as well as cells that the particle may encounter, which have net negative outer membranes
due to the charged polysaccharides bound to most mammalian cells. Furthermore, polyanion
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nanoparticles inhibited gel contraction by
cardiac fibroblasts, suggesting that these
LbL nanoparticle architectures influence
cell behavior via multiple mechanisms.
As demonstrated above, the biophysi-
cal interactions of LbL nanoparticles are
highly dependent on their physiochemical
properties and while, size- and charge-
dependent interactions are well-described
in many cases, others such as shape 114,
124-12, surface topography (roughness) 127
and mechanical stiffness 128-130 - recently
explored with micron and submicron LbL
particles - have yet to be fully described
with nanoscale LbL particles. Future re-
search in these areas will no-doubt expand
the diversity of potential biomedical appli-
cations utilizing these novel structures.
Chemically tailoring LbL films
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functional groups that introduce a number of bound water molecules at physiological conditions
may provide additional energetic barriers that enable longer plasma half-lives. Antifouling bio-
polymers such as polyanionic hyaluronic acid 106, 115-116 and alginate 113 for example, allow LbL
nanoparticles to circulate for significantly longer residence times - in some cases as long as 24
to 28 hour elimination half-lives 104, 112 - than their non-sterically shielding anionic counterparts.
The density of the macromolecular brushes generated on the nanoparticle surface is a function
of the underlying charge of the positively charged layer as well as the charge density and size of
the polyanion adsorbed as the final layer - both of these parameters are readily adapted with pH,
ionic strength and choice of polyion in generating the LbL film. The resulting outer layer may in
some cases present a much denser and therefore more effective brush layer than those gener-
ated using other means such as covalent chain grafting to particle surfaces. Because a number
of native extracellular matrix molecules may be used in this process, it may also be possible to
optimize these systems to achieve lowered recognition by the immune system or some form of
self-recognition that avoids monocyte uptake.
Along with the use of intrinsically charged polyions, it is possible to incorporate neutral stabilizing
polymer layers. Due to their intrinsic ability to block adsorption 133, such steric stabilizers are typi-
cally appended to already-adsorbed polymer layers in a "grafting-to" type fashion. As with other
biomedical colloids, PEG is the most common steric polymer employed with LbL nanoparticles,
however poly(2-ethyl-2-oxazoline) (PEO), poly(vinyl alcohol) (PVA), and other water-borne poly-
mers provide opportunities for further research. In its simplest form, a neutral steric stabilizing
layer can be achieved using a polyelectrolyte-containing block copolymer such as poly(ethylene
glycol-b-L-aspartate)134, many of which are commercially available.
Kim and coworkers 134 demonstrate the use of a PEG block copolymer to sterically stabilize LbL-
functionalized liposomes, here, with the block copolymer incorporated as both the terminal and
intermediate polyanion layers. Doxorubicin-containing cationic liposomes were layered with 5.5
bilayers of poly(ethylene glycol-b-L-aspartate) and PLK, resulting in a neutral (ca.-5 mV) PEG-
stabilized nanoparticle. In this block copolymer multilayer format, layer thicknesses were relatively
large, adding ca. 15 nm to particle diameter per adsorbed layer (Figure 1.2b). Interestingly, drug
release kinetics were significantly slowed for nanoparticles of identical terminal composition but
increased multilayer numbers; circulation half-lives in mice, however, were identical for composi-
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tionally related LbL nanoparticles (ca. 5.8 h, first order).
Click-type and carbodiimide coupling chemistries are also highly amenable to the installation of
steric polymers onto LbL nanoparticle surfaces. Polyelectrolytes containing biorthogonal azide
and alkyne moieties, or transcyclooctene (TCO) and tetrazine groups, are also widely available or
obtained in high yield and allow for the facile conjugation of end-functional linear polymers such
as PEG-azide or PEG-tetrazine, respectively. Carbodiimide coupling is an attractive option for
LbL nanoparticles terminated with weak polyelectrolytes such as polyacids and polyamines and
allows for the addition of a wide variety of linear and/or branched stabilizers. For example, Shen
and coworkers 135 used carbodiimide coupling to covalently conjugate PEG to the surfaces of
PLGA submicron particles coated with PEI/PAA multilayers. The authors demonstrated significant
reduction in the magnitude of anionic surface charge (ca. -37 to -12 mV), interestingly, in the
absence of interparticle crosslinking as indicated by dynamic light scattering (DLS) measure-
ments. Lastly, although less-explored with nanoscale LbL particles, surface stabilization can also
be achieved via living polymerization (e.g. atom-transfer radical-polymerization, ATRP 130) off of
particles bearing surface-bound initiator groups, allowing for radially heterogenous multilayered
coating with antifouling terminal groups such as hyaluronic acid 106,116
Another powerful aspect of LbL nanoparticle modularity is the ability to further decorate par-
ticle surfaces with affinity ligands that can bind or associate with a given cell type, organ, or
tissue of interest. With LbL nanoparticles, this targeting can be directed towards surface proteins
on diseased or peripheral cells and often initiates ATP-dependent cell uptake through various
mechanisms including phagocytosis, caveolin- or clathrin-mediated endocytosis, micropinocyto-
sis, and other pathways. Common LbL nanoparticle affinity ligands include small molecules 136-137
peptides 136, glycopolymers 13, aptamers 139-140, and antibodies 1. For modifications with poorly
water soluble targeting ligands such as folic acid, carboxamide coupling 142 is an attractive op-
tion for the amidation of polyacids that can proceed in both aqueous and methanol solvents. For
example, we previously used carboxamide coupling to install hydroxyapatite-binding bisphospho-
nate alendronate ligands onto PAA which was used to terminally layer doxorubicin-containing LbL
nanoparticles 143. 143B osteosarcoma xenograft-bearing mice intravenously treated with the par-
ticles exhibited progressive disease from the untargeted constructs, but significant disease sta-
bilization from the targeted nanoparticles, reflecting the altered biodistribution profiles of actively
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targeted LbL nanoparticles. Lin and coworkers 136 have also explored the use of affinity targeting
to develop an LbL nanoparticle-based magnetic resonance imaging (MRI) contrast agent based
on Gd 3 -conjugated silica nanoparticles. By electrostatically adsorbing a cationic, integrin-binding
K7RDG peptide onto the PSS-terminal LbL nanoparticles, in vitro targeting and T1-weighted MRI
contrast from HT-29 colon cancer cells was markedly improved. Boyer et al. 138 employed a re-
lated approach whereby a copolymer synthesized by reversible addition-fragmentation (RAFT)
polymerization was side chain modified with glucose and galactose, the latter of which can spe-
cifically bind with hepatic galactose/N-acetylgalactosamine receptors. The particles underwent
crosslinking in the presence of the glucose-binding lectin, concavalin A, and were competitively
displaced by free sugar, demonstrating target-specific binding by the LbL nanoparticles.
Stimuli-responsive LbL films
The outer layers can serve as outstanding passive targeting agents; however, LbL systems can
be tuned to be responsive to microenvironments that are medically relevant. In prior work 104,
il, we demonstrated a biotin-avidin conjugation approach to prepare pH-responsive multilay-
ered nanoparticles via a biotinylated cationic terminal layer. Using neutravidin as an intermediate
linker, iminobiotin-labeled PEG was installed on the outer particle surface, shielding an underlying
cell-penetrating polycation surface that was revealed at hypoxic tumor pH conditions 106,116. While
particles displaying both iminobiotin-PEG and pH-nonresponsive biotin-PEG freely circulated
for > 24 h, only pH-sheddable LbL nanoparticles efficiently targeted breast tumor xenografts for
extended periods in vivo, colocalizing with hypoxia inducible factor 1 a (HIFla) and decreasing
relative hepatic accumulation.
On the other hand, it is also possible to take advantage of the physicochemical nature of an LbL
film to devise a bilayer of two weak polyelectrolytes (e.g. polyacid and polybase) that exhibit a
shift in charge at a given pH. A pH responsive outer layer LbL film of (PLK/HA) is a strongly nega-
tively charged particle at bloodstream pH that swells, increases in surface roughness, and loses
cell-repulsive anionic surface charge at hypoxic tumor pH106 116, thus causing significant uptake
in hypoxic tumor regions; the same HA terminated film also targets the CD44 receptor, which is
overexpressed highly in many aggressive cancer types including ovarian and lung cancer, thus
imparting multiple targeting mechanisms within a singular bilayer thin film.
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Another means of enabling cell-responsive behavior is to utilize other aspects of the cellular mi-
croenvironment, such as the more highly reducing cytoplasmic environment. Yang et al. 144 have
developed methods for the efficient cellular delivery of LbL nanoparticles by making use of a pH
responsive, 'bioreducible' polymer layer consisting of a disulfide crosslinked low molecular weight
BPEl obtained by reaction with dithiobis(succinimidyl propionate) (DTSSP, Lomat's reagent). The
thiol-modified polyamine was used to condense siRNA and was subsequently shielded using a
polycation-b-PEG copolymer containing poly(2-(2-aminoethyoxy)ethoxy) phosphazene) (PAEP).
At pH 6.8, cell internalization and in vitro cell killing was augmented ca. 4- and 2.8-fold, respec-
tively, compared with physiologic pH (7.4). In vivo, the pH-responsive LbL nanoparticles targeted
subcutaneous tumor xenografts >2-fold more efficiently than non-pH responsive constructs, with
tumor-specific mRNA silencing improved ca. 2.4-fold.
1.3.2. LbL films as regulators of drug release kinetics
While the outer layers of LbL-modified drug carriers can bestow favorable in vivo stability and ac-
tive targeting properties, the rest of the film is capable of additional functionalities useful for drug
delivery. In this section we address the ability to regulate the release of therapeutics encapsulated
in the core template through the generation of an LbL membrane around the core, which acts as a
nanoscale drug reservoir. This useful feature is highly tunable through the rational selection of LbL
film constituents, which can work in concert to provide a desirable release profile for numerous
applications ranging from cancer therapy to oral insulin administration. This section is organized
by the identity of the core template for various LbL formulations, but it should be noted that any of
the LbL films discussed below could be formed on any suitable template as needed.
LbL films as regulators of drug release
One of the great strengths of the LbL platform is its broad applicability towards modifying conven-
tional nanoparticles that have already been extensively characterized. This includes important
drug-carriers such as poly(lactide-co-glycolide) (PLGA) 135 145-14, mesoporous silica 136,147, and
liposomal 76,148 colloidal systems. Each of these vectors has attractive properties for drug delivery,
but each also has weaknesses that have hindered their clinical translation. This section reviews
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how recent work in the LbL community is addressing some of these weaknesses through further
functionalizing these important drug-carriers with multifunctional LbL films.
LbL modification of PLGA cores
PLGA particles are well studied materials that can encapsulate a variety of cargo, including small
molecule drugs, proteins and nucleic acids 145, commonly through emulsification techniques 149 .
These templates benefit from LbL modification in several ways, the first being increased specific
targeting and avoidance of MPS clearance, as discussed in Section 1.3.1. Another major benefit,
and what will be focused on in this section, is greater control over drug release by minimizing
the initial burst-release of cargo, as well as by extending the duration of release. For example,
Venkatraman and coworkers150 characterized the effects of LbL-modification on submicrometer
sized PLGA particles, and found that LbL coatings of either PAH/PSS or PLK/DXS were able
to suppress burst release of FITC-dextran (4 kDa) and extend its release over 4 days under
physiological conditions in vitro (Figure 1.3a-b). While both PAH/PSS and PLK/DXS films slowed
release of the model drug in these systems, only PAH/PSS films benefited from increased layer
depositions. This is likely due to differences in the binding affinity that holds these films together,
and hydrophobicity of the polymer backbones involved, leading to a more swollen and permeable
film in the case of PLK/DXS. Once crosslinks were introduced however, both films efficiently
reduced burst release (ca. 3 fold) and extended the duration of release.
Morton at el.113 described the in vitro and in vivo regulation of small molecule drug release from
several LbL-modified PLGA nanoparticles. This work demonstrated that three different LbL formu-
lations (PLGA-(PLK/DXS) 3, PLGA-([PLK/DXS] 2/PLK/Alginate), and PLGA-([PLK/DXS] 2/PLK/HA))
could reduce initial burst-release from 35% (uncoated PLGA) to less than 20% of the entrapped
doxorubicin under physiological conditions in vitro, and extended drug release over the course of
5 days (Figure 1.3c). This work also demonstrated that alginate and HA-terminated formulations
could sustain the delivery of the model drug cardiogreen (indocyanine green dye) in vivo for up to
24 hours, in stark contrast to bare PLGA cores that release their full cargo within 8 hours (Figure
1.3d).
LbL modification of mesoporous silica cores
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Figure 1.3. LbL films regulate the release of drugs encapsulated in the core template, allowing for extended
release and reduced burst-release both in vitro and in vivo. a) Submicrometer PLGA particles can be coated
with poly(allylamine hydrochloride) (PAH) and poly(styrene sulfonate) (PSS) to slow the release of the model drug
FITC-dextran (4 kDa) from the core. Additional layers further slow release, and crosslinking of the amines in the film
(via glutaraldehyde) provides the slowest release profile. b) Similarly, coating these particles with poly(L-lysine)
(PLK) and dextran sulfate (DXS) slowed release, but differ from PAH/PSS films in that additional layers do not slow
release, highlighting the differences in permeability between different LbL films. c) PLGA nanoparticles also ben-
efit from LbL modification, and can be coated with PLK, DXS, alginate (Alg), and hyaluronic acid (HA) to signifi-
cantly slow the release of doxorubicin from the PLGA core. d) These observations carry over to in vivo experiments,
where PLGA nanoparticles coated with biocompatible LbL films prolong the release of a model drug, cardiogreen
(CG), over 24 hours. Reprinted with permission from (a-b) [150], (c-d) [113]. Copyright (a-b) 2012 WILEY-VCH Verlag
GmbH & Co., (c-d) 2013 Elsevier.
Another excellent template for LbL assembly is colloidal mesoporous silica (MS), a highly char-
acterized material system with great potential for multifunctionality 151*. Sub-100 nm MS nanopar-
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ticles can be prepared at large scales 152, and with extensive control over their porosity 13, which
subsequently dictates their drug loading and release behaviors. The versatility of MS drug-carriers
is highlighted by their capacity to carry either hydrophilic 154 or hydrophobic cargo 155, depending
on the loading technique employed. MS particles are naturally amenable to LbL-modification due
to their innate negative charge, but can be chemically modified to yield cationic particles as well
156. Due to their stability in organic solvents, these materials can also be functionalized through
hydrogen-bonding driven LbL assembly 157. While MS drug-carriers provide several distinct ad-
vantages, their clinical translatability has been hindered by toxicity concerns 158-159. However, in
LbL-modified MS systems, it appears that problems with toxicity can be resolved either by core-
dissolution to remove silica from the final carrier 156,160 or by introduction of biocompatible surfaces
147
Several stimuli-responsive LbL formulations have been prepared from silica templates, which
highlight the capacity for LbL films to be more than passive diffusion barriers. By exploiting the
well-characterized pH-dependent swelling of LbL films 161, Chen and coworkers 16 2 were able to
design LbL drug carriers templated from MS nanotubes that exhibited pH-specific drug release
in vitro depending on the choice of film constituents. This approach takes advantage of the pH-
dependency of LbL assembly, where it is generally found that the ideal pH is that which maximizes
the charges of the precursor polyelectrolytes. By titrating away from this ideal pH value, the
electrostatic forces that hold the LbL film together weaken and allow for swelling, becoming more
permeable to the diffusion of cargo. Therefore, by carefully choosing the polyelectrolytes for a
given application, an LbL nanoparticle can selectively respond to pH of the target tissue to initiate
drug release. This effect is demonstrated nicely by Shu et al.160, who designed smart LbL carriers
suitable for oral delivery of an encapsulated protein. In this system, BSA-loaded MS nanoparticles
were coated with low molecular weight (6 kDa) water-soluble chitosan (WSC) and DXS. By us-
ing WSC, which is only cationic under acidic conditions, the nanoparticles were highly stable
in conditions similar to the stomach environment (pH 1.4, 370C, and agitation) and prevented
release (<10%) of the encapsulated protein (Figure 1.4a). However, at the neutral pH found in
the intestinal lumen, WSC loses its cationic charge and the capsules readily release their cargo.
This platform was later modified by replacing WSC with cysteine-conjugated chitosan (CS-SH) in
order to generate disulfide crosslinks within the LbL film 156, which prevented drug release at neu-
tral pH until exposure to intracellular levels of glutathione (Figure 1.4b-c). By generating CS-SH
32
Introduction
with different degrees of cysteine conjugation, the authors were able to generate a crosslinking
gradient within the film, which they demonstrate is more effective in preventing burst-release after
GSH addition. Importantly, this approach highlights the broad range of release profiles achievable
with the use of an LbL system, and the ability to introduce orthogonal responsive elements in a
hierarchical manner to specifically control not only when release occurs, but also the kinetics once
release is initiated.
The pH-responsive functionality of LbL films is not limited to electrostatically stabilized formula-
tions, as was recently demonstrated by Li et al. 163 with a biomolecular LbL particle templated from
MS nanoparticles. In this system, MS nanoparticles were electrostatically coated with a layer of
PEI and concanavalin A (Con-A). Con-A is a carbohydrate-binding protein that can be adsorbed
onto surfaces via hydrophobic attraction, and allows for subsequent bio-templated LbL assembly
with the neutral polysaccharide glycogen or galactomannan1 6. Con-A loses its carbohydrate-
binding ability at acidic pH, causing the LbL film to rapidly disassemble and release doxorubicin
encapsulated in the core. These types of films are also sensitive to degradation via competitive
binding 161, wherein Con-A dissociates from glycogen in favor of a carbohydrate to which it has
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Figure 1.4. Careful selection of LbL film constituents generates smart, responsive films that regulate the
release of drugs from the core template. Such films can significantly reduce payload leakage outside of the tar-
geted environment through several means. a) LbL films can be triggered to degrade and release drugs by changes
in pH, and in this case a film constructed from water-soluble chitosan (WSC) and dextran sulfate (DS) exhibits
stability at acidic pH (WSC protonated) but begins to disassemble at neutral pH (WSC deprotonated). [Si = silica
nanoparticle, BSA = bovine serum albumin] b) Introduction of bio-responsive elements adds further control to
such films, and in this case silica nanoparticles were coated with cysteine-conjugated chitosan (CS-SH) in order to
form disulfide crosslinks throughout the film. These crosslinks prevent release of cargo until exposure to intracel-
lular, disulfide-breaking enzymes (glutathione, GSH). Additional control over release is introduced by spatially
controlling crosslinking density through the film by using CS-SH with differing degrees of cysteine conjugation.
c) Disulfide-crosslinked LbL films are stable at extracellular GSH concentration but slowly release cargo over 14
hours at intracellular concentrations of GSH. Reprinted with permission from (a) [160], (b-c) [156]. Copyright (a-c)
2010 Elsevier.
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greater binding affinity towards, such as glucose.
LbL modification of liposomal cores
Highly biocompatible liposomal drug carriers are among the most promising templates for LbL
modification. Liposomes are of particular interest due to their versatility and use in some of the
most well-known and readily produced nanomaterials for therapeutic applications, such as Doxil,
Onivyde and Vyxeos. Like other traditional nanoparticle cores, liposomal drug carriers can be
modified via LbL assembly to improve stability and drug release characteristics while simultane-
ously providing new stimuli-responsive behavior and targeted biological interactions. Work by
Fukui and Fujimoto148 demonstrated that chitosan and dextran sulfate-coated liposomes exhibited
increased stability against surfactants and improved drug-retention. This work tested the retention
of several model drugs (1-hydroxy pyrene-3,6,8-trisulfonic acid (HPTS), alendronate, and glu-
cose) and observed prolonged in vitro cargo-retention over 60, 85, and 144 hours, respectively.
Interestingly, if the films were built using DNA instead of DXS, then heating the liposomes to 600C
could trigger release, likely via denaturation of the adsorbed DNA (Figure 1.5a). Along these
lines, Kim and colleagues 134 described an LbL-modified liposome loaded with doxorubicin, which
exhibits a pH dependent release profile under physiological conditions in vitro (Figure 1.5b). This
formulation leveraged the pH-sensitivity of LbL films composed of weak polyelectrolytes, in this
case PLK and the block co-polymer poly(ethylene glycol-b-L-aspartate). At slightly acidic pH,
such as in the tumor microenvironment, protonation of aspartic acid's carboxylic acid side chain
initiates film breakdown down and release of cargo. However, at pH 7.4 the films are stable, and
improve drug retention significantly relative to bare liposomes after deposition of only 3 layers.
Liposomal cores present a special advantage due to their ability to easily co-encapsulate drugs,
including the simultaneous loading of hydrophilic and hydrophobic payloads 16.-166. Combining this
capability with responsive LbL films can drastically improve the efficacy of liposomal combination
therapies, as was demonstrated by Dreaden et al.116 with a nanoparticle formulation consisting
of dual-inhibitor loaded liposomes functionalized with a bilayer of PLK and HA. With the aid of
the pH-responsive and CD44 receptor-targeted functionality of the LbL film, this nanoparticle
successfully and safely delivered a synergistic inhibitor pair in a murine model of triple-negative
breast cancer, leading to disease stabilization and a 4-fold decrease in tumor size compared to
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controls (Figure 1.5d). Notably, use of a non-responsive and non-targeting drug-loaded liposome
(coated with PLK/DXS) exhibited less therapeutic efficacy, whereas drug-free vehicles of the PLK/
HA formulation exhibited a small but significant (ca. 1.6 fold) reduction in tumor size. This intrigu-
ing result may indicate an antiproliferative role of the LbL film itself, though further work is required
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Figure 1.5. LbL films introduce multiple avenues of control over the delivery and release of drugs from clini-
cally-approved drug carriers like liposomes. a) Temperature-responsive film constituents can allow a thermally-
triggered release profile, as is achieved in this nanoparticle formulation where 1 -hydroxy pyrene-3,6,8-trisulfonic
acid (HPTS)-loaded liposomes were coated with chitosan (CHI) and DNA. Heating the particles to the denaturation
point of DNA disrupts the film and allows slow leakage of the cargo over 60 hours. b) Use of weak polyelectrolytes
such as poly(L-aspartic acid)-b-polyethylene glycol (PLD-b-PEG) and poly(L-lysine) to generate LbL films produces
nanoparticles that begin to disassemble at acidic pH, such as in the hypoxic tumor microenvironment. [LNP =
liposomes]. c) Films composed of PLK and hyaluronic acid (HA) combine the pH sensitivity of weak polyelectrolyte-
based LbL films with receptor-ligand targeting via HA-CD44 binding. This bimodal targeting allows for favorable
accumulation of liposomes into tumors in vivo, and d) maximizes the effect of the drug cargo to stabilize disease
progression in a model of triple-negative breast cancer. Reprinted with permission from (a) [148], (b) [134], (c-d)
[116]. Copyright (a) 2009 American Chemical Society, (b) 2014 Elsevier, (c-d) 2015 American Association of Cancer
Research.
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to fully characterize the possible mechanisms at play. Importantly, this approach overcame the
profound hepatotoxicity associated with free administration of this combination therapy.
Overall, responsive LbL films highlight the versatile and tunable multifunctionality offered by LbL
nanomedicines. Importantly, the functionality provided by the LbL film is independent of the iden-
tity of the core template, introducing the possibility to develop modular therapies that can be
adapted to different templates as needed. By careful selection of the individual components of
the film, as well as clever use of chemical modifications after film assembly, researchers can
develop highly specialized materials to control the release of therapeutics from a diverse range of
nanoparticle drug-carriers.
1.3.3. LbL films as a drug carrier and vector for combination therapy
A key advantage to the LbL platform is the capacity to incorporate therapeutics directly into the
LbL film itself. This can be achieved through a variety of means, including direct adsorption of
charged biopolymers including proteins 167, peptides 168, and nucleic acids 169, as well as through
the incorporation of synthetic drug-conjugated or drug-loaded polymers 170. Because the drug
is adsorbed into the nanocomposite, and deposition steps can be repeated, very high weight
percentage loading is possible 171-174. This section discusses how researchers have leveraged
this capability to successfully deliver therapies without a drug-loadable template. Additionally, this
section covers formulations that combine drug-loaded templates with therapeutic-containing films
to create sophisticated combination therapy vectors.
Gene delivery from responsive LbL films
One of the most promising applications of therapeutic LbL films is gene therapy. Incorporation
of DNA into planar LbL films was first described in 1993 by Lvov and colleagues175, and sub-
sequent work in the early 2000s extended this to colloidal templates176179. Soon after, efforts
with DNA-loaded LbL microcapsules demonstrated the ability to successfully transfect cells in
vitro1 80 . By 2008, Fuller et al. demonstrated the in vitro transfection capability of silica "C dot"
nanoparticles coated with PEI and DNA. Shortly thereafter, Breunig and colleagues181 fabricated
LbL particles composed of gold nanoparticles coated with PEI/siRNA/PEI. This formulation dem-
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onstrated significantly reduced polymer-mediated cytotoxicity compared to free PEI and mediated
gene-specific knockdown in CHO-K1 cells in vitro. Notably, this platform was capable of effective
siRNA delivery even in the presence of serum. Follow-up work by this group 182 demonstrated that
the same platform could deliver plasmid DNA to cells in vitro, though expression of exogenous
genes was not reported. Subsequent research focused on developing robust gene delivery vec-
tors capable of both in vitro and in vivo gene delivery by optimizing the parameters that influence
nucleic acid stabilization in vivo", efficient uptake into cells11 2, desirable sub-cellular trafficking
via endosomal escape1 84 , and efficient cytosolic release of the nucleic acid cargo185. In particular,
clever selection of LbL film constituents, particularly cationic elements, has shown promise in
mediating endosomal escape and cytosolic cargo release.
Previous work found that the choice of the cationic polymer can strongly influence transfection
efficiency with polyplexes in vitro186 . Green and colleagues 187 recently demonstrated that this prin-
ciple holds for LbL nanoparticles as well by demonstrating how different combinations of PEI and
custom biodegradable polycations (SS37 and 447) impacted nucleic acid loading and transfec-
tion efficiency. Notably, non-degradable PEI exhibited significantly higher loading (ca. 5-fold) of
nucleic acid into the LbL film relative to the biodegradable polycations (Figure 1.6a). The authors
also found that the degree of terminal layer saturation played an important role in final in vitro
transfection efficiency, implying the need to explore this parameter more closely (Figure 1.6b).
Although not all permutations of the LbL film were fully explored, this study touches on critical pa-
rameters for the design of LbL films for gene therapy, namely the balancing between nucleic acid
loading efficiency, polycation toxicity, and endosomal escape capability. Important future work
should systematically compare the transfection efficiency, toxicity, and sub-cellular localization
of nanoparticles composed with different polycations, including more detailed trafficking studies
that can examine the mechanism of endosomal escape and release in these unique systems in
comparison to more typical synthetic gene vectors.
Responsive LbL films show promise for mediating endosomal escape and subsequent release of
nucleic acid cargo. In particular, implementation of charge-reversing polymers for LbL assembly
appears to be an effective strategy for triggering disassembly of the nanoparticle within an acidify-
ing endosome. Guo et al. 185 demonstrated this approach by using poly(allylamine hydrochloride)-
citraconic anhydride (PAH-Cit), nucleic acids, and PEI in an LbL assembly templated from gold
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nanoparticles. PAH-Cit exhibits a negative charge at neutral pH, but at pH 5 becomes cationic and
rapidly destabilizes the LbL film through electrostatic repulsion (Figure 1.6c). Nanoparticles con-
sisting of gold core-(PEI/PAH-Cit/PEI/Nucleic acid) exhibited improved in vitro gene transfection
and silencing, approximately 3 and 2-fold, respectively, compared to free PEI and lipofectamine
(Figure 1.6d-e). Subsequent work by this group extended this platform towards therapeutic gene
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Figure 1.6. Gene delivery through LbL films presents the opportunity to build sophisticated nanostruc-
tures to optimize transfection efficiency. Multiple variables are involved in the development of successful LbL
gene carriers, and among the most important to optimize is the cationic elements of the LbL film. a) Different
nucleic acid loading efficiencies have been observed between nondegradable polyethylenimine (PEI) and bio-
degradable poly(beta-amino-esters) like SS37 and 447. Chart generated from raw data from [146]. b) Additional
consideration should be given to the degree of functionalization of outer cationic layers, and in this case improved
biocompatibility and transfection occurred if the surface was less saturated. [LD = low dose, HD = high dose, Lipo
= lipofectamine; the fold excess of polycation to core during assembly is given by the number following LD or HD].
c) Responsive polymers, such as charge-reversing poly(allylamine hydrochloride)-citraconic anhydride (PAH-Cit),
facilitate the release of nucleic acid cargo at lysosomal pH where they become cationic and trigger film disas-
sembly. In contrast, LbL nanoparticles built from nonresponsive poly(styrene sulfonate) (PSS) films retained their
cargo. d) Charge-reversing elements within the film improved gene delivery significantly, and e) similarly aided
in gene silencing via siRNA delivery. Reprinted with permission from (b) [187] and (c-e) [185]. Copyright (b) 2015
Elsevier, (c) 2012 American Chemical Society, (d-e) 2010 American Chemical Society.
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delivery 188 and silencing 189 in several drug-resistant cancer cell lines in vitro.
In a similar approach, Chen at al. 190 designed charge-reversing LbL carriers of plasmid DNA
encoding small hairpin RNA (shRNA) for gene silencing in vivo. This work used chitosan-aconitic
anhydride (CS-Aco) as an anionic constituent in a gold-(PEI/CS-A/PEI/shRNA) formulation. In
the acidic lysosome, the CS-Aco polymer is hydrolyzed into cationic chitosan to trigger film disas-
sembly and cargo release. Importantly, this formulation was stable and nontoxic in vivo, mediating
efficient silencing of the drug-resistance protein ABCG2 in HepG2 liver cancer cells. Mice harbor-
ing HepG2 xenografts exhibited improved tumor reduction using the charge-reversing formulation
alongside doxorubicin. These results are interesting given that the nanoparticle's outermost layer
is composed of the nucleic acid cargo, which could be damaged by nucleases during delivery.
Other reports 191-192 also demonstrate that nucleic acids are resistant to degradation after adsorp-
tion onto an LbL particle in vitro, but further documentation of the limitations of this stability should
be explored. Nonetheless, additional outer layers can provide critical benefits to LbL nanopar-
ticles that include extended blood circulation times and active targeting properties, as discussed
in Section 1.3.1.
Combination therapies from therapeutic LbL films and functional cores
One of the key strengths of the LbL nanoparticle approach is the ability to introduce two or more
drug types within the layers and the core of the nanoparticle. Combining therapeutic-loaded LbL
films with functional core templates is a powerful means to deliver combination therapies that
can attack disease from multiple angles. Multipronged therapeutics are gaining a great deal of
interest, particularly for the treatment of drug-resistant cancer with molecules that can engage or
silence genes to enhance the effects of chemotherapy. Because of the modular nature of the LbL
platform, nanomedicines can be designed that combine various therapies into a single particle,
thereby guaranteeing co-delivery to target cells. Moreover, recent efforts 114 to modulate the tem-
poral release from these systems indicate the potential to stage drug release in such a way as to
maximize the effects of each drug.
Deng et al.112 have recently demonstrated the therapeutic efficacy of a targeted LbL combination
therapy platform that co-delivers siRNA and chemotherapy to a subcutaneous murine model of
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Figure 1.7. Assembly of a therapeutic LbL film
onto a drug-loaded core can generate sophisti-
cated carriers of synergistic combination thera-
pies. In this case, a doxorubicin-loaded liposome is
coated with a gene-delivering LbL film composed of
poly(L-arginine), siRNA against MRP1, and hyaluronic
acid (PLA/siRNA/PLA/HA). a) This approach allows for
differential release profiles of the therapeutics, with
siRNA being released prior to the cytotoxic agent. b)
The resulting nanoparticles efficiently silence expres-
sion of MRP1, a drug-resistance protein, within triple-
negative breast cancer xenografts. c) The combina-
tion of gene therapy with chemotherapy provides
significant improvements in therapeutic efficacy over
monotherapy. Reprinted with permission from [112],
2013 American Chemical Society.
triple-negative breast cancer. This approach
functionalizes a doxorubicin-loaded liposome
with a functional, therapeutic-containing LbL
film composed of PLA/siRNA/PLA/HA. In
this formulation, the highly hydrated outer
HA coating promotes biostability by reducing
opsonization and nonspecific uptake, while
simultaneously mediating receptor-mediated
endocytosis via the CD44 receptor commonly
overexpressed in breast cancer. Meanwhile,
the biodegradable cationic PLA layers help
to mediate endosomal escape and siRNA
release into the cytoplasm. More specifically,
this work aimed to overcome drug-resistance
towards doxorubicin in triple-negative breast cancer, which is often mediated by enhanced drug
efflux via upregulation of transmembrane drug efflux pumps, like the multidrug resistance protein
1 (MRP1). To that end, the applied therapy introduced siRNA against MRP1 (siMRP1) to break
down the cancer's defense mechanisms and thereby maximize the effect of the co-delivered
cytotoxic agent. The combination of siMRP1 with and doxorubicin led to both efficient in vivo gene
silencing and synergistic therapeutic efficacy when compared to the effects of monotherapy (Fig-
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ure 1.7). Notably, this work reported a differential release profile of the siRNA and chemothera-
peutic, demonstrating the potential for staggered release from an LbL nanoparticle platform. This
provides a key advantage, as it allows the siRNA time to sensitize the cell before the cytotoxic
agent is released.
Overall, LbL technology facilitates the development of multifunctional nanocarriers that can control
the delivery of synergistic combinations of drugs. The approach allows researchers to carefully
select different therapeutics and incorporate them into the carrier in such a way as to individually
regulate their release. Simultaneously, careful selection of film constituents can provide further
control over the biodistribution, pharmacokinetics, and stimuli-responsive drug release of these
systems.
1.3.4. LbL nanoparticles as theranostics
The LbL approach also lends itself towards other important biomedical applications such as
imaging-based diagnostics through the incorporation of an imaging core of the linking of appropri-
ate dye molecules to one of the thin film components. Moreover, because the LbL approach is
highly modular, it is possible to simultaneously achieve all the advantages and functionalities as
discussed in the previous section to develop sophisticated diagnostic and theranostic systems.
Theranostic nanoparticles provide a single nanocarrier which integrates diagnostics and ther-
apy 93. Although still in its early stages, this approach is already generating interesting results.
For example, Cheng el al.194 have used LbL assembly to coat superparamagnetic iron oxide
(SPIO) and gold nanoparticles onto lanthanide-doped rare-earth up-conversion nanoparticle
(UCNP) cores, yielding multifunctional theranostic nanoparticles. Here, the diagnostic functional-
ity is provided by the luminescent UCNP core and the MRI-compatible SPIO nanoparticles in
the film. Simultaneously, the SPIO nanoparticles also help to guide nanoparticles to the tumor
via exogenous magnetic cues, and the gold nanoparticles provide a photothermal therapeutic
effect upon light activation (Figure 1.8). Promisingly, using magnetic guidance and light activated
photothermal therapy, suppressed tumor growth and prolonged survival, indicating the potential
to provide effective therapeutic treatments alongside multimodal diagnostics (Figure 1.8d-e).
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Figure 1.8. LbL modification allows the preparation
of potent theranostic nanoparticles. a) Schematic
illustration showing the composition of LbL assem-
bled theranostic nanoparticles and the concept of in
vivo imaging-guided magnetically targeted PTT. b)
Representative in vivo upconversion luminescent imag-
es of tumor-bearing mice with or without magnetic field
(MF). c) Representative T2 weighted images of tumor-
bearing mice. d) The tumor growth curve under different
treatment groups. e) Survival curve of tumor-bearing
mice after different treatment groups. Reprinted with
permission from [194], copyright 2012
vitro and provided spatially-resolved near-infrared
One avenue for LbL theranostics takes advan-
tage of the photoresponsive nature of certain
core templates, like gold or UCNPs, to initiate
phototherapy in addition to triggering drug
release from therapeutic-loaded films. For ex-
ample, Wang and colleagues195 described the
assembly of a therapeutic LbL film onto a NIR-
responsive UCNP. In this system the UCNP is
coated with PAA and PEI, loaded with the pho-
tosensitizing molecule chlorin e6, and finally
terminated with siRNA against the oncogene
PIk1. This nanoparticle could silence PIk1 in
HeLa cells in vitro, and interestingly exhibited
better performance in serum-containing media
relative to serum-free media. Excitation of the
UCNP by NIR light also caused entrapped
chlorin e6 molecules to generate cytotoxic sin-
glet oxygen, and combination of this photody-
namic therapy with delivery of functional siRNA
exhibited a stronger antiproliferative effect in
vitro than either treatment by itself. Shen et
al. 191 have employed a related approach, using
PEI-terminal LbL gold nanorods to complex
anionic siRNA. These multifunctional nucleic
acid carriers silenced their target protein, py-
ruvate kinase isoenzyme type M2 (PKM2), in
laser photothermal cell killing in triple-negative
breast cancer monolayer cultures (808 nm, 500 mW, 7 min).
Chen et al. 196 evaluated the in vivo efficacy of a similar approach, using noble metal-based
photothermal contrast agents110,197-203 to fabricate polyelectrolyte-coated (PDADMAC/PSS) gold
nanorods that could be loaded with doxorubicin post-synthesis. Following tissue-penetrant near-
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infrared laser exposure of immunocompetent mice bearing S1 80 murine sarcoma xenografts (765
nm, 1.8 W cm-2, 5 min), tumor progression was markedly slowed compared with equivalent doses
of free doxorubicin.
In current theranostic platforms, diagnostic tools can be a limiting factor for promising disease
detection because of their intrinsic drawbacks. For example, MRI is of high cost and requires
sophisticated magnetic tuning and prolonged imaging processing incompatible with real-time
tracking. Current fluorescence imaging tools, including UCNP, QD, and organic dyes, are within
the visible or first window of NIR region, which has limitations in tissue penetration and imaging
resolution. Fluorescence imaging in the second window of the NIR region (NIR-I, 1000 nm - 1700
nm) has attracted much attention as it can enhance the penetration and provide high-resolution
images in a real-time scale and low cost204-2 09 . A variety of systems such as polymeric micelles 207
lipids 2 05-2 06 , and bacteria phages 210 have been used for NIR-Il imaging; however, these systems
lack the modularity to package multiple functionalities such as stealth, targeting, and therapeutics.
LbL-based NIR-1l imaging is a promising future approach towards addressing these concerns.
In a different vein, incorporation of non-invasive diagnostic utilities into nanoparticle platforms,
such as urinary based biomarker systems, can transform drug carriers into diagnostic devices
that require no specialized imaging equipment. This approach is used in Chapter 5 of this thesis
to develop a novel LbL theranostic device that mediates both gene silencing and urinary tracking
of tumor burden.
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1.4. Current obstacles for clinical translation
The LbL platform is a promising means to develop modular and multifunctional nanoparticles with
important biomedical applications that span drug delivery and diagnostics. However, before this
technology can be successfully translated to the clinic, the field must focus on resolving persistent
barriers limiting the preparation of these materials. In this section, we discuss efforts to develop
automatable fabrication processes for LbL nanoparticles that can be scaled to meet the needs of
clinical and industrial implementation. Additionally, efforts to characterize the long-term stability of
LbL nanoparticles, both in aqueous and lyophilized states, will be discussed.
1.4.1. Scalable manufacturing
LbL assembly is a facile technique that generally only involves repeating two key steps: (1) expos-
ing the substrate to a solution of adsorbable polymer, and (2) washing of the substrate to remove
excess polymer. This simplicity is fully realized for the LbL functionalization of macroscopic mate-
rials, which can make use of hands-off automatable devices such as dipping robots. In contrast,
colloidal LbL assembly lacks such an automatable and robust synthetic approach because the
washing step becomes highly nontrivial at the submicron- and nanometer scale. The necessity
for efficient purification between layer depositions has been well documented through system-
atic experiments by Decher and colleagues 211, who demonstrate that LbL nanoparticle assembly
requires a significant excess of polyelectrolytes relative to the core template to fully saturate the
surface and avoid particle flocculation. Excess polymer must then be removed prior to the addi-
tion of the subsequent layer, otherwise flocculation and the generation of a polyplex byproduct will
occur. Traditionally, this has been carried out through extensive centrifugal wash steps following
each layer deposition. Centrifugation is time intensive, requires manual handling of materials at
every step, necessitates extensive optimization, and is notorious for losing significant product by
driving the formation of insoluble aggregated pellets 2 12.
Soon after colloidal LbL assembly was first described, efforts were underway to solve the problem
of fabrication. Reports spanning the past 16 years have yielded several interesting options for
automating the production of large (>5 micrometer) particles 213-217. Several promising options
have also been presented for preparing LbL nanoparticles, such as an innovative template-free
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Figure 1.9. This figure summarizes the major advances in
LbL nanoparticle fabrication and highlights each meth-
od's key strengths and weaknesses. For details on these
methodologies, refer to the main text. Reprinted with
permission from (a) [218], (b) [219], (c) [114]. Copyright
(a) 2011 American Chemical Society, (b) 2013 WILEY-VCH
Verlag GmbH & Co, (c) 2013 WILEY-VCH Verlag GmbH &
Co.
100-200 nm particles
can use biopolymers
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Uncertain scalability
Possible safety hazards
35-3000 nm particles
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High yield
Autoratable
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In 2013, Richardson et al. 219 described a novel LbL assembly method in which core templates
could be immobilized in agarose gel, and then coated through the systematic electrophoresis of
charges species through the gel (Figure 1.9b). This approach generated both micro and nanome-
ter scale LbL colloidal systems (3 pm to 35 nm) at high yields (85%). The main drawback of this
approach is the need to melt the agarose to recover the LbL nanoparticles, which could damage
sensitive formulations. Indeed, this work observed that regardless of the charge of the terminal
layer, all formulations exhibited a negative charge. This was attributed to potential re-arrangement
of the films during the agarose melting step. Such rearrangement could initiate premature release
of cargo located in the film, and could conceal elements of the outer layer that may be needed for
biostability and active targeting.
A novel synthetic approach described by Morton et al.114 leverages PRINT (particle replication
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approach to LbL assembly described by Yeo
and colleagues 218. In this work, LbL was car-
ried out through a series of atomization and
suspension steps, and produced particles on
the order of 100-200 nm composed entirely
of assembled polymers (Figure 1.9a). This
approach successfully creates nanoscale LbL
nanoparticles, but at the expense of being
able to functionalize a core nanoparticle tem-
plate. As such, it limits the ability to incorpo-
rate promising functionalities such as imaging
cores and drug-loaded cores. Furthermore,
it is unclear whether the atomization tech-
nique could limit the types of polyelectrolytes
introduced into this system. The potential to
aerosolize biologically active nanoparticles
into the workspace also necessitates serious
investigation of potential safety hazards as-
sociated with this technique.
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in non-wetting templates) technology to facilitate the high-scale fabrication of LbL nanoparticles
(Figure 1.9c). PRINT technology allows for the production of highly uniform PLGA nanoparticle
arrays onto planar surfaces. Notably, these particles can be produced in a variety of shapes and
sizes ranging from 50 to 200 nm, and can be functionalized via aqueous spray-assisted LbL as-
sembly while still immobilized on the planar array, eliminating the tedious centrifugal washing step.
Subsequent recovery of the NPs requires only sonication of the macroscopic array to release the
particles into solution, providing high yields even for highly layered formulations. This approach
has significant potential to be automated to develop in-line manufacturing of LbL nanoparticles
in a high-throughput, roll-to-roll fashion, and may well prove to be a solution for polymeric or
biomacromolecular core particles that can be manipulated in PRINT. However, this technique is
unable to use alternative core materials, such as liposomes and quantum dots.
Despite these efforts, the manufacture of LbL nanocarriers at a scale and higher throughput
that is also widely accessible to academic laboratories remains a challenge. Work described in
Chapter 2 aims to provide new tools towards establishing fabrication processes that provide these
features.
1.4.2. Long-term stability and shelf life
With the growing reports of clinically relevant LbL nanomedicines, it is becoming increasingly
important to satisfy important questions about the long-term stability of LbL therapeutics. Unfortu-
nately, little documentation exists on the shelf lives of different LbL formulations, particularly those
that are drug-loaded and may experience leakage during storage. These questions are vital for
the eventual commercial success of these materials, both in terms of stockpiling, shipping, and
storage in the clinic.
Full reports on this matter are lacking, but important information can be inferred from the charac-
terizations of various drug-loaded systems. For example, during characterization of their surface-
enhanced Raman spectroscopy LbL nanoprobes, DeVetter et al. 220 observed temperature-de-
pendent encapsulation stability. In these studies a Raman-active small molecule, methylene blue,
differentially diffused out from an LbL film composed of PAA and PAH over the course of 5 weeks,
depending on the storage temperature. Samples stored at 220C and 370C exhibit a notable decay
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in spontaneous Raman signal over 5 weeks, suggesting outward diffusion of methylene blue
away from the gold core. Samples stored at 40C provided more stable Raman spectra over 5
weeks, but still displayed some loss of signal. The authors then explored the effect of cross-linking
on the stability of these probes, and found that crosslinking the amines on the outer PAH layer
could significantly improve signal retention at 40C over the course of 5 weeks. These results are
interesting, and provide insight on how drug-loaded LbL nanoparticles may behave under pro-
longed aqueous storage conditions, as well as means to extend their shelf lives. Work from this
thesis contributes additional knowledge on this front, as described in Chapter 2.
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1.5. Scope of thesis
This dissertation documents improvements made to the fabrication of LbL nanoparticles, it docu-
ments the application of these new synthetic methods towards the systematic study of the role of
LbL nanoparticle surface chemistry in the specific context of improving drug delivery to ovarian
cancer, it also documents the engineering of a multifunctional nanoparticle for combined gene
therapy and noninvasive tumor detection.
The introductory Sections 1.2 and 1.4 provide the background on which Chapters 2 and 4 build
from in the development of an improved synthetic method based on tangential flow filtration and
optimization of solution conditions and the LbL substrate. Innovation in the purification methods
for the intermediate steps of LbL assembly provide the throughput, scale and yield of synthesis
needed for later studies. Study of the solution conditions and substrate for LbL synthesis provide
a basis for more stable nanocarriers with favorable siRNA encapsulation efficiency.
Sections 1.3.1 and 1.3.2 are the basis for the work of Chapter 3, where the methodical compari-
son of different LbL nanoparticle surface chemistries yields insights into ovarian cancer-targeting
formulations with unique subcellular trafficking and the most advantageous means of administer-
ing these nanocarriers in vivo. These studies reveal the discrimination between sulfated and car-
boxylated LbL nanoparticles, and that ovarian cancer cells interact differently with LbL nanopar-
ticles relative to uncoated particles bearing similar surface chemistry. Notably, ovarian cancer
cells distinguish minute differences in LbL nanoparticle surface chemistry, translating to unique
subcellular fates between formulations with similar surface coatings. Significant advantages are
reported for administration methods that take advantage of intraperitoneal injection, which yields
highly specific localization of nanoparticle to tumor tissue in a metastatic model of ovarian cancer.
The work for Chapter 5 is framed by the introductory Sections 1.3.3 and 1.3.4, a primer on com-
bination therapy and theranostic nanomedicine. This portion of the dissertation documents the
design and fabrication of an LbL-modified liposome for simultaneous siRNA delivery and de-
tection of tumor burden. The diagnostic utility is incorporated into the LbL nanoparticle through
click-chemistry modification of the terminal layer to introduce a biosensing peptide developed by
collaborators in the Bhatia lab at MIT. This peptide is cleaved by tumor proteases, producing a
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small peptide fragment that is readily excreted in the urine for noninvasive detection of tumors.
The theranostic nanoparticle is validated in several metastatic model of cancer, including ovarian.
The successful delivery of siRNA is documented in ovarian cancer, and the role of introducing
additional targeting ligands via click-conjugation is explored.
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Chapter 2. New methods for LbL synthesis
This chapter is in part adapted from:
Correa, S.; Choi, K. Y; Dreaden, E. C.; Renggli, K.; Shi, A.; Gu, L.; Shopsowitz, K. E.; Quadir, M. A.;
Ben-Akiva, E.; Hammond, P. T., Highly scalable, closed-loop synthesis of drug-loaded, layer-by-layer
nanoparticles. Adv Funct Mater 2016, 26 (7), 991-1003.
Layer-by-layer (LbL) self-assembly is a versatile technique from which multicomponent and stimuli-
responsive nanoscale drug carriers can be constructed. Despite the benefits of LbL assembly, the
conventional synthetic approach for fabricating LbL nanoparticles requires numerous purification
steps that limit scale, yield, efficiency, and potential for clinical translation. This chapter describes
a generalizable method for increasing throughput with LbL assembly by using highly scalable,
closed-loop diafiltration to manage intermediate purification steps. This method facilitates highly
controlled fabrication of diverse nanoscale LbL formulations smaller than 150 nm composed from
solid-polymer, mesoporous silica, and liposomal vesicles. The technique allows for the deposition
of a broad range of polyelectrolytes that included native polysaccharides, linear polypeptides, and
synthetic polymers. In Section 2.3, we also explore the cytotoxicity, shelf life and long-term stor-
age of LbL nanoparticles produced using this approach. We find that LbL coated systems can be
reliably and rapidly produced: specifically, LbL-modified liposomes could be lyophilized, stored at
room temperature, and reconstituted without compromising drug encapsulation or particle stabil-
ity, thereby facilitating large scale applications.
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2.1. Introduction to challenges of scale and translation
Multifunctional nanoscale therapies have the capacity to transform modern healthcare by provid-
ing greater control over the spatial and temporal release of drugs.1 3 Formulations sized from 15
to 100 nm exhibit unique properties and functions that promote accumulation in target tissues
while minimizing nonspecific clearance from the body.4 These nanotherapies are by their own
nature a complex composite of materials that can simultaneously protect, guide, and release
biologically active compounds in a desirable manner. Complex materials, in turn, provide signifi-
cant challenges from a translational point of view - particularly in terms of their eventual scalable
fabrication. Effective nanoscale therapies must further exhibit adequate shelf lives under clinically
relevant storage conditions in order to facilitate their eventual translation.
LbL assembly is a well-established technique for the solution-phase synthesis of hierarchical and
multifunctional nanoscale therapeutics. 5-7 LbL nanoparticles can possess a range of desirable
properties for drug and gene delivery due to the versatility granted by the technique. In its most
frequently employed form, LbL assembly is driven by the electrostatic interaction between oppo-
sitely charged polyelectrolytes on a charged substrate. Possible substrates include colloids such
as gold, polymer, silica, and liposomal nanoparticles, amongst others. 3  Along with the flexibility
in the choice of a core substrate, any polyelectrolyte with a multivalent charge can be incorpo-
rated into an LbL construct, including native polysaccharides, nucleic acids, linear polypeptides,
and synthetic polymers.8 14-16 The LbL technique has been well characterized and studied by the
materials community since the fundamental concept of alternating electrostatic assembly was first
described by ler in 1966.17-23 In addition to electrostatics, it is well documented that LbL assembly
can be driven by a multitude of intermolecular interactions that include hydrogen bonding, cova-
lent bonding, and biologically specific interactions. 24 More recent research into LbL nanomaterials
has yielded important developments for a variety of fields including chemical sensing, catalysis,
energy storage, optics, and drug delivery.13 25-29
Several advances specifically highlight the promise of LbL nanoparticle systems for drug delivery,
including the ability to generate novel hybrid organic-inorganic nanoparticles with tunable cell-
particle interactions, and the generation of nanoparticle systems that can release combination
drugs and small interfering RNA (siRNA) in a staged and synergistic fashion.3032 Importantly, the
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thickness of polyelectrolyte multilayers formed by LbL is on the order of nanometers, providing
investigators a high degree of control over the final size of an LbL nanoparticle. As generally the
polymer film is very thin, the size of an LbL formulation is largely determined by the core sub-
strate, which has been reported to be as small as 10 nm in diameter.33 36 Using the LbL platform,
researchers have been able to preserve the size of a conventional nanoparticle formulation while
providing improved stability and environmentally sensitive functionalities that capitalize on cues
from the tumor microenvironment to initiate cellular uptake. 15,37 Additional functionalities provided
by the multilayer film allows for tuning of drug release and the incorporation of therapeutics into
the polymer film.13, 31 38
Despite their numerous advantages, both basic research and clinical translation of LbL nanopar-
ticles have been impeded by scalability problems associated with their preparation. Traditional
preparation of these materials relies on centrifugal purification to eliminate excess polyelectrolyte,
but this approach is both time-intensive and prone to causing irreversible aggregation of LbL
particles. Unfortunately, centrifugation becomes much more problematic when transitioning from
micro- to nanoscale formulations, due to the need to significantly increase the spin speed and
time needed to isolate smaller particles. Work to optimize centrifugal protocols rely on meticulous
optimization of polymer molecular weight, charge ratios, centrifugal force, and spin times.39 Efforts
to try and resolve problems with scalability have generated creative techniques including vacuum-
filtration, atomization, microfluidic, electrophoresis, and fluidized bed-mediated LbL assembly.40-46
While these innovative approaches do offer advances in efficacy and yield during the preparation
of colloidal LbL materials, they place limitations on the types and sizes of materials that can be
used, reducing LbL versatility. Our group previously described another LbL preparation method,
which relies on PRINT@ technology. While this approach is robust, it does not allow for the layer-
ing of many nanoparticle cores that are of great interest for drug delivery and theranostics, such
as quantum dots, liposomes, and responsive self-assembled polymeric colloids.47
To address the need for an accessible, robust, and scalable approach for preparing diverse LbL
nanoparticles, we incorporated tangential flow filtration (TFF) into our synthetic workflow. TFF
works by a process known as diafiltration, where permeable molecules are removed from a solu-
tion while passing through a hollow ultrafiltration membrane. Diafiltration for nanoparticle purifica-
tion has been well characterized for colloidal solutions.48 -9 When a solution of LbL nanoparticles
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is pumped through the fiber membrane, the permeable polyelectrolytes rapidly exit through the
pores in the membrane and are removed from the system. Meanwhile, the larger nanoparticles
are retained and re-circulated through the system until the desired purity is reached. The sample
volume can be held constant by the introduction of replacement buffer at the same rate that waste
is removed from the system, allowing the purification to be continued for any desired amount of
time. Collected waste (permeate) solution can also be recovered and re-concentrated in order to
recycle reagents and reduce synthetic costs. Furthermore, these devices are easily scalable to
prepare samples ranging anywhere from a single milliliter to more than a liter.
Lohse and colleagues previously described the use of a TFF-based reactor for the synthesis
and functionalization of gold nanoparticles, including LbL modification with poly(acrylic acid)
and polyallylamine.50 This early application of TFF towards LbL modification faced issues of ef-
ficient purification, requiring washing nanoparticles with upwards of 20 volume equivalents before
achieving sufficient purity to perform the next deposition step. Inefficient polyelectrolyte removal
also appeared to cause off-target toxicity due to the carryover of free polycations. Here, we em-
ploy high surface-area, porous hollow-fiber filtration cassettes that provide improved flux rates
that allow TFF purification to occur more rapidly and completely. Indeed, very recently the work by
Bj6rnmalm and coworkers demonstrated the effective preparation of LbL particles with this new
class of membrane, with more emphasis on the generation of micrometer- and submicrometer-
sized particles and capsules.51 Here, we specifically describe a generalizable method for using
TFF to prepare LbL nanoparticles ranging from 40 to 150 nm, which are within the size range
important for systemic drug delivery, tumor targeting, and tissue penetration. We document major
improvements in efficiency and yield using this method relative to traditional protocols. Further-
more, we demonstrate the compatibility of this method with a broad range of biomedically relevant
materials through the fabrication of LbL nanoparticles composed from a variety of substrates
and biocompatible polyelectrolytes, and include several novel LbL formulations. To highlight the
clinical relevance of these materials, we go on to demonstrate that LbL nanoparticles fabricated
using this new technique are biocompatible, and can be stably stored in both refrigerated and
lyophilized states.
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2.2. Results: Streamlining LbL nanoparticle synthesis using tangen-
tial flow filtration for improved scale and yield
2.2.1. Preparation of filter membranes for LbL assembly
In LbL assembly, the role of salts is well known to promote the generation of thicker films by
shielding the Coulombic repulsion between adsorbed polyelectrolytes.3 9 ,2 - 4 Extensive discussion
relating to salt and bulk conditions in colloidal LbL is provided in Chapter 4, but here we briefly
outline some of the challenges associated with working with salts in the context of the interlayer
purification steps.
While salts can provide a measure of control over film thickness, they also promote particle floc-
culation by masking the repulsive forces between distinct particles. The inclusion of salt is par-
ticularly problematic in LbL formulations where the researcher must balance the electrostatic
repulsion between polyelectrolytes that are also subject to intermolecular attractive forces like
hydrogen bonding. Consideration for delicate materials aside, the purification of LbL particles
requires the eventual removal of salt to halt the gradual re-organization and decomposition of
the LbL film. 54 Normally, salt-removal is accomplished by using pure water during the sequential
centrifugal washing steps, where salt-removal actually helps to better stabilize the particles by
improving their electrostatic repulsion. Unfortunately, this poses a challenge for efficient puri-
fication using filtration, due to the slight negative charge associated with most polymeric filter
membranes.40 55 For LbL preparations, the sequential exposure of alternatively charged particle-
polymer solutions leads to the buildup of an LbL film onto the filter membrane itself, which reduces
yields and fouls the membrane.5 6
To overcome this problem, we separate the purification of positively and negatively charged par-
ticles to their own filter membranes (Figure 2.1a). To discourage cationic nanoparticles from
adhering to the negative membrane walls, dilute solutions of free polycation (10 mg mL 1) are
re-circulated through the filter membrane for 10 minutes. This pre-treatment allows free poly-
cation to bind to anionic sites on the membrane via electrostatic attraction, and reduces the
membrane's capacity for nonspecific adsorption of cationic nanoparticles during purification. For
the membrane that processes negatively charged particles, no modifications were made as its
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Figure 2.1. Tangential flow filtration (TFF) facilitates the rapid and controlled fabrication of layer-by-layer
nanoparticles. (a) TFF purification schematic depicting continuous diafiltration through a porous membrane. A
peristaltic pump drives nanoparticle samples through a circuit containing a filter membrane. Polyelectrolytes,
driven by a mild pressure gradient, exit the circuit through the pores in the filter membrane and into a waste
reservoir. Removal of solution generates a vacuum within the system, which draws replacement buffer from an
attached reservoir to hold sample volume constant. To prevent nonspecific adsorption onto the filter membrane,
purification of cationic and anionic nanoparticles was separated to different purification loops, each with its own
filtration membrane.The left panel denotes the cationic purification loop, and the right panel denotes the anionic
purification loop. (b) Purification of excess poly-L-lysine (PLL) or dextran sulfate (DXS) following LbL deposition
can be completed in minutes using TFF. The concentration of PLL extracted using TFF was determined using a
BCA assay on samples taken sequentially from the waste stream. DXS concentrations were determined by ana-
lyzing permeate samples by gel permeation chromatography. Data were fitted using a one-phase exponential
decay model. (c) High yields (68 5% after 10 layers) are reproducibly obtained using TFF-assisted LbL fabrication.
Nanoparticle concentration was quantified using a fluorescence plate reader following each purification step dur-
ing the fabrication of 100 nm, carboxy-modified latex particles coated with five bilayers of PLL and DXS (CML-[PLL/
DXS],). Error bars represent standard deviation of three independent syntheses.
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membranes greatly improved yields with salt-free conditions and allowed us to easily and quickly
prepare diverse LbL constructs.
2.2.2. Purification kinetics and product yields
We assessed purification kinetics using 500 kDa molecular weight cut off (MWCO) membranes
and observed the rapid removal of excess 15 kDa poly(L-lysine) (PLL) and 10 kDa dextran sulfate
(DXS) from an LbL nanoparticle grown on a fluorescently labeled, 100 nm, carboxy-modified latex
(CML) substrate (Figure 2.1b). During purification, permeate waste was sequentially collected
and then analyzed by either the bicinchoninic acid (BCA) assay or by gel permeation chroma-
tography (GPC) to quantify the removal of polyelectrolyte. The results indicated that removal of
polyelectrolytes of this size reaches a plateau within four minutes of purification while operating
the TFF at a transmembrane pressure between 3-5 PSI. We applied a linear regression analysis
to fit the data and calculate the time required to reach a desired purity. The results were similar
to the qualitative interpretation of the data, indicating that 95% purity could be expected in 5.1
minutes for PLL and 3.8 minutes for the smaller DXS.
To assess the yield from TFF-assisted LbL synthesis, we repeatedly fabricated ten-layer LbL
particles composed of a fluorescently labeled, 100 nm CML core coated with 15 kDa PLL and
10 kDa DXS (100CML-[PLL/DXS] 5 ). After each purification step, a sample was taken to quantify
particle recovery. Data from three independent syntheses were combined to determine the typical
yield possible using this technique (Figure 2.1c). The results indicated that a total yield of 68 5%
could be expected after ten layer depositions. Linear regression analysis of the data suggested
that 96.9 0.4% yield could be expected per layer deposition.
One of the major findings of this work was the rapid timescale of nanoparticle purification using
TFF, which reduced purification time to 4-6 minutes per layer. Relative to the 30-60 minutes typi-
cally required for a single centrifugal spin during traditional synthesis, TFF-assisted LbL assembly
is dramatically more efficient. Analysis of recovered permeates during the purification of either 15
kDa PLL or 10 kDa DXS revealed that free polymers were efficiently removed after washing with
5 volume equivalents of the eluent solution, a significant improvement upon the 20 equivalents
required by previous TFF-based approaches for nanoparticles.50
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Figure 2.2. Diverse layer-by-layer (LbL) nanoparticles are prepared in a controlled manner using the tan-
gential flow filtration (TFF)-assisted method. (a-c) Solid-core LbL particles were prepared by coating 100 nm,
carboxy-modified latex particles with five bilayers of poly(L-lysine) and dextran sulfate (1 OOCML-[PLL/DXS],). (d-f)
LbL-modified liposomal particles were prepared by coating negatively charged, doxorubicin-containing lipo-
somes with four bilayers of PLL and DXS followed by a bilayer of PLL and heparin sulfate (Lipo-[PLL/DXS],-PLL-HS).
(a, d) These particles exhibited controlled size increase during layer deposition. (b, e) Nanoparticle uniformity was
maintained throughout the layering process as indicated by the low polydispersity index (PDI). (c, f) Complete
charge reversal was observed after each layer deposition indicating successful LbL modification. Size and polydis-
persity data were acquired by dynamic light scattering, and zeta potential data was measured using laser Doppler
electrophoresis. Error bars represent standard deviation of three technical replicates. For population-based data
see Supplemental Appendix A Figure 5.
Using our diafiltration-based system, rapid purification times are complimented by a reliable, high
degree of product yield of 96.9 0.4% per layer, leading to 68 5% yield after ten layer deposi-
tions on 100 nm latex cores. This provides 83 2% yield after four layer depositions, which is
the number of layers in the formulations we have previously described for applications involv-
ing targeted drug delivery to tumors.31 These results are a marked improvement over previously
published optimized centrifugal protocols that report a 54.1 % yield after the deposition of ten lay-
ers. 39 Improved yields will facilitate the exploration of LbL drug-carriers that incorporate useful but
costly materials, such as siRNA, into the multilayer film. Similarly, recovery of the polyelectrolytes
from the permeate solution, as was examined in this study to quantify purification kinetics, could
lead to recycling of excess polymer to further reduce costs. Overall, our system allows for faster
synthesis of LbL nanoparticles, with a higher yield as compared to previously described methods.
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2.2.3. LbL modification of solid carboxy-modified latex and drug-loadable
nanoparticle substrates
To confirm that our method retains the desirable versatility of the LbL technique, the hydrody-
namic size, uniformity, and surface charge were monitored throughout the preparation of several
different LbL formulations. Initial work focused on solid polymer core formulations, such as the
100CML-[PLL/DXS]5 prepared during yield studies (Figure 2.2a-c). Another latex core formula-
tion was prepared by depositing alternating layers of 15 kDa polyethylenimine (PEI) and unfrac-
tionated heparin sulfate (HS) onto a 100 nm CML substrate (1OOCML-[PEI/HS], see Appendix
A Figure 1). Finally, to demonstrate the capacity to prepare smaller sized products, a formulation
using 40 nm CML coated with PLL and DXS was prepared, reaching a final hydrodynamic size
of 58 3 nm, a low polydispersity index of 0.12 0.01, and a surface charge of -71.6 0.9 mV
(40CML-[PLL/DXS]3, Appendix A Figure 2).
To demonstrate the fabrication of clinically relevant LbL nanoparticles, focus was shifted to the
LbL modification of two drug-loadable nanoscale templates, mesoporous silica and liposomal
vesicles. We successfully prepared LbL nanoparticles from 30 nm mesoporous silica coated with
poly(L-arginine) (PLA) and poly(L-glutamic acid) (PG) (MSN-[PLA/PG] 3, Appendix A Figure 3).
The final LbL silica particles possessed a hydrodynamic size of 41 4 nm, a polydispersity index
of 0.22 0.02, and a surface charge of -58 2 mV.
Subsequent efforts focused on the LbL modification of colloidal liposomal cores, where PLL, DXS,
and HS-containing multilayers were formed on the negatively charged surfaces of doxorubicin-
loaded liposomes (Lipo-[PLL/DXS] 4-PLL/HS, Figure 2.2d-f). An additional LbL liposome formu-
lation was prepared using PLA and DXS and later used for freeze-dried storage experiments
(Lipo-[PLA/DXS] 2, Appendix A Figure 4). Notably, the TFF-assisted method did not need to be
altered with any of these formulations, with the exception of changing the MWCO of the filter
membrane when working with smaller or more flexible formulations. For particles 100 nm or larger
in diameter, 500 kDa MWCO membranes were suitable. For smaller formulations, or liposomal
formulations, 100 kDa MWCO membranes were more appropriate. In general, the optimal MWCO
was determined by assessing changes in filter flux, where if the MWCO was large enough to per-
mit nanoparticle penetration, then a decay of flux was observed. If flux decay was observed, the
70
New methods for LbL synthesis
MWCO was decreased until stable flux rates
were achieved. When changing MWCO of the
membrane, the feed flow rate of the peristaltic
pump was adjusted to keep the transmem-
brane pressure between 3-5 PSI and the
shear rate below 6,000 s1 .
Hydrodynamic diameter was tracked using
dynamic light scattering (DLS) after each
purification, and revealed the steady growth
from 86 3 nm to a final size of 110 1 nm
(Figure 2.2a) for the case of 100CML-[PLL/
DXS 5. The Lipo-[PLL/DXS] 4-PLL/HS formu-
lation exhibited thinner film formation, but
nonetheless grew steadily from 58 2 nm
to 63 2 nm (Figure 2.2d). The difference
between film thicknesses on these two cores
b.
4 4
Figure 2.3. Cryogenic TEM images of core particles
before and after layering confirm the presence of
a thin film. Cryogenic TEM of (a) uncoated, carboxy-
modified latex particles; (b) purified, LbL-coated car-
boxy-modified latex (CML-[PLL/DXS]5); (c) uncoated,
doxorubicin-loaded liposome; (d) purified, LbL-coated,
doxorubicin-loaded liposome (Lipo-[PLL/DXS]4-PLL-HS).
was anticipated, given previous experience with these substrates.31 , s In addition to size mea-
surements, successful layering was confirmed by tracking the complete charge reversal of LbL
particles throughout the synthesis. Both 1 OOCML-[PLL/DXS] 5 and Lipo-[PLL/DXS]4-PLL/HS alter-
nated between zeta potentials of roughly +60 mV and -60 mV during alternate deposition steps, in
accordance to the deposited polyelectrolyte's charge (Figure 2.2c,f). Nanoparticle uniformity was
well preserved throughout the synthesis, as indicated by the low polydispersity index (PDI) mea-
sured by DLS - 0.06 0.01 for 100CML-[PLL/DXS], and 0.16 0.02 for Lipo-[PLL/DXS] 4-PLL/
HS (Figure 2.2b,c). The other LbL formulations discussed exhibited similar characteristics, and
that data can be seen in Appendix A. Further, population based, documentation on the ten-layer
formulation's size and charge can also be seen in Appendix A Figure 5.
To further validate the successful LbL assembly of the two principle formulations, cryogenic trans-
mission electron microscopy (Cryo-TEM) was used to evaluate changes in particle morphology
after LbL modification (Figure 2.3). Comparison of the electron micrographs showed the presence
of thin films on the LbL nanoparticles that are not visible on the unmodified substrates. These
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Figure 2.4. The quantification of Cryo-TEM images confirm statistically significant increases in size consis-
tent with LbL modification. (a) Comparison of the diameters of bare, carboxy-modified latex (CML) particles and
LbL-modified CMLs indicate a statistically significant (P<0.0001) shift in the size distribution. Dashed line denotes
the mean size. N = 103 for bare and 153 for LbL CML. (b) Similarly, comparison of the liposome membrane thick-
ness reveals statistically significant (P<0.0001) increase in thickness after LbL modification. Dashed lines denote
the mean thickness. N = 113 for bare and 298 for LbL liposomes. (c) Calculation of LbL film thickness from either
Cryo-TEM data or dynamic light scattering data give statistically consistent results for both CML (13.3 0.6 nm by
Cryo-TEM and 12 1 nm by DLS) and liposomal (2.65 0.09 nm by Cryo-TEM and 2 1 nm by DLS) substrates.
Error bars represent SEM. These data highlight important changes in LbL film thickness due to substrate selection.
Individual particle measurements were plotted as a histogram and the kernel density function was estimated
using R Statistical Software. All statistical tests were performed using one-way ANOVA (alpha = 0.01), with the
Bonferroni post-test, on PRISM graphing software.
images were further analyzed using lmageJ to quantify size changes from the unmodified and
layered formulations. The data reveal statistically significant (P<0.0001) increases in nanoparticle
diameter (for 1 OOCML-[PLL/DXS] 5) and membrane thickness (for Lipo-[PLL/DXS]4-PLL/HS ) rela-
tive to the unmodified substrate (Figure 2.4a-b). Furthermore, comparison of LbL film thickness
calculated from either Cryo-TEM or DLS produced statistically consistent estimates for particles
formed on CML (13.3 0.6 nm by Cryo-TEM and 12 1 nm by DLS) and liposomal (2.65 0.09
nm by Cryo-TEM and 2 1 nm by DLS) substrates (Figure 2.4c).
These results indicate the highly efficient and scalable fabrication of LbL nanoparticles smaller
than 150 nm using TFF. Another major finding of this study was that the TFF-assisted meth-
od could be generalized to a diverse number of nanoscale formulations including solid latex,
mesoporous silica, and liposomal cores. The breadth of polyelectrolytes used to construct LbL
nanoparticles shows that TFF-assisted LbL assembly is compatible with many different material
systems. Careful tracking of the nanoparticle size, surface charge, and uniformity during synthe-
sis indicated that this method provided a great deal of control over these important nanomaterial
characteristics. The results from Cryo-TEM validated the presence of intact and uniform films on
LbL-modified latex nanoparticles and liposomes. Furthermore, the agreement between film thick-
nesses calculated from Cryo-TEM or DLS measurements further support the presence of a thin,
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but measurable, film on the nanoparticle surface. These small changes in size are representative
of the highly controllable growth of the polyelectrolyte multilayer afforded by the LbL technique.
The generalizable nature and excellent quality control of this method has important implications
for the future of basic research into LbL nanomedicines, as TFF is a highly accessible technology
that could be employed by most laboratories.
2.2.4. Generation of an LbL small library
The generation of a small library of LbL nanoparticles demonstrated the potential of TFF-assisted
LbL assembly to increase experimental throughput, allowing researchers to better evaluate the
contribution of different variables in their nanoparticle formulations. Since one of the greatest
strengths of the LbL platform is its ability to generate diverse material systems, there is a large
parameter space to be explored. It has been well documented that nanoparticle surface chem-
istry plays an important role in particle-cell interactions.60-61 The work by Murphy and colleagues
Table 1. Ten formulations of LbL nanoparticles with unique terminal polymer layers were fabricated using the
TFF method. Each particle is a bilayer formed on carboxy-modified polystyrene substrates (CML-[poly(L-arginine)/
polymerX], where polymerX is one of the terminal layers described below). The size, uniformity and zeta potential
of each nanoparticle formulation was determined by dynamic light scattering and laser Doppler electrophoresis.
Error represents the standard deviation of three technical replicates.
Terminal Layer Average Hydrodynamic Size [nm] Polydispersity Index Zeta Potential [mV]
Carboxy-modified latex 95 5 0.10 0.03 -63 1
Poly(L-arginine) 105 2 0.03 0.01 66 1
Poly(L-aspartic acid) 101 9 0.08 0.02 -63 1
Poly(L-glutamic acid) 106 3 0.04 0.04 -61 1
Poly(L-glutamic acid)-b-polyethylene glycol 105 9 0.08 0.01 -51 3
Poly(acrylic acid) 99 7 0.05 0.03 -68 2
Hyaluronic acid 153 8 0.05 0.02 -56 2
Dextran sulfate 109 9 0.13 0.04 -75 1
Heparin-folate conjugatea 120 9 0.07 0.03 -61 2
Sulfated beta cyclodextrin polymer 110 8 0.05 0.06 -50 2
Heparin sulfate 107 4 0.11 0.04 -73 2
Fucoidan 126 4 0.12 0.05 -61 1
a) Heparin sulfate was conjugated to folic acid using NHS addition chemistry. See supplemental
information for more detail.
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has highlighted several biological effects of LbL nanoparticles that depend on surface chemistry,
demonstrating the importance of broadly studying different terminal coatings.30, 2 To this end, ten
unique LbL nanoparticle formulations were generated from 100 nm CML cores. Each particle
was coated with PLA and then terminated with one of ten polyanions described in Table 1. These
terminal coats include a variety of polysaccharides, linear polypeptides, and synthetic or modi-
fied polymers. In particular, the hyaluronic acid and heparin-folate conjugate coated formulations
possess known targeting properties. 3 -4 Of note, the inclusion of hyaluronic acid into LbL particles
can be challenging due to the polymer's propensity to form secondary and tertiary structures that
can drive aggregation.- 67 However, hyaluronic acid is a highly desirable material that benefits
biomedical applications with its unique biological behaviors such as mucoadhesion, receptor tar-
geting, and antifouling.1, 37,6 8 Use of the TFF-assisted method greatly increased the throughput of
nanoparticles functionalized with hyaluronic acid (ca. 10-fold per particle). Each particle prepared
for the library exhibited excellent size, uniformity, and surface charge, consistent with the descrip-
tions of the more highly layered formulations.
Importantly, this work describes the manufacture of several novel LbL formulations that incorpo-
rated sulfated beta-cyclodextrin polymer, the algae-derived polysaccharide fucoidan, and a hepa-
rin sulfate-folate conjugate. The fabrication of stable LbL particles composed of a cyclodextrin
polymer opens the door to generating LbL films with drug-loaded polyelectrolytes for the inclusion
of hydrophobic small molecules. LbL nanoparticles coated with fucoidan present opportunities to
investigate emergent reports of this molecule's involvement in cellular differentiation and immune
modulation. 69-70 The inclusion of a heparin-folate conjugate also raises opportunities to leverage
both molecules' biological interactions towards an effective targeted therapy. Furthermore, given
the success of this technique with a variety of material systems, it is likely that this approach could
be adapted to prepare LbL formulations that utilize alternative attractive forces such as hydrogen
bonding and hydrophobic interactions.
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2.3. Results: Characterization of the safety and the long-term stability
of drug-loaded LbL liposomes
2.3.1. Evaluation of LbL nanoparticle toxicity
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Figure 2.5. LbL nanoparticles prepared using the
TFF-assisted method do not exhibit nonspecific cyto-
toxic effects in vitro. SKOV3 cells were incubated with
poly(L-aspartic acid), herparin sulfate, and hyaluronic
acid terminated LbL nanoparticles that were prepared
by either the TFF method (solid, blue bars) or the con-
ventional centrifugal method (striped bars). After 72
hours, the cellular viability was determined using the
Cell-Titer Glo luminescence assay. The results were nor-
malized relative to untreated controls, and subsequent
analysis by one-way ANOVA failed to find any statistically
significant changes in cellular viability for any formula-
tion, regardless of preparation method.
To address the concern that TFF-made LbL
nanoparticles may have unintended cyto-
toxic effects due to the carryover of excess
polycation, a viability assay was performed
on SKOV3 cells with three LbL formulations.
Poly(L-aspartic acid), hyaluronic acid, and
heparin sulfate terminated nanoparticles
were prepared by either the TFF-method or
the conventional centrifugal method and incu-
bated with SKOV3 cells over the course of 72
hours. Cell viability was measured at 24, 48,
and 72 hours and compared to the viability of
untreated cells and cells exposed to the bare
latex core (Figure 2.5 and Appendix A Fig-
ure 6). None of the nanoparticle formulations
exhibited statistically significant changes in
viability compared to untreated controls, indi-
cating that TFF-made LbL nanoparticles show
low toxicity in vitro.
These results provide evidence that LbL nanoparticles prepared using the TFF method are cell-
compatible by performing a head-to-head comparison of toxicities between several formulations.
The results further prove that TFF purification provides highly pure LbL nanoparticles free of
cytotoxic contaminants such as free polyelectrolytes.
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Figure 2.6. LbL nanoparticles have long refrigerated shelf lives as indicated by the preservation of their
size, uniformity and charge characteristics. Ten different LbL nanoparticle formulations consisting of a carboxy-
modified latex core and a bilayer of poly(L-arginine) and a unique polyanion were stored for three months at
4 degrees Celsius. (a) We compared the hydrodynamic number average size for the particles after storage and
compared them to the particle's original size. With the exception of the Fucoidan-coated particle, all others main-
tained statistically consistent sizes during storage. (b) These particles likewise exhibited statistically consistent
polydispersity index, suggesting that particle uniformity is maintained during storage. (c) The z-average size
measurement, which is more sensitive to aggregates, demonstrated that 7 out 10 formulations exhibited statisti-
cally consistent sizes during storage. (d) Generally, the zeta potential of the nanoparticles was conserved during
storage with a few exceptions. Sulfated beta cyclodextrin-coated particles exhibited a significant charge increase
during storage. On the other hand, hyaluronic acid and dextran sulfate-coated particles exhibited a small, but
statistically significant decrease in zeta potential. Overall these data indicate that LbL particles would be ame-
nable to months-long refrigerated storage without concern of loss of colloidal stability. One-way ANOVA with the
Bonferroni post-test (alpha = 0.01) was used to determine statistical significance between the indicated samples.
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2.3.2. LbL nanoparticle refrigerated shelf-life
The capability to increase the scale, yield and throughput of LbL preparations is an important step
towards realizing clinical translation. Another important factor for translation, which to our knowl-
edge has not been addressed previously for LbL nanoparticles, is their shelf life. We evaluated
whether appreciable destabilization would occur with nanoparticles from our small library during
a three-month storage period in pure water at 40C. We found that LbL nanoparticles broadly
retained their number-average and z-average sizes, as well as their low PDI and high zeta po-
tentials (Figure 2.6). Relative to the freshly prepared nanoparticles, nine out of ten formulations
exhibited statistically consistent hydrodynamic sizes. Using the more aggregate-sensitive size de-
terminant, z-average size, seven out of ten formulations retain their original size. Interestingly, the
PDI of all formulations remained statistically consistent during storage, which may indicate that
size changes are due more to swelling of the film than to aggregation events. Furthermore, the
zeta potential of the LbL nanoparticles remained very high during storage, although some statisti-
cally significant changes were noted. Two formulations (HA and DXS-terminated) exhibited minor
but significant (P<0.05) loss of charge. On the other hand, sulfated beta-cyclodextrin-terminated
particles exhibited a modest (14.9 mV) and significant (P<0.001) increase in magnitude of surface
charge during storage. Overall, these data suggest that LbL formulations are stable on the order
of at least 3 months when stored under refrigerated, aqueous salt-free conditions. Stability is
important because it indicates that these formulations could be kept at-the-ready in clinical set-
tings, and furthermore, could facilitate use in clinical settings by minimizing the need for constant
reconstitution prior to administration.
2.3.3. Freeze-dried, room temperature storage of drug-loaded LbL lipo-
somes
Refrigerated storage can pose its own problems for clinical translation in terms of transporta-
tion and accessibility. Moreover, storing LbL nanoparticles in an aqueous state can allow for the
slow release of encapsulated small molecule drugs. With this in mind, lyophilization and room
temperature storage of freeze-dried powders is ultimately a far more convenient and manage-
able option for clinical and industrial scale operations. 71 To determine if LbL nanoparticles can
survive such storage conditions, the doxorubicin-loaded Lipo-[PLA/DXS] 2 formulation was used
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Figure 2.7. Layer-by-layer (LbL) modified liposomes can be lyophilized and reconstituted for long-term
storage. Doxorubicin-loaded liposomes were coated with two bilayers of poly(L-arginine) and dextran sulfate
(Lipo-[iPLA/DXS] 2), using the TFF-method. (a) Lipo-[IPLA/DXS] 2 nanoparticles were lyophilized with different cryo-
preservatives. (b) TEM of particles before lyophilization (left panel) and after being reconstituted from freeze-dried
powder (right panel). (c) LbL modified liposomes (blue data) retained more drug than bare liposomes (red data)
regardless of choice of cryoprotectant, though several protectants facilitate nearly 100% drug retention during
storage and reconstitution. (d) The presence of cryoprotectants prevents aggregation upon LbL liposome recon-
stitution. (e) Reconstituted LbL liposomes exhibit lower polydispersity index than reconstituted bare liposomes,
indicating improved uniformity. (f) Cryopreservation with 10% sucrose or 11% trehalose prevented decreases in
the zeta potential of LbL liposomes. Size and polydispersity data were acquired by dynamic light scattering, and
zeta potential data was measured using laser Doppler electrophoresis. Error bars represent standard deviation of
three technical replicates.
as a model system for cryogenic storage. LbL liposomes were combined with several different
cryoprotectants (5% glucose, 10% sucrose, 11 % trehalose), and with or without a poly(vinyl al-
cohol) preservative (PVP). LbL-modified and bare liposomes were flash-frozen in liquid nitrogen
and lyophilized to produce a fluffy, cotton-like powder (Figure 2.7a). The powder was kept at room
temperature for a week prior to being reconstituted in pure water.72 The reconstituted particles
were dialyzed overnight and then analyzed to determine if particle integrity or drug encapsulation
had been compromised.
The results indicated that LbL liposomes protected their drug payload better than bare liposomes
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under these storage conditions (Figure 2.7c). In five out of seven conditions, including the cryo-
preservative-free control, statistically significant (P<0.05 or P<0.01) improvements in retention
relative to bare liposomes were observed. Notably, preservation by 5% glucose or 11% trehalose
led to virtually no drug loss in LbL liposomes (97 3% and 97 2% encapsulation, respectively).
The rest of the formulations retained at least 89% of the drug payload, whereas the liposomes
only retained 79-89% of their encapsulated drug after reconstitution.
Generally, we observed that inclusion of PVP was detrimental to overall stability of these nanopar-
ticles. These results are consistent with previous work, which demonstrated that poly(vinyl acid)-
based preservatives fail to adequately stabilize liposomes unless modified.73 In contrast, it has
been seen that PVP is sufficient for protection of polymeric nanoparticles, such as those composed
of poly(dl-lactide-co-glycolide), poly (D,L-lactic acid), and poly(lactic acid-co-ethylene oxide).74 76
Therefore, the presence of a polymeric film on the LbL-coated liposomes may help to explain their
better stability relative to bare liposomes when lyophilized in the presence of PVP.
Cryoprotectants were found to be essential for LbL nanoparticle survival under long-term storage
conditions. Without cryoprotectants, LbL particles undergo irreversible aggregation into micron-
sized particles. With protectants, there is no statistically significant impact on LbL nanoparticle
size after freeze-dried storage (Figure 2.7d, Appendix A Figure 7). On the other hand, the use
of cryoprotectants led to statistically significant (P<0.001) increases in the z-average diameter of
bare liposomes (Appendix A Figure 7). Inclusion of PVP partially rescued liposomes protected
with either glucose or sucrose, but the resulting z-average size was still significantly larger than
the original formulation. Bare liposomes also undergo statistically significant (P=0.001) increases
in PDI after reconstitution, in contrast to LbL liposomes, which retain low PDIs that are statistically
consistent with their original PDI (Figure 2.7e).
Zeta potential measurements of the reconstituted particles indicated that the choice of cryoprotec-
tant was important in preserving the original surface charge on LbL nanoparticles (Figure 2.7f).
Either 10% sucrose or 11% trehalose managed to prevent any decrease in zeta potential for LbL
particles. These results are consistent with prior work, which demonstrated that disaccharides are
more suitable cryoprotectants for lipid-based nanoparticles than monosaccharides.77 Overall this
choice of cryoprotectant is an important characteristic to optimize, as loss of surface charge may
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compromise the reconstituted particle's shelf life or further in vivo stability.
Overall, these results strongly indicate that LbL liposomes can be stably stored under freeze-dried,
room-temperature conditions. This finding has major implications for the clinical and industrial
translatability of this technology, as it would facilitate the stockpiling, shipping and distribution of
future nanomedicines. Our work compared the efficacy of several cryoprotectants head-to-head,
and revealed that 11% trehalose was the most consistent protectant and maintained the size,
uniformity, and charge of our LbL liposomes. Furthermore, preservation by trehalose facilitated
high drug payload retention, with a 97 2% encapsulation of doxorubicin. Notably, LbL liposomes
exhibited superior drug cargo retention compared to bare doxorubicin-containing liposomes, and
could represent a safe and straightforward means towards the improvement of already clinically
approved nanotherapies that may suffer from suboptimal drug-retention under storage.
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2.4. Conclusions and future work
LbL nanoparticles represent a desirable class of materials that are modular, hierarchical, and
multifunctional. These characteristics are critical for the advancement of potent next-generation
nanomedicines. Until now, these materials were difficult to prepare, despite their straightforward
assembly behavior. So far, intermediate purification steps between layer depositions presented
the greatest barrier for both lab scale research and clinical translation. Here we described a
solution to this bottleneck by using tangential flow filtration to handle the cumbersome and time-
consuming washing steps. This approach did not restrict the hallmark versatility of LbL assembly,
allowing us to prepare nanoparticles ranging from 40 to 150 nm from solid polymer, mesoporous
silica, and liposomal substrates. Furthermore, this technique was compatible with several distinct
LbL formulations composed of over a dozen biologically relevant polyelectrolytes. This versatility
was accompanied by rapid purification/processing times, excellent product yields, and control over
important nanoparticle characteristics (e.g., size, uniformity, and surface charge). This approach
has the potential to become fully automated, which would benefit the colloidal LbL community in
a similar way that robotic dipping machines have enhanced research into the LbL modification of
macroscopic substrates. In particular, future work that focuses on incorporating programmable,
robotic operation of TFF devices would provide hands-off synthesis of LbL nanomaterials.
This report also highlights that LbL materials can be stored in aqueous, refrigerated conditions on
the order of months. Additionally, we demonstrate that LbL liposomes loaded with small molecule
drugs, namely doxorubicin, can be stored under freeze-dried, room temperature conditions with-
out compromising drug encapsulation or nanoparticle characteristics. Overall, this work provides
a new path towards ramping up basic research into this important class of drug-delivery vehicles,
as well as a means to scale-up existing and future technologies to the clinic.
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2.5. Methods
Colloidal Substrate And Polyelectrolyte Preparation: The polyelectrolytes poly(L-lysine) HBr
(PLL, 4-15 kDa; Sigma Aldrich), dextran sulfate sodium salt (DXS, 6.5-10 kDa; Sigma Aldrich),
poly(acrylic acid) (PAA, 15 kDa; Sigma Aldrich), poly(L-arginine) (PLA, 9.6 kDa; Alamanda Poly-
mers), poly(L-glutamic acid) (PG, 15 kDa; Alamanda Polymers), poly(L-aspartic acid) (PD, 14
kDa; Alamanda Polymers), poly(L-glutamic acid)-b-polyethylene glycol (PG-b-PEG, 30 kDa PG, 5
kDa PEG; Alamanda Polymers), linear polyethylenimine (PEI, 25 kDa, Polysciences), hyaluronic
acid (HA, 40 kDa; LifeCore Biomedical), sulfated beta-cyclodextrin polymer (18kDa; Cyclodextrin
Technologies), and fucoidan (57 kDa; Santa Cruz Biotechnology) were used without modifica-
tions. Heparin sodium salt (HS, unfractionated; Celsus Labs) was used both unmodified and as
a conjugate with folic acid (Sigma Aldrich) as described previously.78 For additional detail on the
synthesis see Appendix A.
The fluorescent, carboxylate-modified latex nanoparticles (100 nm, blue fluorescent (350/440)
and 40 nm yellow-green fluorescent (505/515); Life Technologies) were used without modification.
Mesoporous silica nanoparticles were prepared according to the protocol for 40 nm particles
described by Zhang and coworkers.79 The procedure was as follows: (i) 1.52 g of hexadecyl-
trimethylammonium bromide (CTAB, Sigma Aldrich), 0.35 g triethanolamine (0.311 mL, Sigma
Aldrich), and 100 mL Millipore water were mixed and heated at 800C for 1 hour, until dissolved.
(ii) 14.6 g of tetraethyl orthosilicate (Sigma Aldrich) was added quickly to the solution, which was
left stirring for another 2 hours. (iii) Particles were isolated by high-speed centrifugation (30,000
x g for 1 hour) and washed once with water and then once more with methanol. Particles were
resuspended in methanol for CTAB extraction (iv) Template removal was accomplished by first
adding 1 mL of 12 M HCI followed by refluxing the solution at 80 0C for 14 hours. (v) The silica
particles were recovered by centrifugation and washed twice with methanol prior to being dried
under vacuum. For LbL preparations, dried silica was reconstituted in Millipore water. The size of
these particles was measured to be 30 10 nm by dynamic light scattering. For the porosity of
these nanoparticles, the reader is referred to the original paper describing this protocol.79
Doxorubicin-loaded liposomes were prepared as follows: (i) 1,2-distearoyl-sn-glycero-3-phospho-
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choline (DSPC; Avanti Polar Lipids), 1 -palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol)
sodium salt (POPG; Avanti Polar Lipids), and cholesterol (Sigma Aldrich) prepared at a 56:5:39
weight ratio were dissolved in a cosolvent of cholesterol and methanol (2:1 volume ratio). (ii)
The solution was evaporated using a rotary evaporator at 40*C at 150 mbar to make a thin lipid
film. (iii) The film was hydrated in 300 mM citric acid buffer (pH 4) under sonication at 650C until
uniform liposomes are generated. (iv) 300 mM sodium carbonate buffer was added into the lipo-
some solution to adjust the pH of the solution to 6.5, which generated a pH gradient between the
buffer solution outside liposomes and the internal environment of liposomes. (v) Doxorubicin HCI
salt (Dox; LC Laboratories) was dissolved at 3 mg mL 1 in sodium chloride solution (154 mM, 0.9
wt/vol %), and the Dox solution was added into the liposome solution under sonication at 650C for
5 min. Dox-loaded liposomes were purified using the TFF system (500 kDa MWCO filter module;
Spectrum Labs) as described below.
Tangential Flow Filtration Assisted LbL Fabrication: Colloidal substrates (CS) and polyelectrolytes
(PE) were dissolved in equal volumes of purified water at a 1:5 mass ratio of CS to PE. Prior to
the first layer deposition, the CS solution was sonicated for 5 minutes and the PE solution for 15
minutes to disrupt any pre-existing aggregates. The CS solution was added to the PE solution
under sonication to generate the PE film. Once mixed, the CS-PE mixture was sonicated for 5
more seconds and incubated on an orbital shaker for 15 minutes. The CS-PE mixture was then
transferred to a 50 mL conical flask (Corning) and connected to a tangential flow filtration (TFF)
device (KrosFlo Research Ili; Spectrum Labs). All connections were made using MasterFlex size
14 Pharma-Pure tubing, with the exception of the tubing that runs through the peristaltic pump,
which is size 16. The TFF was connected to a suitable filtration membrane composed of modified
polyethersulfone, either a 100 kDa MWCO or a 500 kDa MWCO membrane (Spectrum Labs, Mi-
diKros Class) depending on the size of the CS being used. Refer to the supplemental information
for a video showing the experimental set up.
The filter membranes were used exclusively with one charge type to prevent product loss and
membrane fouling. The membrane used to process positively charged nanoparticles is pre-pro-
cessed by recirculating salt-free, cationic PE solution for 10 minutes to mask anionic sites. The
negative-particle membrane is used without further modification.
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The CS-PS mixture was pumped with a constant feed rate (190 mL min- for 500 kDa membrane
and 170 mL min-' for 100 kDa membranes) through the appropriate TFF membrane using a
peristaltic pump. Feed rate was chosen to maintain a transmembrane pressure between 3-5 PSI
and a shear rate below 6,000 s 1. These values were calculated using the provided software and
sensors within the TFF device.
To maintain a constant sample volume during purification, a 2 L buffer reservoir filled with Millipore
water was connected to the sample container. The CS-PE mixture was washed until 5 complete
volumes were eluted (for a 40 mL sample that would be 200 mL of permeate) when using a 500
kDa membrane. With the 100 kDa membrane, 7 complete volumes were eluted. Permeate solu-
tion was collected in sequential 20 mL aliquots to determine purification kinetics as described
below.
After adequate purification, the nanoparticle sample was disconnected from the buffer reservoir in
order to concentrate the pure product down to 20 mL in anticipation for the next layer deposition.
At this stage, samples were taken for characterization of the nanoparticles as described below.
After removing the pure CS sample from the TFF device, another layer was deposited as before,
with an oppositely charged PE solution. During this incubation, filter membranes were briefly
rinsed with water and switched to the appropriate charge-specific membrane for the next purifica-
tion. This process was repeated until reaching the desired number of layers.
Note that the mass ratio of 1:5 for substrate to polyelectrolyte generally yielded stable layer de-
positions, but for certain polyelectrolytes the ratio was shifted until a zeta potential measurement
with a magnitude of at least 40 mV was observed in the unpurified mixture. For example, our CML
cores were used at a 1:5 mass ratio with PLL, whereas we used a 1:3 mass ratio with DXS, which
equates to 10 mg of PLL and 6 mg of DXS being used per layer deposition during the modification
of 2 mg of CML substrates.
Characterizing Purification Kinetics and Yield: Permeate samples were taken from purifications
involving PLL and DXS. To quantify the amount of PLL extracted using the TFF, we directly ana-
lyzed the PLL permeate samples as well as PLL standards using the bicinchoninic assay (BCA;
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Pierce). Absorbance measurements were taken with a TECAN Infinite M200 Pro plate reader and
used to calculate the mass of PLL removed from the system.
The concentration of DXS in the permeate was determined by gel permeation chromatography
(GPC). DXS permeate samples and standards were lyophilized and re-dissolved in the appropri-
ate GPC eluent. The measurements of DXS was performed on an Viscotek GPCmax system
(Malvern) equipped with Agilent PL aquagel-OH columns (PL aquagel-OH Guard 8 pm (50 mm x
7.5 mm), and PL aquagel-OH MIXED-M 8 pm (300 mm x 7.5 mm, exclusion limit > 6x105 g mol- 1))
thermostated to 350C and a refractive index detector maintained at 350C. 100 mM NaNO 3 and
10 mM NaH 2PO4 in aqueous solution at pH 7.4 containing 4:1 (v/v) MeOH was used as mobile
phase with a flow rate of 1.0 mL min-1. The refractive index area (mVmL) of each sample (injection
volume constant at 50 pL) was measured and calibrated against a DXS standard curve.
To determine nanoparticle yields, purified product was weighed in tared conical flasks to deter-
mine recovered sample volume. Then, 10 pL samples of the product were taken and diluted to
100 pL in pure water and analyzed using the Infinite M200 plate reader. Sample fluorescence
measurements (350 nm excitation, 440 nm emission) were compared to standards of known CML
concentration in order to calculate the product yield.
For LbL nanoparticles prepared by centrifugation, instead of processing with the TFF the nanopar-
ticle solution was centrifuged at 15,000 rcf for 15 minutes. Supernatant was removed and spun
again until no nanoparticle pellet was formed, about 6 spins total per layer. Recovered pellets
were gently resuspended in pure water, to avoid dislodging any insoluble aggregates from the
tube wall. HA terminated nanoparticles was spun at 10,000 rcf for 5 minutes to minimize product
loss.
LbI Liposome Lyophilization And Storage: Samples were prepared with cryoprotectant (5% glu-
cose, 10% sucrose or 11 % trehalose; Sigma Aldrich), cryoprotectant plus poly(vinyl alcohol) pre-
servative (PVP, Mowiol 4-88; Sigma Aldrich), or without any stabilizer. Samples were flash frozen
in liquid nitrogen for 15 minutes and lyophilized for 48 hours. The freeze-dried powders were
backfilled with N2 and stored at room temperature on the bench top for a week prior to reconstitu-
tion in pure water (reverse osmosis, MilliQ) followed by an overnight equilibrium dialysis (8 kDa
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MWCO, 4C).
Nanoparticle Characterization: Hydrodynamic size and polydispersity index were measured us-
ing dynamic light scattering (Malvern ZS90 particle analyzer, A = 633 nm, material/dispersant RI
1.590/1.330). Zeta potential measurements were made using laser Doppler electrophoresis with
the Malvern ZS90 as well. All measurements were conducted in water (reverse osmosis, MilliQ).
Cryo-TEM was performed with a JEOL 2100 FEG instrument, and quantitative image analysis
was performed using ImageJ software. For Cryo-TEM, 3 uL of the sample solution was dropped
onto a lacey copper grid coated with a continuous carbon film. The sample was blotted to remove
excess liquid by Gatan Cryo Plunge Ill. The grid was mounted on a Gatan 626 cryo-holder, and
then the specimen and holder tip were cooled using liquid nitrogen. Imaging was performed using
the minimum dose method to prevent damage to the sample by the electron beam. The micro-
scope was operated at 200 kV with a magnification setting of 10,000-30,000 for assessing particle
size and distribution. All images were then recorded on a Gatan 2kx2k UltraScan CCD camera.
Conventional TEM was conducted using either a FEI Tecnai Multipurpose TEM (120 kV) or JEOL
2011 High Contrast Digital TEM (120 kV). Specimens for conventional TEM were prepared by
drop-casting nanoparticle solutions onto mesh copper grid coated with a continuous carbon film.
Drug encapsulation was determined for Dox-loaded nanoparticles by measuring Dox fluores-
cence (500 nm excitation, 600 nm emission) from particle and diafiltrate solutions (50% DMSO)
following an overnight equilibrium dialysis (8 kDa MWCO, 4C) against lyophilization solutions.
Fluorescence measurements were made using the Infinite M200 plate reader.
Cytotoxicity Characterization: SKOV3 (ATTC) ovarian cancer cells were maintained in regular
Dulbecco's modified Eagle medium (DMEM, Corning) supplemented with 10% fetal bovine serum
(Seradigm) and 1 % penicillin-streptomycin (Corning). Cells were seeded in tissue-culture grade
96-well plates (Greiner) at a density of 5,000 cells per well the night before treatment with LbL
nanoparticles. The next day, the cells were incubated in media containing a 20 pM concentration
of LbL nanoparticles. At the reported time points, the cellular viability was determined using the
Cell-Titer Glo luminescence assay (Promega).
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Data Processing And Statistical Analysis:
Purification kinetics data were fit to a one-phase exponential decay model with PRISM software.
The model constrained yO (set to 0), plateau (set to known amount introduced into the system),
and K (must be greater than 0). PRISM was also used to fit a basic linear model to yield data.
One-way ANOVA with the Bonferroni post-test was used to determine statistically significant
differences in most cases (results from this test are annotated in gray on all plots). To assess
statistically significant changes between original nanoparticles and the various cryogenic storage
conditions, one-way ANOVA with the Dunnet post-test was performed. Determinations from this
particular test are denoted in blue (for LbL particles) and red (for bare liposomes) in Figure 7. Un-
less noted otherwise, alpha was set to 0.01 (99% confidence). All tests were conducted in PRISM
software.
Size measurements taken from ImageJ were imported and analyzed in R studio. The data were
visualized as probability density histograms, and overlaid with their kernel density distribution
estimate using the ggplot2 package. Size and charge distribution data exported from the Malvern
Zetasizer software were processed in Microsoft excel to convert the raw data into a frequency
table for import into R studio. The distributions were then plotted using the violinplot functionality
of the ggplot2 package to produce the figures seen in the supplemental documentation.
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Chapter 3. Discovery of ovarian cancer targeting surface
chemistries through a library approach
Surface chemistry plays a crucial role in determining tumor-targeting abilities of nanoparticle drug
carriers, but this role remains poorly understood. Notably, there are few studies that system-
atically inspect diverse and complex surface chemistries. In light of this, we report a methodical
study of colloidal surface chemistry and its role in targeting ovarian cancer both in vitro and in a
metastatic murine model. Using the layer-by-layer (LbL) assembly method, we varied the surface
chemistry of 100 nm polystyrene nanoparticles in order to study ten different sulfated or carboxyl-
ated surfaces that span native polypeptides and polysaccharides. We report that carboxylated
LbL nanoparticles shared an intrinsic affinity toward ovarian cancer cells, whereas sulfated LbL
and non-LbL carboxylated formulations mediated poor binding. Despite this shared affinity, the
various carboxylated LbL nanoparticles maintained distinct subcellular fates. These insights led
to the discovery of several promising tumor-targeting LbL coatings as well as principles to guide
the future design of therapeutic nanoparticles.
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3.1. Introduction
Nanoparticle (NP) drug delivery vehicles can preferentially steer drugs to neoplastic tissue1 and
deliver therapeutic cargos that were previously undeliverable2 . The advantages that nanoparticles
bring to the table ought to lead to meaningful improvements for cancer therapy, where these capa-
bilities can directly translate to improved efficacy, safety and the development of next-generation
therapies, like combined RNAi and chemotherapy . But the clinical success of nanomedicines
has been frustrated by their inability to improve efficacy over free-drug formulations - although
meaningfully reduced toxicities are often noted5 7 . Clinical studies do indicate that nanoparticles
improve drug accumulation in neoplastic tissue relative to surrounding healthy tissue8 -9, but it also
appears that the overreliance on passive targeting strategies and the enhanced permeability and
retention (EPR) effect has contributed to lackluster drug delivery in humans 10-11 . The next steps for
nanomedicine require exploration of alternative targeting strategies, including new approaches
for active targeting tailored to the unique challenges and opportunities posed by specific cancers.
Active targeting has been a topic of extensive research, largely focused on chemical conjuga-
tion of targeting ligands onto colloids1 2 . More often than not, the surfaces of these particles are
PEGylated to improve EPR-mediated passive targeting. It is not surprising, then, that systematic
studies of NP surface chemistry - and the role surface chemistry plays in tumor targeting - have
primarily focused on varying ligand and PEG brush density1 17 . But there is a much broader
parameter space beyond this to consider.
The surface of a nanoparticle ultimately interfaces with soluble factors, cellular membranes and
extracellular matrix, all of which form sophisticated interactions with one another. But the rich
physiochemical diversity in biological systems is not reflected in the surface chemistries used by
most NPs. Part of the problem is that we do not know how to deploy complex surface chemistries
to achieve a particular outcome, because there are few systematic studies that compare truly
different surface chemistries- 20
One reason for the dearth of studies into this area may be the difficulty of installing complex
biopolymers onto colloids using covalent conjugation techniques. To overcome this issue, we use
the layer-by-layer (LbL) assembly method to systematically study nanoparticles bearing diverse
surface chemistries. The LbL technique allows traditional colloidal substrates as small as 10 nm
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(e.g., liposomes, mesoporous silica nanoparticles, and poly(lactic-co-glycolic acid) nanoparticles)
to be functionalized with multilayered, nanoscale polymeric films through the sequential adsorp-
tion of polyelectrolytes of alternating charge21- 22. The process is mediated by electrostatic interac-
tions, making it compatible with an extensive list of bioactive and biocompatible polyelectrolytes
(e.g., polysaccharides, polypeptides, nucleic acids). As a result, the technique is able to incorpo-
rate materials of significant chemical complexity without the need to develop similarly complex
chemical conjugation techniques. And recent advances in the scale and throughput of LbL NPs
now make it possible to study many more formulations than was previously feasible23 24 .
The modular nature of the LbL platform allows us to de-couple the role of different elements of
the nanoparticle. This makes the LbL-NPs an ideal tool for systematic appraisal of the numerous
parameters that influence nanoparticle engagement with cells and the body. In a previous study,
we used the LbL technique to homogenize the surface chemistries of several disparate core sub-
strates to better discern the effects of size and shape on the biodistribution of NPs in models of
ovarian cancer25 . Here, we shift our focus toward surface chemistry by functionalizing fluorescent,
100 nm carboxylate-modified latex (CML) nanoparticles with ten distinct LbL films. We used this
panel of LbL NPs to disentangle the role of surface chemistry in mediating binding and internaliza-
tion across a panel of ovarian cancer cells, normal stromal cells, and normal immune cells.
We focus this study on ovarian cancer (OvCa) because it presents particular drug delivery chal-
lenges. OvCa is characterized by the rampant spread of smaller tumors throughout the intraperito-
neal (IP) space. Free-floating tumor spheroids often form that can subsist from nutrients available
in the IP fluid, making some tumors difficult to access via systemic delivery routes - essentially
establishing a protected reservoir of cancer cells 26 . However, the confinement of metastasis to
the IP cavity also provides a unique opportunity to explore IP-administration routes of NPs, an
approach that is already showing clinical benefits in the administration of free-drugs 27 -29{Wright,
2015 #251;van Driel, 2018 #252;Narod, 2016 #253}.
Our results reveal a fascinating capability for carboxylated LbL nanoparticles to bind preferentially
to ovarian cancer cells in vitro and in vivo, a capability not shared with non-LbL carboxylated
NPs and sulfated LbL formulations. In this work, we explore both systemic and IP routes, and
report significantly higher NP accumulation in neoplastic tissue following IP-administration. Our
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approach identified several surface chemistries with no known ligand-binding capabilities that
have cancer cell affinities comparable to NPs with well-documented active targeting mechanisms.
Notably, we also document the subcellular trafficking of these NPs and ovarian cancer cells' im-
pressive ability to distinguish between even highly similar surface chemistries. Overall, this work
provides a framework for future studies that leverage the versatility and compatibility of the LbL
platform toward more systematic assessment of critical nanoparticle parameters.
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3.2. Results: Surface chemistry dictates LbL nanoparticle affinity for
ovarian cancer cells
LbL NPs were synthesized to explore the role of different sulfated and carboxylated surfaces on
nanoparticle-ovarian cancer cell interactions. CML cores were first coated with poly(L-arginine)
to establish a cationic polymer film suitable for subsequent layering of polyanions (Figure 3.1a).
The two chemistry families were then fabricated through the electrostatic adsorption of a variety
of natural and synthetic polyelectrolytes (Figure 3.1a, right panel). The carboxylate (COOH)
family includes LbL nanoparticles terminated with the polysaccharide hyaluronic acid (HA), which
binds to several known ligands overexpressed on ovarian cancer including the CD44 protein3 .
The sulfated (SO 3) family includes the polysaccharide heparin sulfate (HS), which has a variety
of biological binding partners that include growth hormones and differentiation factors enriched
in certain cancers31. The sulfated family also contains a derivative of HS that bears folic acid
pendant groups (HF) to target folic acid receptor, also known to be overexpressed on ovarian
cancer3 1. The LbL-NPs prepared for this study possess average hydrodynamic diameters ranging
from 100 to 155 nm and average polydispersity indices between 0.04 and 0.13 (Figure 3.1 b). And
consistent with successful layering, we observe charge reversal during the deposition of the first
PLR layer (-61 1 mV to +63 2 mV) followed by another charge reversal (ranging from -51 mV to
-75 mV) after deposition of the final anionic layer (Figure 3.1 c). The nanoparticle morphology was
assessed using TEM, where all formulations appeared well dispersed and within the size ranges
predicted by light scattering techniques (Appendix B Figure 1).
The surface chemistry family (e.g., COOH or SO3) had an outsize role in determining binding
affinity between the various LbL NP formulations and ovarian cancer cells, where COOH-LbL-
NPs exhibited an intriguing OvCa-targeting behavior. The binding affinity of the LbL NPs was
determined using flow cytometry to measure increases in NP-associated fluorescence for cells
incubated with the NPs for 4 or 24 hours (Figure 3.1d-e). A panel of ten human ovarian cancer
cell lines (Caov3, COV318, COV362, Fuov1, JHOS2, JHOS4, OVCAR3, OVCAR4, OVCAR8,
and SKOV3) were tested, as well as a subset of healthy cells consisting of induced pluripotent
stem cell (iPSC)-derived endothelial cells and primary immune and stromal cells isolated from
fresh murine spleens. The median NP-associated fluorescence intensity (MFI) for each cell was
normalized by the MFI of untreated cells to obtain a MFI ratio (MFR), which corresponds to the ex-
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Figure 3.1. Layer-by-layer nanoparticles (LbL-NPs) with carboxylated terminal layers interact preferen-
tially with ovarian cancer cells, in contrast to LbL-NPs with sulfated terminal layers and carboxy-modified
latex (CML) nanoparticles. a) LbL-NPs were prepared from a fluorescent 100 nm CML core template by adsorb-
ing a cationic layer of poly-L-arginine followed by adsorption of one of ten different terminal anionic polymers.
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Figure 3.1 continued: b) LbL-NPs retain similar size and monodispersity relative to the CML template, and c)
exhibit charge reversal upon adsorption of each layer as expected with the LbL technique. Size and polydispersity
data were acquired by dynamic light scattering, and zeta potential data were measured using laser Doppler elec-
trophoresis. Error bars represent standard deviation of three technical replicates. To determine the role of LbL-NP
surface chemistry on cell-binding, LbL-NPs were incubated with a panel of ten human ovarian cancer cell lines
and seven noncancerous primary cells and analyzed using flow cytometry to quantify increases in nanoparticle-
associated fluorescence after d) 4 hours and e) 24 hours. Sulfated LbL-NPs bound less to cancer cells at 4 hours,
and showed a highly variable binding by 24 hours. On the other hand, carboxylated LbL-NPs bind more efficiently
to cancer cells by 24 hours and exhibit significantly higher enrichment in cancer cells relative to noncancerous
cells. f) Hierarchical clustering of LbL-NP binding data leads to a grouping of formulations by their surface chemis-
try, with the exception of the core CML template that behaves more similarly to sulfated LbL-NPs. g) Clustering of
NP-binding data in noncancerous cells does not lead to surface chemistry-based groupings.
tent of nanoparticle bound to the cells. The results shown group all OvCa lines and healthy cells.
After 4 hours, COOH-LbL-NPs bind well to both OvCa (average MFR of 10 to 42) and healthy
(average MFR of 6 to 49) cells. On the other hand, at 4 hours SO-LbL-NPs have low overall bind-
ing in OvCa cells (average MFR of 3 to 6) and a higher but more variable uptake in healthy cells
(average MFR of 4 to 22) (Figure 3.1d). The unmodified CML cores, which are simply decorated
with carboxylate groups, behaved very differently from the COOH-LbL-NPs, and accumulate to a
lesser extent with an average MFR of only 4 for OvCa cells and 5 for healthy cells.
By 24 hours, the COOH-LbL-NPs are enriched in OvCa cells (average MFR of 76 to 595) relative
to healthy cells (average MFR of 13 to 71), and despite the variability amongst the different OvCa
and healthy cell lines this finding was significant with a p value <0.0001 (one-way ANOVA, Bonfer-
onni post hoc test, Figure 3.1e). This behavior does not extend to SO3-LbL-NPs, where uptake is
highly variable among OvCa cells, and while these NPs accumulate more in OvCa cells (average
MFR of 18 to 191) relative to healthy cells (average MFR of 5 to 22) the difference was not statisti-
cally significant. Surprisingly, HA and HF-coated NPs did not bind to OvCa cells as efficiently as
formulations with no known receptor-binding abilities. For example, HA-coated NPs on average
exhibited a 154-fold increase in MFI, but poly(L-aspartate) (PLD)-coated NPs had an average
MFI increase of 595-fold. HF-coated NPs (average MFR of 72) improved their uptake relative
to HS-coated NPs (average MFR of 19), but were outperformed by sulfated beta cyclodextrin
(SBC)-coated and fucoidan-coated NPs (average MFR of 107 and 192, respectively). Interesting
results involving the SBC-coated NPs and endothelial cells were noted, and are discussed in
Appendix B. These results suggest that while inclusion of a targeting ligand can improve tumor
targeting, their contribution to binding affinity may be overshadowed by the contribution from the
surface chemistry of the terminal layer (e.g., COOH or SO3 ). Importantly, unmodified CML cores
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behave more like SO-LbL-NPs even at 24 hours, with an average MFR of 50 for OvCa and 29
for healthy cells. This result indicates a special role for the LbL film in mediating the interactions
observed with COOH-LbL-NPs, which may explain why prior studies of carboxylated inorganic
cores do not observe elevated cell-binding properties. It is also possible that the affinity towards
COOH-LbL-NPs is based on biology particular to ovarian cancer cells.
Hierarchical clustering of the uptake data provides additional confirmation of a surface chemistry
effect on NP-binding for OvCa cells (Figure 3.1f), but not healthy cells (Figure 3.1g). The MFR
data for both time points were used to generate a clustered heatmap using the heatmap.2 func-
tion in the gplot package on RStudio. Clusters were calculated using the default function settings.
For the OvCa cells, the NP formulations primarily cluster together in an order that corresponds
to their surface chemistry. The exception to this is the CML core, which clusters along with the
So3-LbL-NPs. The clusters generated for the healthy cells do not order the formulations based on
their surface chemistry, supporting the notion that ovarian cancer cells may possess an affinity for
certain surface chemistries that are not shared by the healthy cells assayed here.
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3.3. Results: Carboxylated LbL nanoparticles mediate distinct subcel-
lular trafficking routes
Subcellular localization of NPs determines the types of drugs that can be delivered with a given
formulation. And while our flow cytometry study indicated NP-association with cells, it did not
provide insight into the role that surface chemistry plays in determining the subcellular fate of the
different formulations tested. To answer that question, we performed live cell confocal microscopy
on JHOS4 ovarian cancer cells that had been incubated with 20 pM NP concentrations for 24
hours. The findings from this study generally confirmed the observations from flow cytometry
(e.g., improved accumulation with COOH-LbL-NPs relative to CML and SO3-LbL-NPs), but also
revealed distinct subcellular fates particular to the two surface chemistry families.
At 24 hours, COOH-coated LbL NPs without a targeting ligand (PLD, poly(L-glutamate) (PLE),
poly(ethylene glycol-b-poly-L-glutamate) (PEG-PLE), and polyacrylate (PAA)) were often associ-
ated with the cell membrane (Appendix B Figure 2a). PEG-PLE and PAA-coated NPs were al-
most entirely surface-bound, whereas PLD and PLE-coated NPs were both internal and external.
HA, on the other hand, is generally internalized at this time point, which we hypothesize is due
to its CD44-binding capabilities. In contrast, the unmodified CML core is much less abundant but
also generally internalized. The SO 3-LbL-NPs are not bound to all cells, consistent with the high
variability seen by flow cytometry (Appendix B Figure 2b). But when they are bound, they are
generally internalized - with the exception of fucoidan-coated particles which appear primarily on
the surface of JHOS4 cells.
Of note, the PLD and PLE-coated NPs exhibited a remarkable affinity for ovarian cancer cells,
leading to 4.5 to 5.5-fold more nanoparticles per cell than the HA-coated particles (Appendix
B Figure 2c). Flow cytometry results of other ovarian cancer cell lines consistently recapitu-
lated this trend (Figure 3.2a). The reproducibility and magnitude of this observation led us to
hypothesize that some unknown specific binding interaction may be occurring between these
polypeptide-coated systems and ovarian cancer cells. Efforts to determine apparent dissociation
constants (Kdapp) through a saturation binding isotherm confirmed that PLD, PLE, and HA-coated
NPs possess a high binding affinity for OVCAR8 ovarian cancer cells, whereas unmodified CML
core, dextran sulfate (DXS)-coated and PEGylated NP controls exhibit binding curves typical to
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Figure 3.2. Carboxylated LbL-NPs have improved binding to ovarian cancer cells, but possess distinct sub-
cellular localization despite their similar surface chemistries. Flow cytometry analysis indicates that LbL-NPs
terminated with the carboxylated polymers poly-L-aspartate (PLD), pol-L-glutamate (PLE) and sodium hyaluro-
nate (HA) bound to a) COV362 and Caov3 ovarian cancer cells to a much greater extent than dextran sulfate
(DXS)-terminated LbL-NPs and the unmodified carboxylated latex core. b) A binding saturation isotherm experi-
ment was conducted to estimate apparent Kd values for these nanoparticles. The results indicate a strong specific
interaction for the PLD and PLE-coated systems with respective Kd values of 6.8 1.6 and 6.2 2.2 pM. HA-coated
NPs had a Kd value of 18.7 18.4 pM. DXS-coated, PEGylated and unmodified CML cores could not be fit to the
model, but the shape of their curve suggests a nonspecific binding interaction. c) Confocal microscopy of OVCAR8
ovarian cancer cells demonstrate a minimal accumulation of DXS-terminated LbL-NPs, which are internalized at
24 hours. Nuclei are psuedocolored cyan, lysosomes are red, actin is blue, and nanoparticles are in green. d) HA-
terminated LbL-NPs accumulate to a much greater extent, and are mostly internalized at 24 hours. c) In contrast,
PLE- coated LbL-NPs have a significant fraction of bound nanoparticle retained on the surface of the cell at 24
hours. d) PLD-coated systems presented a distinct subcellular trafficking pattern relative to the highly similar PLE-
coated particle, resulting in a sizeable fraction of internalized and surface-bound nanoparticles at 24 hours. Scale
bars indicate 10 micrometers. Error bars in b) represent SEM, error on the apparent Kd value are SEM.
nonspecific interactions (Figure 3.2b). Further study is needed to determine the binding mecha-
nisms between PLE/PLD and OvCa cells, but a potential clue may come from prior studies that
indicate carboxylated polymers are mucoadhesive33-34 , and since OvCa cells have been found to
overexpress a variety of mucins35 it warrants further study.
While PLE and PLD-coated NPs bind to OvCa cells with a high affinity, their subcellular fates
were distinct from HA, and even from one another. We confirmed that the unique morphologi-
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Figure 3.3. Surface chemistry on LbL NPs shapes subcellular fate and influences the partitioning of NPs on
the membrane and on the interior of OVCAR8 cells. Cells were treated with 20 pM LbL NP for 24 hours and then
fixed and processed for super resolution microscopy. Wheat germ agglutinin (WGA) was used to stain membranes
(including outer membrane, vesicular membranes and the nuclear membrane) and is shown in red.
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Figure 3.3 continued: Nanoparticles are shown in green and nuclei in blue. Scale bars denote 10 microns, with
the exception of the scale bar for the detail panels, where they denote 1 micron. a) Dextran sulfate (DXS)-coated
NPs are observed on the interior of the cell within vesicular structures. b) Sodium hyaluronate (HA)-coated NPs
are found in enlarged vesicles within the cell, but also in small punctate spots on the membrane surface as indi-
cated with white arrows. c) Poly-L-glutamate (PLE)-coated NPs are observed inside enlarged vesicles, but with
a considerable fraction on the membrane with a seemingly diffuse morphology as indicated by the arrows. d)
Poly-L-aspartate (PLD)-NPs are found both inside enlarged vesicles and on the membrane. However, PLD-NPs on
the membrane appear more as punctate structures as indicated by arrows in the detail row.
cal features observed in the JHOS4 cell line could be reproduced in COV362 and Caov3 cells
through additional live cell imaging studies (Appendix B Figures 3-4). And we also confirmed the
unique surface-bound morphology in fixed cell confocal imaging studies using the OVCAR8 cell
line (Figure 3.2c-f). In general, HA-coated NPs are mostly internalized in these cells, PLD-coated
NPs exhibit punctate localization both inside and on the cell membrane, and PLE presents with a
seemingly fibrous surface coating as well as some punctate internalization.
We continued to study the subcellular trafficking of these NPs in OVCAR8 cells through a sys-
tematic confocal microsopy study to inspect co-localization of NPs with key organelles such as
early endosome (EEA1 or RAB5+), caveolae (CAV1 +), clathrin-coated vesicles, late endosomes
(Rab7+), lysosomes (Lamp1 +), and trans golgi (RCAS1 +) (Appendix B Figures 5 and 6). These
initial studies indicated that NPs that are internalized by 24 hours are almost entirely in the late
endolysosomal compartment (Appendix B Figure 5i-p). However, for the PLE and PLD-coated
NPs we observed frequent co-localization with caveolae for surface-bound NPs (Appendix B
Figure 5c-d). Intriguing but inconclusive data demonstrating NPs near the trans golgi stacks for
COOH-LbL-NPs were also noted (Appendix B Figure 5r-t).
To improve the conclusiveness of these studies, a similar set of co-localization experiments was
repeated using super resolution microscopy (Figure 3.3, Appendix B Figures 7-10). The im-
proved dynamic range of this approach revealed a previously undetected, smaller subset of HA-
coated particles that were surface-bound (Figure 3.3b) and associated to caveolae (Appendix B
Figure 8b). Super resolution microscopy also further confirmed an enriched surface-bound frac-
tion for PLD and PLE-coated particles (Figure 3.3c-d). However, while this fraction was typically
associated to caveolae for PLD (Appendix B Figure 8d), the membrane-bound PLE-NPs did not
necessarily always co-localized with caveolae (Appendix B Figure 8c). And while trans-golgi
co-localization was ultimately not observed, the vesicles containing COOH-NPs were often found
very near or between trans golgi stacks (Appendix B Figure 10).
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Figure 3.4. LbL-NP surface chemistry deter-
mines uptake pathways in OVCAR8 cells, in-
dicating a shared role for ATP and lipid-raft
mediated internalization as well as pathways
unique to each formulation. a) OVCAR8 cells
were pretreated with endocytosis inhibitors prior
to a 4-hour incubation with LbL-NPs, followed by
flow cytometry analysis. Poly-L-aspartate (PLD)-
coated NPs depended upon caveolar uptake, and
may be involved in macropinocytosis and clathrin-
mediated processes, although those trends were
not statistically significant. Notably, none of these
pathways impact uptake of PLE. And while not
statistically significant, HA appears to be impacted
by most inhibitors except for caveolar inhibition.
b) OVCAR8 cells incubated with LbL-NPs for 24
hours were depleted of cholesterol using methyl
beta cyclodextrin prior to analysis by flow cytom-
etry. Removal of cholesterol causes a significant
decrease in nanoparticle-associated fluorescence
in cells incubated with PLE-coated LbL-NPs. Error
bars represent SEM, and statistical analysis was
performed using one-way ANOVA test with a
Dunnett post-hoc test and an alpha of 0.5.
These LbL-NPs were then tested on patient-derived xenograft (PDX) spheroids grown briefly (2
days) in culture. Flow cytometry on the dissociated spheroids and confocal microscopy of the
intact spheroids provide evidence consistent with what we observed with the established cell
lines (Appendix B Figure 11). Namely, that the COOH-LbL NPs possess a strong affinity for
ovarian cancer cells, whereas sulfated LbL-NPs do not. However, even the COOH-LbL NPs do
not penetrate into the spheroids, as indicated by a nanoparticle-negative population in the flow
cytometry results.
During the microscopy studies, it was noted that PLE-treated cells permeabilized with saponin
(all intracellular stains except caveolar) exhibited less membrane-bound nanoparticles than prior
experiments that used triton-based permeabilization. This difference indicated a potential role
for lipid rafts in the binding and trafficking of the COOH-LbL-NPs, because saponin acts to spe-
cifically remove cholesterol from the membrane 36 -37. To investigate this, as well as other uptake
mechanisms, we performed an uptake-inhibition study to probe the relative roles of ATP, caveo-
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lar, clatherin, macropinocytosis, and cholesterol-mediated uptake in OVCAR8 cells (Figure 3.4).
Cells were pre-treated with inhibitor and then co-treated with LbL-NPs for 4 hours prior to flow cy-
tometry analysis (Figure 3.4a). We observed that ATP and cholesterol-mediated processes were
critical for the uptake of all NPs tested. But interestingly, only PLD-coated NPs were dependent
on caveolar uptake - potentially indicating their role in internalizing these particles but not in the
internalization of HA or PLE.
In a similar experiment, OVCAR8 cells were incubated with LbL-NPs for 24 hours and then treated
with methyl-beta cyclodextrin to deplete cholesterol, in order to determine if at later time points
the NPs associate with cholesterol-rich portions of the cell membrane. Notably, the PLE-treated
cells bear significantly fewer nanoparticles after cholesterol depletion. Surprisingly, HA-treated
cells see a smaller but statistically significant impact, whereas PLD-treated cells are unaffected
(Figure 3.4b). These results suggest an early role for cholesterol in the uptake of PLD, where the
NP may be associated with cholesterol-rich regions of the cell membrane. But at later time points,
that association appears to fade. On the other hand, PLE appears to be highly associated with
cholesterol throughout the time points studied. These differences among COOH-LbL-NPs are
remarkable, particularly in the context of the PLE and PLD formulations, which differ by a single
methylene group.
These results suggest an exquisite sensitivity to surface chemistry among ovarian cancer cells,
which translates to unique subcellular fates for even highly similar formulations. Each of these
formulations presents interesting opportunities from a drug delivery standpoint. PLE, for example,
has applications for presenting therapeutic compounds on the surface of cancer cells, such as
immunostimulatory cytokines and polymers. PLD-coated systems, on the other hand, present
opportunities for nanoparticles to perform both intracellular and extracellular functions. HA-coated
systems have clear benefits for drugs that require internalization, like siRNA and mRNA. Overall,
this indicates how a systematic study of surface chemistry using the LbL platform can supply
researchers with useful new formulations and nanoparticle design insights.
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3.4. Results: Carboxylated LbL nanoparticles improve biodistribution
in a orthotopic model of ovarian cancer
Ovarian cancer presents particular challenges and opportunities from a drug delivery perspective.
The ability for OvCa spheroids to form and subsist from the nutrient-rich IP fluid creates a protect-
ed population of tumor cells, and evidence suggests these cells possess the stemlike properties
needed to regenerate tumors 26 . But although OvCa metastasizes widely through the IP cavity, it
rarely spreads outside of this space8 . It also has the unique characteristic of growing superficially
on organs rather than penetrating the mesothelial lining to invade those tissues 26 . As a result,
OvCa may benefit from IP-administration of therapeutics moreso than other malignancies, and
in fact clinical trials with free-drug therapies have found benefits to this approach. Nanoparticles
50-720 nm administered IP are known to be readily cleared into the lymphatic drainage, driving
NPs directly into the thoracic lymph duct where they can be readily scavenged39. But recent work
demonstrates that NPs with avid binding to the mesothelium are able to coat the lining of the IP
space and serve as local drug depots40. Given the avidity of our NPs to OvCa cells in vitro, we set
out to compare how IV and IP administration alters the biodistribution of COOH-LbL-NPs, control
sulfated LbL NPs (DXS), PEGylated NPs, and unmodified CML cores.
We observed that IP administration confers a significant improvement in NP association with
neoplastic tissues in an orthotopic model of metastatic ovarian cancer (luciferized/mCherry ex-
pressing OVCAR8 cells). Tumor-bearing mice were injected IP or IV with infrared-fluroescent LbL
NPs, PEGylated NPs or unmodified CML NPs. After 24 hours, the mice were sacrificed and the
bioluminescence and infrared fluroescence of each organ was measured using an IVIS imaging
device. Systemically administered NPs were present in most metastatic nodules and in parts of
the primary tumor masses (Appendix B Figures 12-17), and of note the PLD-coated NPs ap-
peared to co-localize particularly well. But after IV administration, the bulk of the NP dosage was
observed in the liver for LbL-NPs and CML cores, and in the liver and spleen for the PEGylated
NPs. On the other hand, the IP-administered NPs co-localize with neoplastic tissues but also
accumulate to a much greater extent for all NPs tested (Appendix B Figure 18). PEGylated and
unmodified CML NPs accumulate to a lesser extent than all the LbL-NPs, and notably PEGylated
NPs are detected diffusely throughout the liver and spleen, suggesting they are being cleared
into the lymphatics and are penetrating the blood compartment where they can be scavenged by
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Figure 3.5. Tracking biodistribution over 72 hours shows a durable enrichment of COOH LbL-NPs in neoplas-
tic tissue relative to dextran sulfate-coated and PEGylated NPs. NPs were administered IP to murine models
of metastatic ovarian cancer, and a) infrared fluorescence from the nanoparticles were measured for each organ
using an IVIS imaging device at the indicated time points. For CML core images, reference Appendix B Figure 12. b)
Quantification of percent recovered NP fluorescence per gram of tissue indicated that LbL NPs had significant and
improved accumulation in neoplastic tissue relative to PEGylated control NPs. Notably, unmodified CML cores did
not significantly differ from PEG controls. c) At 48 hours, NP enrichment decreases for all NPs, but PLD and HA-NPs
retain significant improvements over PEGylated controls. Notably, PLD-coated NPs are also significantly improved
relative to PLE and DXS-coated systems at this time point. d) At 72 hours, all the COOH LbL-NPs demonstrate
significantly improved tumor accumulation relative to both DXS and PEGylated controls. While not statistically
significant in these data, it is interesting to note that the PEGylated control NP accumulates more in the liver and
spleen than any LbL-NP, especially after 24 hours.
phagocytic cells. Unexpectedly, the DXS-coated NPs associate well with tumors at this time point,
in contrast to our in vitro observations.
Although surface chemistry did not appear to shape LbL-NPs interactions with tumor tissues at 24
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hours, the contribution from surface chemistry becomes more apparent at later time points. LbL-
NP and PEGylated NP biodistribution was measured at 48 and 72 hours after IP administration
in tumor bearing mice, using the same approach as in our IV and IP comparison study (Figure
3.5). We noted a less variable biodistribution profile emerged beginning at 48 hours, around
which time we also note that PEGylated NPs begin to spill significantly into the liver and spleen
compartments. It is likely that the antifouling properties of the PEG NPs prevents binding and
internalization into tumors, and thus the NPs are eventually cleared into the lymphatics where
they can be efficiently scavenged by the phagocytic cells of the liver and spleen. We also note that
at these later time points the results fall in line with our earlier in vitro observations on the role of
surface chemistry, with COOH-LbL-NPs systems providing improved tumor localization relative to
the DXS-coated control particle (Figure 3.5c-d). By 72 hours, the COOH-LbL-NPs were broadly
retained in the tumor tissue, whereas DXS-coated NPs and PEGylated NPs are cleared. Promis-
ingly, LbL-NPs administered IP do not accumulate in off-target tissues even at later times, which
would suggest that these NPs avoid lymphatic drainage into the blood compartment. The extent
to which NP signal is observed in off-target organs is almost always co-localized to a metastatic
lesion (Appendix B Figures 19-23). On the other hand, PEGylated nanoparticles clear into the
liver and spleen by 48 and 72 hours. This leads to a ca. 4 and 3-fold increase in recovered
nanoparticle signal from liver and spleen of PEG NP-treated mice relative to the liver and spleens
from LbL NP-treated mice (average of all COOH-LbL-NPs) by 72 hours. This biodistribution profile
indicates that the COOH-LbL-NPs may provide a highly selective delivery of drugs to tumor tis-
sue when administered IP, potentially allowing for the delivery of drugs with narrow therapeutics
windows.
Histological and whole-tissue imaging modalities were used to determine if LbL-NPs are able
to penetrate tumor tissue when administered IP, and in general indicate that while these NPs
are enriched on the tumor surface, they do penetrate as far as 100-300 microns. Histological
samples obtained from these biodistribution experiment indicate that IP-injected NPs accumulate
on the surface of tumors at 24 hours (Figure 3.6a). It was also noted that extensive handling and
processing steps used to prepare histological samples from formalin-fixed tissue led to significant
loss of NP in the tissue, leaving many surface regions of the tumors bare. Cryohistology of PLE-
NP treated mice indicates a more uniform coating exists on pristine tissues, but cryohistology was
not carried out for all other conditions and time points (Appendix B Figure 24). Nonetheless, the
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Figure 3.6. LbL-NPs penetrate into tumor tissue and may be aided by receptor-ligand interactions. Tumors
from the prior biodistribution study were fixed and preserved for histology or for multi-photon whole-tissue imag-
ing. a) Tissue sections 24 hours after IP-administration of nanoparticles shows enrichment of nanoparticles on the
periphery of the tumor, with some penetration into the tissue. Red and blue signal are psuedocolored auto fluo-
rescence from H&E staining, green signal indicates nanoparticle. Scale bar on the first image indicates 100 microns
for all histological images. b) Representative slices and orthogonal views of z-stacks acquired from whole-tumor
imaging using multi-photon microscopy. Blue signal corresponds to the second harmonic autofluorescence from
collagen, red corresponds to the mCherry signal from tumor cells, and green signal is from nanoparticles. c) The z-
stacks from multi-photon imaging were quantified to measure the deepest NP penetration into tumor tissues. HA-
coated NPs penetrated the deepest into tissue with an average depth of 200.0 23.4 microns. While DXS-coated
NPs had more variable penetration, their penetration was not significantly different from the PLE or PLD-NPs.
Because HA-NPs have a known receptor ligand interaction, it is possible that this is mediating deeper distribution
into the tumor.
remaining particles in the more complete formalin-fixed dataset indicate what we believe to be
a reliable representation of nanoparticle distribution within the tumor. Additional studies on intact
formalin-fixed tumors from the 72 hour timepoint were performed using multi-photon microscopy
to more accurately assess tissue penetration depth (Figure 3.6b). The LbL-NPs were detect-
able on the multi-photon microscope at both a normal fluorescence channel catching the tail-end
of the NP emission spectra (Cy5.5) and more clearly at a shorter wavelength channel (DAPI)
capturing a multi-photon event from these NPs. In the z-sections examined, the LbL NP average
penetration depth ranged from 97.5 to 200 microns, with HA-coated NPs managing to mediate
deeper penetration. Quantification of these images indicated that PLD, PLE, HA, and DXS-coated
NPs achieved average penetration depths of 125.0 12.1, 114.5+9.6, 97.5+17.5, and 200.0 23.4
microns, respectively (Figure 3.6c). Notably, the PEGylated nanoparticles were not detectable on
the multi-photon at laser powers that avoided significant tissue autofluorescence, and thus could
not be quantified. The results from whole-tissue imaging provide a more complete picture of NP
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penetration, indicating the ability for LbL-NPs to navigate into tumor tissue after IP-administration.
They also suggest a potentially important role in the ligand-binding capabilities of HA-coated NPs,
which perhaps help to mediate the improved tissue penetration depths observed here. Overall,
this indicates LbL-NPs, particularly ones with carboxylated terminal layers, can selectively coat
and to an extent penetrate OvCa tumors following IP administration. This strategy could be used
to develop new nanomedicines that leverage both the relatively high dose achieved on the tumor
surface and the ability to minimize spillover to other organs and tissues.
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3.5. Conclusions and future work
This work demonstrated the potential of using the LbL self-assembly method to systematically
screen surface chemistries for affinity towards ovarian cancer. Ten unique surface chemistries
were studied that consisted of either sulfated or carboxylated species, including a variety of natu-
ral polymers such as polysaccharides and polypeptides. Notably, this study identified a unique
affinity between carboxylated LbL nanoparticles and ovarian cancer cells, an affinity that was not
recapitulated with polystyrene nanoparticles simply functionalized with carboxylates. Carboxyl-
ated LbL nanoparticles also stood apart from their sulfated counterparts, which generally medi-
ated relatively poor and nonspecific binding interactions with ovarian cancer cells. Interestingly,
the binding of carboxylated LbL nanoparticles to healthy cells was not significantly enhanced rela-
tive to sulfated systems, indicating that biology particular to ovarian cancer cells might mediate
this improved uptake. Notably, while carboxylated LbL nanoparticles exhibited improved binding
as a family, the subcellular trafficking patterns of the individual formulations differed. Hyaluronic
acid-coated systems mediated efficient internalization, likely due to their ability to bind surface
receptors like CD44. On the other hand, poly(L-aspartate) and poly(L-glutamate)-coated particles
exhibited membrane-bound morphologies and possessed even greater affinity towards ovarian
cancer cells than HA-coated systems. Even between these two highly similar surface chemistries,
meaningful differences in their uptake mechanism demonstrated the exquisite ability for ovarian
cancer cells to differentiate between nanoparticle formulations.
The observations made in vitro were recapitulated in vivo using an orthotopic model of ovarian
cancer. Given the difficulties inherent to metastatic ovarian cancer and its relative confinement
to organs of the intraperitoneal space, we also performed a head-to-head assessment of four of
our LbL formulations administered both systemically and intraperitoneally. We found that while
systemically injected nanoparticles do co-localize to the tumor, the majority of the dose is lost to
the liver and spleen. However, if given intraperitoneally, the majority of LbL nanoparticles localize
to neoplastic tissues, with minimal spillage into the liver and spleen. Carboxylated LbL NPs per-
form best, providing a persistent elevated association with tumor tissue over 3 days. The sulfated
LbL control particle, in contrast, clears away from the tissue and has a similar tumor-association
seen with PEGylated controls. Notably PEGylated controls not only clear from the tumor over this
period of time, but also spill over into the liver and spleen. Whole-tissue imaging also confirms
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that the LbL nanoparticles are able to penetrate into the tumor tissue, and not remain relegated
on the tumor's surface. These findings suggest that these LbL surface chemistries may be able
to mediate a specific interaction with ovarian tumors if injected intraperitoneally, and could be
used to functionalize colloidal drug carriers. Because the LbL films explored can be applied to a
diverse number of core substrates, this approach provides flexibility towards the development of
a multitude of novel therapeutic interventions for ovarian cancer.
The systematic appraisal of nanoparticle surface chemistry using the LbL platform is a path towards
a more rigorous mapping of the parameter space available to colloidal drug carriers. Our results
indicate that LbL films may provide novel and unexpected interactions between nanoparticles and
particular cell types. Excitingly, this observation combined with the diversity and modularity of LbL
films means that there are significant opportunities for future work to identify new biomedically-rele-
vant surface chemistries. Mapping out this landscape could begin to unlock a deeper understanding
of structure-function relationships, allowing researchers to better design nanoparticles suited for
particular goals and tasks. We intend to continue studying the role of surface chemistry on biodistri-
bution with a more thorough assessment of tumor and clearance organ histological sections, to bet-
ter understand the penetration of NPs into tissues and other organs. We also plan to perform a flow
cytometry assay that will provide insight into the specific cell types involved in LbL-NP uptake in vivo.
Beyond surface chemistry, the field should look to additional parameters for LbL NPs can also
begin to be explored more systematically, including the role of intermediary layers on important
behaviors like swelling, drug release, and transfection efficiency. Of course, simultaneous work
to understand how core size, shape and rigidity impact the observations described here are also
needed. The field has focused enormous efforts in the development of unique and fascinating
formulations to achieve particular drug delivery goals, but the next stages of nanomedicine will
benefit primarily from efforts that begin to tie all these disparate efforts together through deliberate
and methodological studies aimed at disentangling the roles played by key material properties.
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3.6. Methods
Materials and reagents: The polyelectrolytes dextran sulfate sodium salt (DXS, 6.5-10 kDa;
Sigma Aldrich), poly(acrylic acid) (PAA, 15 kDa; Sigma Aldrich), poly(L-arginine) (PLR, 9.6 kDa;
Alamanda Polymers), poly(L-glutamic acid) (PLE, 15 kDa; Alamanda Polymers), poly(L-aspartic
acid) (PLD, 14 kDa; Alamanda Polymers), poly(ethylene glycol-b-poly-L-glutamic acid) (PEG-
PLE) (30 kDa PLD, 5 kDa PEG; Alamanda Polymers), hyaluronic acid (HA, 20 kDa; LifeCore
Biomedical), sulfated beta-cyclodextrin polymer (18kDa; Cyclodextrin Technologies), and fucoi-
dan (57 kDa; Santa Cruz Biotechnology) were used without modifications. Heparin sodium salt
(HS, unfractionated; Celsus Labs) was used both unmodified and as a conjugate with folic acid
(Sigma Aldrich) as described previously.
The fluorescent, carboxylate-modified latex nanoparticles (100 nm, blue fluorescent (350/440),
100 nm yellow-green fluorescent (505/515), 100 nm infrared (715/760); Life Technologies) were
used without modification for LbL-NP assembly. For PEGylated control NPs, the latex particles
were modified with 3 kDa PEG according to the manufacturer's instructions.
Cell lines: Caov3, OVCAR3 and SKOV3 cell lines were purchased from ATCC (catalog numbers
HTB-75, DSMZ ACC 444, HTB-1 61, and HTB-77). Fuov1 cells were purchased from DSMZ
(catalog number ACC 444). COV362, COV318, JHOS2 and JHOS4 cell lines were donated
to us by the Drapkin Lab. OVCAR4 and OVCAR8 cell lines were donated by the Bhatia lab.
Caov3, COV362, OVCAR3, OVCAR4, OVCAR8, cell lines have been authenticated using STR
profiling. All cell lines were tested for mycoplasma contamination periodically, including imme-
diately upon thawing, and over time when in culture, using the Lonza MycoAlert kit (Catalog #:
LT07-318). Results were always negative for mycoplasma contamination.
Synthesis of layer-by-layer nanoparticles: LbL nanoparticles were prepared as described
previously. Briefly, carboxylate-modified latex nanoparticles (Thermo Fisher) were coated with
poly(L-arginine) in milli-Q water, with no added salts. The deposition step was carried out by
adding an equal volume of 1 mg/mL CML core to 4 mg/mL PLR while under sonication (Branson
bath sonicator). The mixture was allowed to sonicate for 5 seconds, then left to incubate at RT
for 1 hour. The particle was then purified using tangential flow filtration (Spectrum Labs, KrosFlo
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I system) with a 100 kDa molecular weight cut-off filter (Spectrum Labs, D02-E100-05-N). The
filter was pre-treated with a 4 mg/mL solution (10 minutes, continuous flow with permeate valve
closed) of PLR. The nanoparticle was washed until five volume equivalents were collected in the
permeate, using milli-Q water as the exchange buffer. The CML/PLR particles were then split
into different batches to be coated with the various polyanions, using the same steps outlined
above for PLR but using a different filter cassette. The filter cassette for anionic layers was not
pre-treated with polymer solution. The core-to-polymer mass ratios for each polyanion were
determined from polyelectrolyte titrations that identified optimal ratios that provided complete
charge conversion. The ratios used were 1:6 for heparin sulfate folate conjugate; 1:10 for
heparin sulfate and fucoidan; 1:8 for dextran sulfate; 1:24 for randomly sulfated beta cyclodex-
trin; 1:6 for poly(ethylene glycol-b-poly-L-glutamate); 1:4 for hyaluronic acid, poly(L-aspartate)
and poly(L-glutamate); and 1:3 for polyacrylate. No salts were added during the deposition or
purification steps for the polyanion layers.
Nanoparticle characterization: Nanoparticle hydrodynamic size and polydispersity were mea-
sured using dynamic light scattering (Malvern ZS90 Particle Analyzer, A = 633 nm, material/
dispersant RI 1.590/1.330). Zeta potential measurements were also acquired with the Malvern
ZS90, using laser Doppler electrophoresis. Nanoparticle solutions were diluted in milli-Q water
in polystyrene semi-micro cuvettes (VWR) or DTS1070 folded capillary cuvettes (Malvern) to
produce samples for characterization. TEM was performed with a JEOL 2011 High Contrast
Digital TEM (120 kV). Nanoparticle solutions were drop casted onto mesh copper grids coated
with continuous carbon films to produce specimens for TEM.
Binding assay for ovarian cancer and healthy cells: The ovarian cancer cell lines and iPSC-
derived endothelial cells were seeded onto 96-well plates (Nunc) at a density of 15,000 cells
per well in 100 uL of the serum supplemented media corresponding to each cell line. Caov3,
COV318, and COV362 were grown in DMEM media (Corning) supplemented with 10% FBS and
2 mM of L-glutamine (Gibco). Fuov1, JHOS2, and JHOS4 cells were grown in DMEM:Ham's
F-12 (1:1) (Corning) supplemented with 10% FBS. Media for the JHOS lines was further supple-
mented with 0.1 mM MEM non-essential amino acids (Gibco). OVCAR3, OVCAR4, and OV-
CAR8 lines were grown in RPMI-1 640 media (Corning) supplemented with 10% FBS. OVCAR3
cells were further supplemented with 0.01 mg/mL bovine insulin (MilliporeSigma). SKOV3 cells
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were grown in McCoy's 5A media (Corning) supplemented with 10% FBS. Induced-pluripotent
stem cell-derived endothelial cells (iPSC-ECs; Cellular Dynamics International) were grown in
Lifeline, Vasculife VEGF Medium Kit, substituting FBS with media supplement obtained from
CDI, according to the manufacturer's instructions. Splenocytes were harvested from homog-
enized whole mouse (Balb/C female) spleens and seeded at a 500,000 cell per well density.
Splenocytes were grown in RPMI-1060 media supplemented with 10% FBS, 0.1 mM MEM
non-essential amino acids, 1 % sodium pyruvate and 50 uM 2-mercaptoethanol. All media was
supplemented with 1 % penicillin streptomycin. All cells were allowed to adhere/grow for 24
hours before treatment with nanoparticles in a Heracell Incubator (Thermo Fisher) at 37C and
5% CO 2.
Green fluorescent nanoparticle compound plates were prepared in a polystyrene v-bottom 96 well
plates (Corning) and standardized to a concentration of 130 ug polystyrene/mL milli-Q water. A
TECAN Freedom Evo 150 with an MCA96 head was used to mix the nanoparticles in the com-
pound plate, transfer 5 uL of and gently mix the nanoparticle solution in the cell assay plate. Cells
were allowed to incubate with nanoparticles for 4 and 24 hours, and then the plates were washed
3 times with PBS and 20 ul of trypsin-EDTA was added to the cells using a BioTek EL406 plate
washer. The cells were incubated for 5 minutes at 37C to dissociate them from the tissue culture
plastic. The TECAN Freedom Evo 150 was then used to add 80 uL of DMEM supplemented with
10% FBS to each well, and to mix the cells into a single cell suspension. Resuspended cells were
then analyzed using an iQue high throughput flow cytometer and nanoparticle fluorescence data
was collected in the FL1-A channel.
For splenocytes, the protocol differed in order to identify specific cell populations. Splenocyte
plates were spun down at 500 RCF for 5 minutes to pellet suspension cells. The supernatant was
removed using the BioTek EL406 Plate Washer, and 20 uL of trypsin EDTA was added to each
well to dissociate any adherent cells from the plate surface. 80 uL of complete DMEM was added
as described above, and then the cells were spun again at 500 RCF for 5 minutes and washed
with PBS. Dead cells were labeled using live/dead aqua stain (BioLegend), according to the
manufacturer's protocols. Cells were pelleted again as described above and then resuspended in
80 uL PBS supplemented with 3% BSA. 2x antibody master with Fc block (BioLegend, 101302)
mix was prepared to label specific cell types and then added to each well using a multichannel
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repeater pipette (Integra). The cells were incubated in the antibody mix for 30 minutes at 4C and
then washed twice with 3% BSA PBS prior to analysis on a BD Fortessa cytometer. The anti-
bodies used were APC CD45 (hematopoietic marker, BD, clone 30-F11), APC-Cy7 B220 (B cell
marker, eBioscience, clone RA3-6B21), PE CD3 (T cell marker, BioLegend, clone 17A2), PE-Cy7
CD11b (leukocyte marker, BioLegend, clone M1/70), PerCP-Cy5.5 F4/80 (macrophage marker,
Biolegend, clone BM8), and BV605 CD11c (dendritic cell marker, Biolegend, clone N418).
All data were analyzed using FlowJo software. Single-color flow was analyzed without compen-
sation. The splenocytes were analyzed using appropriate compensation matrix generated from
single color controls. Populations were gated such that only single cells (and live cells in the
case of the splenocytes) were quantified for nanoparticle-associated fluorescence. The median
nanoparticle-associated fluorescence was determined for each population, and imported into
an R workspace for further analysis. Triplicates for each treatment condition for each cell type
were averaged and then normalized to the average median fluorescence value acquired for cor-
responding cells that were not treated with nanoparticles to generate a median fluorescence
intensity ratio (MFR). The MFR of the different ovarian cancer cells were combined to visualize
uptake in Figure 1, as were the data for healthy cells. The data for both time points were used to
generate a clustered heatmap using the heatmap.2 function in the gplot package. Clusters were
calculated using the built-in Euclidean distance function.
Saturation binding isotherm: OVCAR8 cells were trypsinized and washed in complete RPMI
media to generate a cell suspension at 500,000 cells/mL in 4C media. 50,000 cells were added
to each well (1 OuL) of a v-bottom 96 well plate. Serial dilutions of nanoparticles were prepared
in a deep v-bottom 96 well compound plate. Both plates were chilled to 4C. A TECAN Freedom
Evo 150 was used to premix the nanoparticle compound plate, transfer 100 uL of 2x nanopar-
ticle solution and mixed into each well of the OVCAR8 suspension plate, which was then kept
on ice for 1 hour. Afterwards, the treatment plate was spun at 500 RCF and the supernatant was
removed using a BioTek EL406 Plate Washer. Cells were washed with 200 uL of PBS and re-
centrifuged. The cells were then resuspended in live/dead far-red stain (BioLegend) at 4C for 15
minutes. The cells were recentrifuged and then resuspended in 100 uL 1 ug/mL hoescht in PBS
for 5 minutes. Finally the cells were recentrifuged one last time and resuspended in 80 uL of ice
cold PBS. The plates were then analyzed using a BD LSR2 cytometer. All data was analyzed
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on FlowJo, and the populations were gated such that only single cells that were hoescht+ and
red- cells were analyzed. The hoescht stain eliminated the chance for any nanoparticle aggre-
gates from the highest concentration conditions might be mistaken for cells on the cytometer.
Median fluorescence intensity data was exported to Prism GraphPab software, where it was
log-transformed and fit using the one site-total binding model without any constraints.
Live ce// confocal imaging: COV362, and Caov3 cells were seeded on 35mm MatTek glass
bottom dishes and allowed to adhere for 24 hours. JHOS4 cells were seeded onto black glass-
bottom 96-well plates and also allowed to adhere for 24 hours. Cells were treated with 20 pM
concentrations of blue-fluorescent nanoparticles and analyzed after a 24-hour incubation. Prior
to imaging, cells were stained for using AlexaFluor 555 wheat germ agglutinin at 10 ug/mL in
serum-free imaging media to label the cell membrane. Lysotracker red was also added and
used to label lysosomes following the manufacturer's protocol. Nuclei were labeled using the
NucRed dye, also according to the manufacturer's protocols. The cells were imaged using a 20x
or 60x objective on a Nikon Al R confocal microscope using the 405 , 488, 561, and 640 laser
lines. The filters cubes used were 450/50, 525/50, and 595/50. Images were linearly adjusted to
improve contrast, and then psuedocolored to represent the cell membrane in magenta, nucleus
in blue, lysosomes in red, and nanoparticles in green.
Fixed cell confocal imaging of nanoparticle subcellular trafficking: LabTek chambered glass
slides were coated with rat tail collagen (300 uL of 50ug/mL in 0.02N acetic acid). After 1 hour,
the wells were washed with PBS and OVCAR8 cells were seeded at 15,000 cells per well. The
cells were allowed to adhere for 24 hours prior to treatment with 20 pM concentration of green
fluorescent LbL nanoparticles. Cells were incubated until 4 or 24 hours, depending on the
desired time point, at which time the cells were washed three times with PBS and fixed in 4%
methanol-free formaldehyde prepared in PBS (15 minutes, room temperature). The cells were
then washed in ice cold PBS three times (5 minutes per wash). For all intracellular stains except
for CAV1, cells were treated with blocking buffer (0.025% saponin and 5% goat serum in 1x
PBS) for one hour. Blocking buffer was removed and replaced with a primary antibody diluted
in antibody diluent buffer (0.025% saponin and 1% BSA in 1xPBS). The antibody dilutions used
were as follows: EEA1 (CST) 1:200; RAB5 (CST) 1:100; RAB7 (CST) 1:400; Clathrin (CST)
1:100; LAMP1 (Abcam) 1:400; and RCAS1 (CST) 1:400. Cells were incubated in the primary
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antibody stain overnight at 4C, then washed three times in PBS (5 minutes per wash). The anti-
rabbit AF647 Fab fragment (CST) was diluted 1:1000 in antibody diluent buffer and added to
the cells. After 1 hour at room temperature, the cells were once again washed three times with
PBS (5 minutes per wash) and then stained with DyLight 554 phalloidin, according to the manu-
facturer's protocols. Afterwards, the phalloidin solution is discarded and replaced with a 1 ug/
mL hoescht PBS solution (2-minute incubation). Finally, the cells are washed three more times
in PBS (5 minutes per wash) and the chamber walls are removed following the manufacturer's
instructions. A no 1.5 glass coverslip is then mounted using ProLong Antifade Diamond. Nail
polish is used to seal the coverslip and the slide is allowed to cure for 24 hours prior to imaging.
For CAV1 staining, a Triton-X based permeabolization technique is used instead. The perme-
abolization step occurs after fixation, and uses a 0.2% Tritron X100 in 1x PBS solution. After-
wards, blocking is performed using a 1x PBS solution supplemented with 10% goat serum and
0.1 % Tween 20 (30 minutes, room temperature). The antibody diluent buffer used in the Triton-X
protocol is 1 % BSA 0.1 % Tween 20 in PBS. The CAV1 antibody is used at a 1:1600 dilution.
Specimens were imaged using an FV1200 Olympus Laser Scanning Confocal Microscope using
a 60x silicon oil objective, 1.30 N.A. and the 405, 473, 559 and 635 laser lines. Hoescht and
nanoparticle signals were captured using the standard PMT detectors with filter cubes 430-455
nm and 490-540 nm, respectively. The phalloidin and organelle signals were collected using the
high sensitivity detectors with filter cubes 575-620 nm and 575-675 nm respectively. Image LUTs
were linearly adjusted to improve contrast on FIJI, and were psuedocolored to represent nuclei
in cyan and phalloidin in blue.
3D-Super resolution microscopy of nanoparticle subcellular trafficking: The protocol used
above for fixed cell imaging was modified to suit the requirements of the Applied Precision
DeltaVision-OMX Super Resolution Microscope. Namely, instead of LabTek chambered glass
slides, chambered coveriglass was used. Also, after fixation, cells were washed three times with
Hank's Buffered Saline Solution (5 minutes per wash) and stained with AlexaFluor 647 wheat
germ agglutinin (WGA, 1 Oug/mL in Hank's Buffered Saline Solution, 10 minutes). The cells were
washed three times with PBS (5 minutes per wash) and then re-fixed using 4% formaldehyde for
2 minutes at room temperature. The phalloidin staining step is omitted on the super resolution
samples, and the hoescht stain is increased to a 1.25 ug/mL stain. After all staining is complete,
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the cells are re-fixed using 1% formaldehyde solution for 5 minutes at room temperature. Fol-
lowing three more rounds of washing with PBS, the wells are filled with 5 drops of VectaShield
(H-1 000) and stored in the dark at 4C until imaged. The cells in Figure 3 were only stained with
WGA and hoescht, and were not processed further with any permeabilization agents, which is
why the vesicular stain is more intact in those images.
The cells were imaged with the Delta OMX- V4 Blaze 3D structured illumination microscope (Ap-
plied Precision, now GE), equipped with 405 nm, 488 nm, 563 nm and 647 nm lasers and three
sCMOS cameras. Images were acquired with a 60X, NA 1.43 oil objective, at 0.125 micron z step,
using 1.518 immersion oil at RT. All images were acquired under the same illumination settings
and then processed with OMX softWoRx software (Applied Precison/GE). Images were saved
as tiff. Image LUTs were linearly adjusted to improve contrast on FIJI, and were psuedocolored in
4-color samples to represent the wheat germ membrane stain in magenta.
Uptake inhibitor study: OVCAR8 cells were seeded at 20,000 cell/well in 96 well plates 24 hours
prior to any further treatment. Drug compound plates were prepared in deep well v-bottom
96 well plates containing complete media containing inhibitors for specific uptake processes.
Sodium azide (0.65 mg/mL) and 2-deoxy-D-glucose (8.2 mg/mL) were used to inhibit ATP-me-
diated processes. Wortmannin (4.3 ug/mL) was used to inhibited macropinocytosis. Genistein
(54 ug/mL) was used to inhibit caveolar uptake. Chlorpromazine (3.6 ug/mL) was used to inhibit
clathrin mediated uptake. Methyl-beta cyclodextrin (6.6 mg/mL) was used to deplete cholesterol
and thereby inhibit cholesterol-mediated uptake. Wortmannin, genistein and chlorpromazine
were prepared using 200x DMSO master stocks. An equivalent amount of DMSO was added to
the water soluble inhibitor solutions to eliminate DMSO as a variable. DMSO-only and untreated
controls were used as well. Nanoparticle master plates were prepared in v-bottom 96 well plates
at 130 ug polystyrene/mL milli-Q water.
Cell assay plates were washed three times with PBS using a BioTek EL406 plate washer and a
TECAN Freedom Evo 150 transferred 100 uL of inhibitor-containing media to each well. Cells
were incubated at 37C 5% C02 for one hour, and then the TECAN was used to transfer 5 uL of
nanoparticle solution to each well. The cells were incubated with nanoparticles for 4 hours and
then the BioTek plate washer was used to wash the plates three times with PBS and to add 20 uL
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of trypsin EDTA to each well. After a 5 minute incubated at 37C 5% C02, the 80 uL of complete
media supplemented with propidium iodide was added to each well. The cells were then analyzed
using a BD LSR2 cytometer.
For the 24-hour cholesterol depletion experiment, cells were seeded at the same density and
allowed to adhere for 24 hours. The cells were then treated with nanoparticles in the same way
as above, but incubated for 24 hours. After 24 hours, the cells were washed three times with PBS
and 100 uL of methyl-beta cyclodextrin-containing media was added to each well. The cells were
incubated for 4 hours and then washed three times with PBS and processed as described above
for analysis by flow cytometry. All data were analyzed using FlowJo software, where live single
cell populations were quantified for nanoparticle-associated fluorescence. Fluorescence quantifi-
cation was exported for visualization and statistical analysis on GraphPad PRISM.
Animal studies: All animal experiments were approved by the Massachusetts Institute of Tech-
nology Committee on Animal Care (CAC) and were conducted under the oversight of the Divi-
sion of Comparative Medicine (DCM).
Biodistribution studies: Female NCR nude sp/sp mice were purchased from Taconic and kept on
AIN-93 imaging diet for at least 1 week prior to biodistribution experiments. Mice were injected
intraperitoneally with 100,000 OVCAR8 mCherry/luciferase cells in PBS, and allowed to develop
metastatic disease over the course of 4-8 weeks. Mice were randomly assigned to a nanopar-
ticle treatment, and were then dosed with 8.3x1 012 nanoparticles / kg formulated in 5% dextrose
in milli-Q water. All nanoparticles prepared for animal experiments were generated from infrared
fluorescent CML cores (ThermoFisher). Dosing was performed either systemically (by retro-
orbital injection or tail-vein injection) or intraperitoneally via an IP-injection. Mice were sacrificed
at 24, 48, and 72 hours depending on the randomly assigned time point. Immediately following,
full necropsies were performed to harvest tumors, lungs, heart, spleen, liver, intestines, kidneys,
and stomach from each mouse. The organs were immersed in 12-well plates containing 300 ug/
mL d-luciferin PBS solution. The organs were allowed to incubate for at least 15 minutes in the
d-luciferin solution prior to imaging on a Xenogen IVIS Imaging System (PerkinElmer). Organs
were imaged using the bioluminescence imaging functionality to identify signal from OVCAR8
cells in the primary tumor masses and from metastatic nodules that could not be removed from
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the other organs. The organs were also imaged to detect nanoparticle signal using the fluores-
cence imaging function, using a 710 excitation and 760 emission filter. After imaging, all organs
were placed into tared tubes and weighed to record organ masses into Excel spreadsheets.
IVIS data was analyzed using the Livinglmage software, where total radiant efficiency (TRE)
for each organ was measured and exported to Excel spreadsheets. A python script was then
used to extract the data from spreadsheets and sort it into a database for subsequent process-
ing. Nanoparticle signal was baseline-corrected using the values measured for empty wells,
and then a total recovered fluorescence value was generated from the sum of the total radiant
efficiency (STRE) measured for each organ of a given mouse. The TRE of each organ was
normalized by the STRE to generate a % recovered fluorescence value (%RFV) for each organ.
The %RFV was then normalized to organ mass in grams to generate the final metric used to
quantify biodistribution. The processed data was then exported to GraphPad PRISM for addi-
tional statistical analysis.
After imaging and weighing all the organs from the biodistribution studies, the tissues were trans-
ferred to 10% formalin for 72 hours. Afterwards, the tissues were rinsed thoroughly in milli-Q water
and then transferred to 70% ethanol for long term storage. Some of the tumor tissues were used
for histology and for whole-tissue imaging described below.
Histology and immunofluorescence: Because the CML cores are destroyed by the xylenes
employed for most histological procedures involving formalin-fixed tissue, the tissue for these
studies were processed through alternative means. The fixed tissue (prepared as described
above) was taken and sucrose-infiltrated by immersion in 15% sucrose milli-Q water for 4
hours at 4C. Tissues were then transferred to 30% sucrose solutions and held overnight at 4C.
Next, the tissues were blotted dry using kimwipes and washed three times using OCT medium.
Finally, the tissue was cryomolded in OCT using a snap-freezing method. Briefly, the technique
floats the cryomold on a petri dish over liquid nitrogen for 10 minutes or until the top of the OCT
mold becomes opaque. The molds were maintained at -80C until they could be cryosectioned
by the Koch Institute's histology core facility. Afterwards, the samples were stained with DAPI
and coverslipped using vectashield mountant. The slides were then imaged using a Pannoramic
Fluorescent Slide Scanner, using the DAPI, TRITC, and Cy7 channels to detect nuclei, mCherry,
and nanoparticle signal, respectively. Detailed images were obtained using an FV1200 Laser
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Scanning Confocal Microscope.
Multi-photon imaging of whole tissues: Fixed whole tumor tissue was imaged using an Olympus
FV1 000 Multiphoton Laser Scanning Confocal Microscope. The 25x, 1.05 N.A. objective was
used to image two tumor z-stacks for each mouse analyzed, following 10 um steps. The 690-
1040 nm laser was used at 710 to excite the nanoparticle, and regular fluorescence data was
acquired in the red filter (572-642 nm) due to the broad emission spectrum from the fluorescent
core. Multi-photon events from the nanoparticle were captured by the UV filter (410-440 nm).
The laser was then set to 840 nm to capture the second harmonic from tissue collagen and to
obtain two-photon event data from the mCherry expressed by OVCAR8 cells. To quantify the
data, the deepest tissue penetration observed for each z-stack was averaged together for each
treatment condition.
Statistical analysis: GraphPad PRISM was used to perform statistical analyses. Unless oth-
erwise noted, statistical comparisons were performed using a two-way ANOVA with a Tukey
post-hoc test, alpha = 0.05. The analysis for the uptake inhibitor study uses a one-way ANOVA
and Dunnett post-hoc test between treatment groups and DMSO-only controls, alpha = 0.05.
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Chapter 4. The role of solution conditions in the robust syn-
thesis of layer-by-layer liposomes
Layer-by-layer (LbL) nanoparticles offer great potential to the field of drug delivery, where these
nanocomposites have been studied for their ability to deliver chemotherapy, small molecule inhibi-
tors, and nucleic acids. Most exciting is their ability to encapsulate multiple functional elements,
which allows nanocarriers to deliver complex combination therapies with staged release and to
act as theranostic devices. However, relative to planar LbL constructs, the colloidal LbL systems
have not undergone extensive systematic studies that outline critical synthetic solution conditions
needed to develop robust and efficient assembly. The multistaged process of adsorbing a series
of materials onto a nanoscopic template is inherently complex, and facilitating the self-assembly
of these materials depends on identifying proper solution conditions for each synthetic step and
each adsorbed material. Here, we focus on the fundamental questions that must be answered in
order to obtain a reliable and robust synthesis of siRNA-containing LbL liposomes. This includes
a study of solution conditions such as pH, ionic strength, salt composition and valency, and their
impact on the preparation of LbL nanoparticles. Our results provide insight into the selection
of solution conditions to control degree of ionization and electrostatic screening length to suit
the adsorption of siRNA, native polypeptides, and polysaccharides. The optimization of these
parameters led to a roughly 8-fold improvement in siRNA loading in LbL liposomes, indicating the
importance of optimizing solution conditions in the preparation of therapeutic LbL nanoparticles.
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4.1. Introduction
Layer-by-layer (LbL) self-assembly is a well-established means for the development of hier-
archically organized nanocomposites'-5, materials with applications for catalysis6 -8 , sensing9-11,
electronics12-14, and drug delivery1 5- 17. Within the realm of biomedical applications, the LbL plat-
form provides the unparalleled ability to incorporate numerous functional materials into discrete
nanoparticles, thereby creating multifunctional drug delivery vehicles. To form LbL nanoparticles
(NPs), polyelectrolytes of alternating charge are sequentially adsorbed onto an appropriately
charged colloidal template. Such templates include nanoparticles with well-documented biomedi-
cal applications, such as drug-loaded PLGA18 -19 and liposomal cores 2 0-2 1 . LbL modification grants
these nanoparticle cores a multilayered polyelectrolyte film coating, and when the polyelectrolytes
in the film are carefully chosen, the resulting LbL nanoparticles gain added functionality beyond
that of the core template. Such functionalities include the introduction of stimuli-responsive drug
release characteristics 22-24 and extended systemic circulation times18 25. Even active targeting
functionality can be incorporated via adsorption of terminal polyelectrolyte layers that are natural
binding partners to surface receptors expressed on target cells, such as the CD44-binding poly-
saccharide hyaluronic acid2 .
One of the most exciting capabilities of LbL nanoparticles is that nucleic acids can be incorporated
directly into the LbL film and independently of drugs loaded into the NP core2 7. This allows the
delivery of promising therapeutics like small interfering RNA (siRNA) that silence expression of
specific genes. Despite its potential, siRNA has yet to be translated to the clinic due to intrinsic dif-
ficulties in the delivery of this delicate molecule28 . Free administration of siRNA fails due to ubiqui-
tous serum nucleases that rapidly degrade extracellular RNA. Additionally, due to its size and high
charge density, RNA is unable to pass through the lipid bilayer of target cells. When incorporated
into an LbL film, siRNA is protected from premature degradation 2 9-3 0; furthermore, a terminal layer
that targets cancer cells allows LbL siRNA-carriers to deliver cargo intracellularly20. Once within
the target cell, the cationic elements of the LbL film, such as polyethylenimine31 , poly(beta-amino
ester)32, or cationic polypeptides 3334 (e.g., poly(L-arginine) (PLR) and poly(L-lysine)), can mediate
escape from the endolysosomal system to deliver the siRNA to the cytoplasm, where the siRNA
can exert its therapeutic function. This capability is currently being leveraged to develop nanocar-
riers that deliver potent chemotherapy alongside siRNA. These combination nanotherapies use
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the siRNA component to silence genes vital for drug resistance, thereby improving the efficacy of
the co-encapsulated chemotherapeutic.
The clinical potential of LbL nanoparticles is being actively explored by studies that describe
increasingly impactful and novel therapeutic formulations 16. While this important work continues
to identify promising new avenues for LbL nanomedicine, there is an outstanding need to further
explore the fundamental parameters that underlie the robust synthesis of nanoscale LbL drug
delivery vehicles. The parameter space for LbL nanoparticles is very broad, and includes a host
of variables that include purification methods, mixing conditions, physiochemical properties of the
polymer and colloidal species, and synthetic solution conditions. This parameter space provides
the LbL platform with its rich diversity and versatility, but requires thorough study into the means
of production in order to guarantee reproducible and high quality end products. The role of solu-
tion conditions on nanoscale LbL self-assembly is especially poorly understood, and this deficit
translates into obstacles, such as batch-to-batch variability and drug loading limitations, that must
be overcome to continue advancing these promising nanomaterials towards the clinic.
Separate batches of LbL nanoparticles can be prepared following the identical sequence of mate-
rial deposition steps, yet yield end products that differ from one another, for example, by using
different interlayer purification techniques. Some techniques, such as Caruso and coworkers'
gel electrophoresis method 35, cause re-arrangement of the film as evidenced by zeta potential
measurements. Centrifugation-based approaches can cause a decrease in zeta potential, pos-
sibly due to the LbL film rearranging in the pellet. On the other hand, tangential flow filtration
approaches can enhance the charge of the terminal layer after purification 36 . Essentially, these
techniques can all produce LbL nanoparticles using the same substrate and layer deposition steps
but yield end products that are inherently distinct from one another. While it is straightforward to
keep purification methods consistent from batch-to-batch, other, subtler, conditions may shift and
compromise the consistency of the end product. These conditions include the solution conditions
during self-assembly, which impact the electrostatic forces that both drive LbL assembly and
provide colloidal stability to LbL nanoparticles.
One way to observe how slight shifts in solution conditions impacts LbL assembly is to track
changes to the core-to-polymer (C:P) mass ratio used to generate layered particles. Optimizing
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the C:P ratio is critical for successful layering, because the core substrate must be exposed to
sufficient polyelectrolyte in order to generate an oppositely charged particle with a surface po-
tential strong enough to electrostatically stabilize the colloid37. Empirically, and in consensus with
prior work 8 , we have noted that LbL nanoparticles require a zeta potential with a magnitude of at
least 130 mVl to yield a stable species. But beyond this threshold, varying the amount of excess
polyelectrolyte influences how subsequent layers are adsorbed39. This cascading effect highlights
the need to maintain consistent C:P ratios in order to achieve batch-to-batch consistency, espe-
cially with regards to the amount of adsorbed materials in the LbL film. And since the individual
constituents of the LbL film play important roles in these systems, keeping the adsorbed amount
of each consistent is critical for their safe and efficacious use.
Extensive work on macroscale, planar LbL films indicates the importance of solution conditions
in mediating efficient LbL assembly, where high concentrations of buffers and salts are routinely
used40. In contrast, very limited work has been done on solution conditions for colloidal LbL sys-
tems, in part due to the sensitivity of electro-sterically stabilized colloids to salts. A few studies on
colloidal LbL systems have been reported, including work by Caruso and coworkers 41, wherein
they demonstrated that colloidal gold was layered more efficiently in the presence of sodium chlo-
ride (NaCI), but that the particles flocculate at NaCl concentration greater than 30 mM. Similarly,
Decher and colleagues 37 found that NaCl could induce thicker film formation on colloidal gold, but
also cause aggregation at some point between 10 mM and 100 mM due to electrostatic shielding
that can compromise colloidal suspension stability. On the other hand, Huang et al.4 2 observed
that carbon nanotubes could only template LbL assembly at very high salt concentrations (0.4-1.0
M NaCI), demonstrating that even highly flexible polymers like poly(allylamine hydro- chloride)
and poly(styrenesulfonate) struggle to wrap around the extreme curvature of this substrate with-
out proper electrostatic screening. Outside of these systematic studies, the field largely relies on
individual reports of novel formulations for insight into synthetic solution conditions, and many re-
ports of LbL colloid syntheses do not explicitly mention solution conditions. For those that do, the
conditions can vary significantly: the absence of salt36, 43-47; the absence of salt but with a specified
pH (presumably via titration)- 50; salt for some layers but not for others2 0 39, 1-55; salt only during
layer deposition but not rinse/purification steps 37 41, 56-65; salt only during interlayer purification 66 ;
or salt throughout the synthesis 26 426 -71. Even when solution conditions are specified, it is rare for
there to be discussion or justification for those conditions. Fortunately, future experimental work
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can be guided by prior computational work that has modeled the role of salts in the wrapping of
polyelectrolytes around charged nanospheres. For example, work by Netz et al. 3 determine a
key role in the charge density on the colloidal substrate in mediating tightly bound polymer coat-
ings. Work by Chai et al.7 predict that ion valency can impact polyelectrolyte wrapping, with bulky
multivalent species destabilizing the layering process. And additional studies by Netz and cowork-
ers 75 predicts advantage to using salt for the complexation of nucleic acids with nanospheres.
The following is a comprehensive study of the solution conditions that influence the synthesis of
siRNA-carrying LbL liposomes, a type of LbL nanoparticle with applications towards the develop-
ment of functional gene therapies and multi-drug delivery vehicles. This study first evaluates the
impact of the liposomal substrate's charge density on LbL synthesis, and identifies some criteria
for selecting a liposomal formulation appropriate for LbL-functionalization. Afterwards, the impact
of salts of differing size and valency on the preparation of LbL liposomes (with an LbL film com-
posed of natural polypeptides and siRNA) is systematically studied to assess how salt impacts
colloidal stability and C:P mass ratios during synthesis. During this investigation, the role of pH
in shifting C:P ratios is noted and leveraged towards mitigating rearrangement of the LbL film
during the final layer deposition step, thereby preventing loss of siRNA. The salt screen ultimately
identified HEPES, Tris-HCI, and NaCl as compatible salts for the preparation of LbL liposomes.
We later determine that using HEPES and NaCl in combination provides excellent means to tune
the degree of ionization and electrostatic screening length during LbL synthesis via controlling the
pH and ionic strength of solution. The role of solution conditions during the interlayer purification
step is also investigated, and reveals a significant advantage to removing salts during purification
using the tangential flow filtration method. With optimized synthetic solution conditions in place,
the weight percent loading of siRNA to lipid is improved 8-fold from 3.7% to 30.8%, indicating the
significance of these conditions for the end product. Furthermore, LbL liposomes prepared using
the HEPES and NaCl method demonstrate superior gene silencing in ovarian cancer cells both
in vitro and in vivo. These techniques were then extended to the optimization of solution condi-
tions for layering the native polysaccharide hyaluronic acid, which can introduce active targeting
capabilities and prolong the circulation of LbL nanoparticles. We report that HA requires specific
solution conditions for successful incorporation, indicating that different polyions may demand
distinct solution conditions in accordance to the particular intermolecular forces at play during the
relevant stage of self-assembly. Finally, we briefly note how the identity of the colloidal substrate
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can lead to surprising differences from the approaches optimized for LbL liposomes. Overall, this
study represents a major contribution towards a more comprehensive understanding of solution
conditions in the context of colloidal LbL self-assembly, and how they can be leveraged towards
the robust synthesis of LbL liposomes with high weight percent loading of siRNA.
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4.2. Results: Optimization of solution conditions improves LbL NP
reproducibility and siRNA loading
Salts and buffers play an invaluable role in the optimization of macroscale LbL-modification of
planar and microparticle substrates 40, 76-81, where they provide control over critical factors like
degree of polyelectrolyte ionization, electrostatic screening length, and the thermodynamics of
self-assembly. The same holds true in nanoscale colloidal LbL37, 41, 82, but these benefits must
be carefully weighed against the risks that even weak ionic strengths pose in terms of colloi-
dal flocculation, film rearrangement and even destabilization and erosion. On the other hand, to
avoid salts altogether risks developing protocols where slight salt contamination or day-to-day
changes in water pH and purity lead to unpredictable effects on LbL synthetic outcomes. Even
slight contamination with salts has a significant impact with regards to which core-to-polymer
(C:P) mass ratio will yield a stable layered nanoparticle. We demonstrate this effect by performing
a polymer titration to determine the C:P ratio for the adsorption of 9.6 kDa PLR onto an anionic
liposome (58:18:24 mole ratio of DSPC:POPG:Cholesterol) in either deionized water (dH 20) or
a. 100 - - dH20 -4- Titrated water (pH 7.5) b- 60 - + C:P - 5:1 for PLR layer ---- C:P - 1:1 for PLR layer
Stable regime 40-
50 20 -
Is a
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Core 40:1 30:1 20:1 10:1 5:1 4:1 2:1 1:1 1:2 1:4 1:8 1:16
C:P ratio C:P ratio
Figure 4.1. The presence of even dilute salt can significantly change the amount of polymer needed to pro-
duce a stable, layered nanoparticle. Layers are deposited onto a core substrate by mixing the substrate with
oppositely charged polyelectrolytes at a core-to-polymer (C:P) mass ratio. At the optimal ratio, the nanoparticle
reverses its charge, and possesses a zeta potential with a magnitude of at least 130 mVI to be electrosterically
stabilized. a) Anionic liposomes (58:18:24 mole ratio DSPC:POPG:cholesterol) were mixed with poly(L-arginine)
(PR) at various C:P ratios to identify ratios that yield charge conversion within the stable regime. Depending on
if the titration is carried out in dH20 or pH 7.5 titrated water (20 VM Na 2HPO4), the optimal C:P ratio varies 4-fold
- from 20:1 in 20 IM Na2 HPO4 or 5:1 in dH20. b) Changes in the C:P ratio in the initial layer have downstream ef-
fects on the subsequent layer. PLR-coated liposomes were formed using C:P ratios of 5:1 or 1:1 in dH20, yielding
two PLR-coated species with zeta potentials of roughly +30 mV and +40 mV, respectively. To successfully add the
subsequent siRNA layer on the +40 mV substrate, we require an 8-fold increase in the amount of siRNA added to
the system, relative to the +30 mV substrate.
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dH 2O titrated to pH 7.5 using 20 1 M Na2 HPO4 (Figure 4.1a). In dH20 (pH 5.5-6), a C:P ratio of 5:1
is sufficient for charge conversion into the stable regime (e.g., zeta potential > 30 mV), whereas
with a pH of 7.5, a C:P ratio of 20:1 is required to yield a stable colloid - a four-fold decrease in
polyelectrolyte. At such a dilute salt concentration, the change in the optimal C:P for layering
reflects the influence of pH on the system.
Changes in C:P ratios for one of the underlying layers of an LbL film can have a cascading effect
on the adsorption of the subsequent layers. To illustrate this, we coated liposomes with PLR in
dH 2O using the 5:1 C:P ratio, but also at a 1:1 C:P ratio that yields a greater charge conversion.
Both species are stable, with the liposomes coated with PLR at a 5:1 or 1:1 C:P ratio generating
layered nanoparticles with approximate zeta potentials of +30 and +40 mV, respectively (Figure
4.1b). To adsorb the next layer, composed of a 21-base pair siRNA, drastically different C:P ratios
must be used to generate a stable colloid. The 5:1 liposome-PLR system produced a stable
siRNA-coated particle at a C:P ratio of 1:2, but the 1:1 liposome-PLR system requires a C:P ratio
of 1:16 to achieve charge conversion. Given the cost of siRNA, such a ratio would be prohibitive
for routine manufacturing. To preserve continuity between batches of LbL NPs, keeping track of
the C:P ratio becomes essential - and given the significant variation of this value due to shifts in
pH it becomes imperative to develop means that robustly control pH while maintaining colloidal
stability.
The ability for dilute salt concentrations and small shifts in pH to meaningfully impact the opti-
mal C:P ratio for generating stable layered particles prompted us to look further into the effects
of various salts and buffers. Different research groups have developed divergent practices for
solution conditions during colloidal LbL assembly, and while some systematic studies have been
performed, to our knowledge, a study comparing a variety of salts at different concentrations has
not yet been reported. There has also been especially little investigation into the solution condi-
tions that facilitate the LbL-modification of liposomal cores or the considerations required to make
liposomal cores appropriate substrates for LbL. To begin addressing this outstanding need, we
performed an assessment of liposome formulations of differing charge density in order to optimize
the liposomal substrate for LbL-modification.
This study focuses on a liposomal formulation composed of 33.3 mol% cholesterol (CHOL) and
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Figure 4.2. The ratio of anionic to zwitterionic phospholipid determines the final liposomes' charge den-
sity, sensitivity to pH, and ability to adsorb polyelectrolytes. Liposomes were formulated using a 2:1 phospho-
lipid/cholesterol mole ratio, where the phospholipid compartment was composed of zwitterionic DSPC and/or
anionic DSPG. a) Liposomes with DSPG mol% of 3.3%,16.7%, 33.3% and 66.7% were prepared to test the impact of
charge density on PLR adsorption. As charge density increases, the optimal C:P ratio shifts towards favoring more
polymer, intuitively indicating that a more charged substrate requires more oppositely charged polyelectrolyte to
reverse its charge. b) Liposomes possessing different DSPG content also differ in their surface charge's sensitivity
to pH, and liposomes with less than 33.3 mol% DSPG become neutral (e.g., 10 mV) at pH 2.4 (25 mM HEPES). c)
The total change in zeta potential over pH 8 to 2 was calculated, and indicated that as DSPG content increases,
the degree of surface charge "elasticity" is reduced. Size and polydispersity data were acquired by dynamic light
scattering, and zeta potential data was measured using laser Doppler electrophoresis.
66.7 mol% phospholipid, in light of studies8 3-4 that find such a composition is ideal for stable
drug encapsulation. The phospholipid content is composed of either the zwitterionic DSPC or
the anionic DSPG, which were chosen for their high melting temperature (ca. 55C) to improve
drug-retention of future formulations"4. By varying the anionic content of the liposome between
3.3, 16.7, 33.3 and 66.7 mol% DSPG, we observe changes in the optimal C:P ratio needed to
layer PLR in pH 7.5 titrated water (Figure 4.2a). Intuitively, greater anionic content on the sub-
strate translated to optimal C:P ratios favoring greater polymer concentrations, with 3.3% DSPG
converting charge at 40:1, 16.7% and 33.3% DSPG converting charge at 10:1 and 66.7% DSPG
converting charge at 5:1. The charge stability of the core substrate was also investigated with a
pH range from 2.4 to 8.4 (Figure 4.2b), which showed that the liposomal cores with less DSPG
content are more sensitive to pH and become more neutral at acidic pH. As expected, the total
zeta potential shift going from pH 8 to pH 2 (Figure 4.2c) indicated that the amount of DSPG in
the liposome determines the extent in the shift in zeta potential. Because retaining a stable sur-
face charge is a desirable quality for LbL synthesis, we determined that 33.3% and 66.7% DSPG
systems would be appropriate substrates for LbL-modification as they retain a strong negative
charge throughout the pH ranges studied and are able to adsorb more polyelectrolyte. In addition,
both empirical and computational studies have found that greater charge density benefits LbL by
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Figure 4.3. Layer-by-layer assembly onto liposomal substrates is affected by both salt concentration and
salt identity, with notable differences in colloidal stability noted based on salt valency and size. a) Schematic
of the LbL process on liposomes in the absence of salt (using deionized water, dH 20) and in the presence of salts
compatible with the LbL process (NaCI and HEPES). Anionic liposomes (1:1:1 DSPC/DSPG/CHOL) were coated with
9.6 kDA PLR using a 1:4 core-to-polymer (C:P) ratio. Solution conditions were varied during this layering step by
introducing distinct salt species at concentrations ranging from 0.01 mM to 100 mM. We assess colloidal stability
under each of these conditions by measuring hydrodynamic diameter (left axis, blue curve) and zeta potential (or-
ange axis, yellow curve) of the resulting LbL particle. Results that indicate particle instability are denoted using red
data points. We demonstrate that multivalent ions like (b) sodium citrate and (c) sodium phosphate are especially
destabilizing to PLR adsorption, even at low concentrations. The monovalent species (d) tris hydrochloride and
(e) NaCl are less destabilizing, but do cause flocculation at mdderate concentrations (100 mM). The zwitterionic
species (f) HEPES was very well tolerated at all concentrations used, with only a slight dip in the zeta potential
at 100 mM. Size and polydispersity data were acquired by dynamic light scattering, and zeta potential data was
measured using laser Doppler electrophoresis.
preventing film delamination41 , (layers desorb because subsequent layers out-compete the core)
and promoting full wrapping of nucleic acids around substrates at moderate salt concentrations 73.
We then performed a screen of different salts at a range of concentrations and determined their
impact on the adsorption of PLR onto these anionic liposomal cores (Figure 4.3). In selecting
the salts used in this study, we were motivated by prior computational studies 74 that modeled the
role of salt valency and size in the wrapping of nucleic acids on histones and charged spheres.
We chose to study the multivalent salts trisodium phosphate and trisodium citrate, the monova-
lent salts tris(hydroxymethyl)aminomethane (tris) hydrochloride and NaCl, and the zwitterionic
salt 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES). Consistent with computational
models, multivalent species were more destabilizing to LbL self-assembly, with sodium citrate
(Figure 4.3b) causing major flocculation at just 1 mM. Flocculation of this system leads to micron-
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sized aggregates, and at the highest salt concentration the aggregates precipitate from solution
and are no longer detected by dynamic light scattering. It is noteworthy that when zeta potential
drops below 30 mV (indicated by red dots on the orange curve), it generally coincides or closely
precedes flocculation as indicated by a sharp increase in hydrodynamic diameter (indicated by
red dots on the blue curve). Sodium phosphate, another multivalent species, caused significant
flocculation, but only starting at 10 mM in this system (Figure 4.3c). We hypothesize that this
difference in stability can be attributed to sodium citrate's ability to chelate with polycations in the
layers, potentially resulting in NP aggregation.
Relative to multivalent species, the monovalent salts allowed for a much more stable PLR adsorp-
tion (Figure 4.3d-e). This improvement in stability may stem from multivalent salts being able
to form ionic crosslinks with PLR34 that can interfere with adsorption and promote aggregation,
whereas this type of ionic crosslinking is not observed for monovalent salts. In both tris hydro-
chloride and NaCl, the LbL nanoparticles possess good size and charge until 100 mM. These
results are consistent with prior work by Caruso and coworkers41 that defined an upper limit of 30
mM for NaCl in LbL-gold nanoparticle synthesis, but now we extend that observation to liposomal
cores and to the monovalent salt tris hydrochloride.
The zwitterionic salt HEPES was the sole salt that avoided flocculation for the entire range of
concentrations tested (Figure 4.3f). Notably, only at 100 mM does the zeta potential slightly dip
below 30 mV, indicating that we are approaching the upper limit for stability in HEPES. This result,
while initially somewhat surprising, is consistent with the underlying molecular forces that medi-
ate flocculation in LbL synthesis. The primary reason that salts can destabilize LbL systems is
because they decrease the Debye length of the system, the length scale over which electrostatic
forces dominate. For electrosterically stabilized colloids, the Debye length must be long enough
to allow for charge-charge repulsion to occur before attractive short-range van der Waals forces
take effect. The Debye length is dependent not on salt concentration per se, but rather on ionic
strength, which depends also on the valency and dissociation state of the salt in question. How-
ever, zwitterionic salts have a complex contribution to electrostatic screening; empirical studies
indicate that zwitterions contribute negligibly to the ionic strength of solution 85, and by extension,
the electrostatic screening length. This unique trait may grant LbL nanoparticles increased stabil-
ity in solutions with moderately high HEPES concentrations. Interestingly, these data also point
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at deeper mechanisms at play in the discrepancy between colloidal stability in the presence of
multivalent and monovalent ions, because when these data are replotted using ionic strength in
place of salt concentration the results do not fully converge (Appendix C Figure 1). This obser-
vation supports the arguments advanced by computational models that ion valency can interfere
with the complexation of polyions with a charged nanosphere.
We then turned our attention to the impact of salt on the formation of more sophisticated LbL-
liposomes, namely the synthesis of siRNA-containing LbL liposomes. In this study, we aimed
to resolve a challenge particular to LbL films which incorporate polyelectrolyte species that
compete for incorporation into the LbL film. Specifically, parameters were explored to determine
whether or not siRNA remains stably incorporated in the LbL architecture after addition of sub-
sequent layers, both cationic and anionic. The formulation studied consists of the sequential
deposition of PLR, siRNA, PLR and a propargyl-modified poly-L-aspartic acid (pPLD) onto a 1:1:1
DSPG:DSPC:Cholesterol liposomal core. Upon addition of the third layer, PLR, on top of the
siRNA-coated substrate, no displacement of nucleic acid was observed via agarose gel (Appen-
dix C Figure 2). However, when the final pPLD layer was added in deionized water, we observe
a displacement of the siRNA from the particle at C:P ratios that yield stable colloidal solutions
(Figure 4.4a, asterisks denote stable species generated). It is likely that this occurs through
competition between pPLD - a more densely charged and flexible polyelectrolyte - and the siRNA
that is interpenetrated with the outermost PLR layer. The displacement of siRNA can account for
a loss of up to 50% of the encapsulated cargo, prompting us to investigate whether different solu-
tion conditions might prevent or mitigate this phenomenon.
Based on the results from our initial salt screen, we fixed the salt concentrations at 10 mM and
performed a pPLD titration on the liposome/PLR/siRNA/PLR substrate to determine stable C:P
ratios (Figure 4.4b). All conditions yielded an appropriate charge conversion at a C:P ratio of
1:4, though the multivalent species produce a visible precipitate. However, regardless of the salt
used, all formulations using a 1:4 C:P ratio exhibit a significant displacement of siRNA from the
particle. But stable formulations (denoted by an asterisk on the figure) revealed that several of the
buffered conditions do yield a stable particle at a C:P ratio of 1:2 where minimal siRNA displace-
ment occurs. We hypothesized that the concentration of pPLD is the primary driver of siRNA
displacement, and thus when the absolute concentration of the species is reduced we also reduce
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Figure 4.4. Tuning the solution conditions allows for stable nanoparticles to be generated at C:P ratios that
prevent rearrangement of the LbL film, which can lead to loss of siRNA after deposition of the terminal
polyanion propargyl poly(L-aspartate) (pPLD). a) In dH20, the synthesis of an siRNA-containing LbL nanopar-
ticle (liposome/PLR/siRNA/PLR/pPLD) is complicated by the addition of the final pPLD layer, which causes dis-
placement of siRNA as observed by agarose gel. C:P ratios that yield a stable formulation are denoted with an
asterisk, and all C:P ratios tested in dH20 led to considerable siRNA loss. Heparin-degraded nanoparticles show
the entire encapsulated siRNA fraction. b) C:P ratio titrations were performed for the final pPLD layer in 10 mM
concentrations of each salt species shown. Notably the different salt conditions cannot abate the siRNA loss at
the 1:4 ratio, but certain solution conditions lead to stable particle at a C:P ratio of 1:2 where minimal siRNA is
displaced. d) Size data of the nanoparticles formulated during the C:P titration of the final pPLD layer indicate
stable sizes for particles prepared in HEPES and Tris-HCI at the 1:2 ratio that minimized siRNA loss. e) Zeta data for
the same titration series confirms stable charge conversion occurs at a C:P ratio of 1:2 in nearly all salt conditions.
This includes some solution conditions that fail to yield stable sizes like sodium phosphate and sodium citrate.
Notably, the commonality between all the solution conditions was a neutral pH of 7-7.5. c) The importance of
pH is confirmed through the synthesis of the LbL nanoparticle in pH 7.5 titrated water (20 LM Na 2HPO4), which is
sufficient to prevent siRNA displacement during the final layer deposition step. Size and polydispersity data were
acquired by dynamic light scattering, and zeta potential data was measured using laser Doppler electrophoresis.
the opportunity for film rearrangement. Additionally, siRNA-containing LbL-NPs synthesized in
the presence of salts might be less susceptible to this displacement by pPLD, perhaps due the
generation of thicker layers.
When assessing the data in terms of pH during assembly (Figure 4.4d-e) it is evident that pH
between 7-7.5 shifts the C:P towards lower polymer concentrations to achieve charge conversion,
suggesting that pH mediates an optimal C:P ratio that prevents siRNA displacement. To confirm
this hypothesis, we demonstrate the complete synthesis of the liposome/PLR/siRNA/PLR/pPLD
system using pH 7.5 titrated water (20 jAM Na2 HPO4), where we are also able to eliminate the dis-
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placement of siRNA from the LbL film (Figure 4.4c, Appendix C Figure 3). These results highlight
the critical role of pH during LbL assembly, where it determines the ionization state of the polymer
chains and the colloidal substrate. Tuning the pH with the pKa of the polymer and substrate in
mind will maximize the number of charged groups and intensify the electrostatic interactions that
drive polymer layering, allowing for more efficient C:P ratios. With the importance of pH in mind,
HEPES becomes a natural tool in LbL synthesis to control pH thanks to its broad buffering range
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Figure 4.5. Synthetic solution conditions influ-
ence the layer deposition and interlayer purifica-
tion steps differently, and judicious application of
optimal conditions facilitates significant improve-
ment in the weight percent loading of siRNA in
LbL liposomes. We compare the impact of preparing
LbL liposomes (liposome/PLR/siRNA) under differ-
ent synthetic solution conditions to handle the layer
deposition and interlayer purification steps. a) The
synthetic solution conditions tested in these experi-
ments are defined. b) LbL liposomes were prepared
under the defined solution conditions and changes in
the optimal core-to-polymer (C:P) mass ratio needed
to achieve a stable colloid were recorded and aver-
aged (green bars). For ease of interpretation, we also
convert the C:P ratio to a mg of siRNA added per mg
of lipid (purple bars) to directly visualize siRNA con-
tent differences across these conditions. Without the
inclusion of NaCl, we observe more variability in the
C:P ratio (conditions 1 and 2), and require much less
siRNA to convert charge. On the other hand, layer-
ing in the presence of NaCl requires more siRNA for
charge conversion but reduced variation in C:P from
batch-to-batch (conditions 3 and 4). Layering in the
presence of NaCl but purifying with dH 20 (condition
4) generated a particle that required roughly double
the siRNA to convert charge. c) The encapsulation ef-
ficiency across solution conditions did not vary signif-
icantly, but meaningful improvement in the weight
percent of siRNA to lipid was noted. Performing the
synthesis in the presence of NaCl triples the average
weight percent load to roughly 10%. Notably, purify-
ing LbL liposomes in dH20 instead of buffered solu-
tion further improved loading, yielding an average
weight percent loading of 30%. Data is representa-
tive of at least three independent syntheses for each
condition. Error bars represent SEM. All statistical
tests were performed using one-way ANOVA (alpha
= 0.05), with the Tukey post-test, on PRISM graphing
software.
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(2.5-3.5 or 6.8-8.2) and, as we demonstrated above, the ability to use concentrations as high as
100 mM without impacting colloidal stability.
We then evaluated whether HEPES alone is sufficient for optimal layering of the siRNA onto the
liposome/PLR substrate. Because siRNA is essentially a stiff charged rod86-88, the adsorption of
this species onto the curved nanoparticle surface can be challenging. Computational work indi-
cates that efficient deposition of a nucleic acid onto a colloidal substrate requires careful tuning
the Debye-Huckel screening length of the solution73 . Since HEPES has a complex contribu-
tion to the screening length 5, we hypothesized that additional screening would be required to
optimally layer siRNA. Because NaCl has a straightforward relationship to the Debye length, and
is tolerable in LbL synthesis up to the tens of millimolar range, we turn to it as a tool to tune the
electrostatic screening length during LbL synthesis. In the following study, we perform the entire
LbL synthesis in either:
1) pH 7.5 titrated water (20 1M Na2HPO 4),
2) 25 mM HEPES,
3) or 25 mM HEPES 20 mM NaCl.
And while these conditions assess the appropriate solution conditions for the layer deposition
step, they do not take into account whether special solution conditions are needed during the
purification step that occurs between each layer. Limited prior literature suggests that removal of
salt is important for preventing further rearrangement of the LbL film89, but there are also empiri-
cal reports from groups that specifically use salt only during the purification step66. Therefore, to
also determine the role that salts may play in the interlayer purification steps, we include a fourth
condition:
4) where particles layered in the presence of 25 mM HEPES 20 mM NaCl are buffer
exchanged to dH 20 during purification.
We first evaluate how these four solution conditions influence the optimal C:P ratio for siRNA
loading into the LbL film (Figure 4.5b). Syntheses were carried out at least three times for each
condition, and the results indicated that titrated water and 25 mM HEPES-buffered systems ex-
hibited highly variable C:P ratios (green bars), with the average ratio being 8:1 and 11.5:1, re-
spectively. On the other hand, layering in 25 mM HEPES 20 mM NaCl increased the uniformity
of inter-batch C:P ratio considerably, and also shifts it to more polymer-heavy ratios of 2.66:1 and
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1.33:1 for both salt-purified and dH 2O-purified conditions. For ease of interpretation, the C:P ratio
is translated to mg of siRNA added per mg of lipid in the same figure, as the purple bars. Overall,
inclusion of NaCl provides an immediate benefit by stabilizing C:P ratio across batches, and also
leads to more siRNA needing to be added to generate a stable particle.
To determine whether this additional siRNA contributes towards the end product, or is simply lost
during purification, we measured the encapsulation efficiency (EE) and weight percent loading
for the buffered conditions (Figure 4.5c). Overall, EE varies little across the tested conditions,
ranging from 20-40%. However, given the significantly different C:P ratios used in the different
conditions, this translates to meaningful changes in the weight percent loading of siRNA to lipid.
Notably, the HEPES-only condition leads to 3.7% 3.1% weight percent loadings that are in line
with our prior published siRNA-based LbL nanoparticles (5.5% 0.5%), which were prepared en-
tirely in dH20. However, the EE efficiency is improved in HEPES, where we see 28.6% 15.5%
of siRNA encapsulated, up from our prior work where we reported an EE of 7.5% 2.5%. These
results suggest perhaps more efficient layering (e.g., less siRNA needed to convert charge) but
not improved weight percent loading.
In contrast, inclusion of 20 mM NaCl tripled the weight percent loading of siRNA from an average
loading of 10.5% 3.7% for particles that are exposed to NaCl and HEPES throughout the entire
synthesis. We propose that this is because 20 mM NaCl decreases the electrostatic screening
length to 2.1 nm, and according to prior computational work90-91, the screening length of solutions
can alter the flexibility of polyelectrolytes. There are also empirical studies that confirm a relation-
ship between nucleic acid flexibility and ionic strength 92. This improved flexibility may allow better
adsorption onto the nanoparticle substrate, as well as help to form a more densely packed siRNA
layer. Computational models also predict that the layering of nucleic acids requires exceeding
a critical screening length, and that layering efficiency continues to improve with greater salt
concentrations 73, 7. In real world situations, the salt concentration must be limited to prevent ag-
gregation, but until that point it appears that LbL systems aiming to incorporate siRNA will benefit
from higher salt concentrations.
While including NaCl during the layering stage improved loading of siRNA, purification in the pres-
ence of NaCl and HEPES had a negative impact on loading. The introduction of the nanoparticles
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to high salt concentrations without free siRNA leads to conditions in which siRNA can diffuse back
into solution. On the other hand, layering in HEPES and NaCl and then switching to dH 20 for the
subsequent purification step yielded an siRNA weight percent loading of 30.8% 15.7% - a roughly
8-fold improvement over HEPES alone. This significant improvement in loading could indicate
that when LbL nanoparticles are purified using the TFF technique in the presence of salt, the
thicker LbL film may be able to rearrange and disassemble. This notion of film deconstruction is
supported by the observation that at most stages, the salt-purified samples required less polymer
to convert their charge relative to their dH 2O-purified counterparts. This shift in C:P ratio could be
indicative of a partial loss of adsorbed material when the particles are purified in salt. To an extent,
this observation is consistent with a prior study93 that demonstrated that planar LbL constructs can
be eroded after exposure to continuous flow of polymer and salt.
These results suggest that NaCI in conjunction with HEPES provide a straightforward means
to tune solution conditions for optimal loading of siRNA into LbL liposomes. We also provide
evidence that the resulting particles are of good size and charge throughout the synthesis of 2:1
DSPG:Cholesterol liposomes coated with PLR/siRNA/PLR/pPLD using either deionized water,
titrated water or 25 mM HEPES and 20 mM NaCl in Appendix C Figure 4. The results indicate
similar monodispersity and charge is achieved (Appendix C Figure 4c-d) albeit using different
C:P ratios (Appendix C Figure 4e). Notably, in non-ionic or low ionic strength conditions, the
size of the LbL liposome appears more or less unchanged throughout the synthesis, within the
range of error for dynamic light scattering (+/- a few nanometers). This observation corresponds
well with past theoretical work in planar LbL films that predicts very thin layer deposition (ca. 1-2
nm) under such solution conditions 94. But with the inclusion of HEPES and NaCl for shielding, we
observe a steady growth in particle size that is measurable with DLS, and is more consistent with
prior LbL colloid literature and our experience with other core substrates. We expect that this is in
part due to the deposition of thicker layers in the presence of salts as described in the literature,
which may also explain the improved loading of siRNA into liposomes prepared in the presence
of salt.
We also directly compare the size and charge of particles purified in salt or in water. Overall, the
nanoparticles generated from both methods were of acceptable uniformity, with salt-purified and
water-purified particles yielding polydispersity indexes of 0.23 0.04 and 0.26 0.02, respectively.
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Figure 4.6. Optimized solution conditions produce LbL siRNA-carriers that mediate improved transfection
of model genes in ovarian cancer in vitro and in vivo. LbL nanoparticles ( liposome/PLR/siLuciferase/PLR/PLD)
were prepared either in dH 20, pH 7.5 titrated water (20 pM Na 2HPO4), or using the optimized HEPES/NaCI condi-
tions (layered in 25 mM HEPES 20 mM NaCl and purified in dH 20). a) Luciferized OVCAR8 human ovarian cancer
cell lines were treated with nanoparticles at doses that exposed the cells to 30 nM siRNA, and then luciferase
expression was assessed after 1 day. LbL liposomes prepared using HEPES/NaCI conditions showed statistically
significant improvement over NPs made either dH 20 or titrated water. b) NCR nude mice bearing subcutaneous
flank tumor xenografts were intravenously injected with nanoparticles to provide a 0.5 mg/kg dose of siRNA.
Luciferase signal was determined using IVIS whole-animal imaging, and indicates a brief knockdown is achieved 1
day post-treatment for particles prepared in dH 20. In contrast, particles prepared using the optimized HEPES/NaCI
method mediate a prolonged knockdown over the course of three days post-injection. c) The data from 2 days
post-treatment indicates the particles prepared in HEPES/NaCI outperform particles made in water. Notably, two
outliers in the HEPES/NaCI group deviate from the mean - but data from the third day indicates continued silenc-
ing for these outliers (see Appendix C Figure 9). d) Representative whole-animal luminescence images of mice
treated with LbL liposomes prior to treatment and 2 days post-treatment. Error bars represent SD of triplicates in
panel a and SEM of at least n=6 in panels b and c. All statistical tests were performed using one-way ANOVA (alpha
= 0.05), with the Tukey post-test, on PRISM graphing software.
But the particles prepared in salt begin to diverge in size during the final (fourth) layer, which
involves adsorption of the anionic polypeptide PLD. This step yields much larger particles with a
Z-average hydrodynamic diameter of 245 7 nm, relative to the 173 4 nm diameter of the water-
purified system (Appendix C Figure 5a). This is perhaps due to the weaker zeta potential (-26 3
mV) of the salt-purified system relative to the water-purified particles (-42 2 mV). Particles that
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were purified in the presence of salt required less polymer in subsequent layers to achieve charge
conversion, ca. 2:1 C:P for the siRNA layer in salt-purified vs ca. 1:1 C:P ratio for deionized water
purified particles. Therefore, for both conditions, separate C:P ratios were chosen at each layer-
ing step in an effort to keep resulting zeta potentials as similar as possible prior to purification
(Appendix C Figure 5b). Nonetheless, the need to shift the C:P ratios potentially indicates rear-
rangement or erosion of the film.
The practical consequences for optimizing siRNA loading become apparent in the ability of the
final siRNA LbL liposomes to transfect cells. We demonstrate that LbL liposomes prepared follow-
ing our optimized solution condition method (layered in 25mM NaCl and 20mM HEPES, purified in
dH 2O) are able to mediate improved gene silencing in the human ovarian cancer cell line OVCAR8,
compared to particles prepared in suboptimal solution conditions (Figure 4.6a). In our experi-
ence, this cell line is especially challenging to transfect using nanoparticle constructs, whereas for
easier to transfect human ovarian cancer cells like COV362, each of these formulations fares well
in vitro (Appendix C Figure 6). Because the OVCAR8 cell line can provide a more realistic model
of ovarian cancer than prior models95, the ability to transfect this line is interesting for advanc-
ing preclinical studies. Here we show that LbL liposomes (2:1 DSPG:cholesterol liposome/PLR/
siLuciferase/PLR/PLD) prepared with optimal solution conditions are able to mediate prolonged
silencing compared to LbL liposomes prepared in dH 2 0 in a subcutaneous flank xenograft of
OVCAR8 (Figure 4.6b). After a single 0.5 mg siRNA/kg injection, the nanoparticle prepared in
dH 2 0 is able to mediate some knockdown of luciferase signal 1 day after treatment (88% 6.8%
expression relative to pre-treatment), but this effect dissipates 2 days after treatment. On the
other hand, the gene silencing effect of the solution condition-optimized formulation becomes
more intense out to 3 days post-treatment, with luciferase expression (relative to pre-treatment)
decreasing from 84.6% 17.3% at day 1, to 70.9% 15.8% at day 2, and finally to 68.5% 6% at
day 3. Notably, at day 2 (Figure 4.6c), two outliers deviate from the mean for the nanoparticles
made in HEPES and NaCl, but by day 3 luciferase expression for those outliers dips back down
in line with the other subjects (Appendix C Figure 7). The ability to mediate prolonged silencing
following a single dose at 0.5 mg/kg in this model of ovarian cancer indicates these particles have
immediate utility in the development of therapeutics for this difficult-to-treat malignancy.
The conditions studied so far have improved the preparation of LbL liposomes composed of poly-
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II such as hyaluronic acid (HA). This polysac-
charide is a native constituent of the extracel-
lular matrix, and provides LbL nanoparticles
with unique capabilities that include pH-dependent swelling, hydrophilic characteristics that pro-
long circulation, and specific binding to the CD44 receptor that is overexpressed by a host of
cancers 1 1, 26. Taking advantage of these traits is complicated by the synthetic challenges that HA
presents in LbL synthesis, due to its ability to form intramolecular hydrogen bonds and signifi-
cantly change solution viscosity96-99. In general, we note that HA mediates the formation of much
thicker layers and introduce the risk of flocculation. The extensive hydrogen bonding available to
145
U
25 mM HEPES dH20 1 mM
20mM NaC! HEPES
Crude
11
""""
Figure 4.7. Figure 5. Ideal solution conditions vary
based on the polymer being layered and the col-
loidal substrate being used. The hyaluronic acid
(HA) layer requires specific solution conditions, and
latex core substrates behave differently from liposo-
mal-core formulations after the first layer deposition.
a) HA deposition onto LbL liposomes is highly sen-
sitive to ionic strength, and leads to immediate ag-
gregation in the presence of 20 mM NaCl. Layering in
25 mM HEPES yields an unstable species of approxi-
mately 250 nm that aggregates during purification
(buffer exchanged to water). HA layers successfully
in 1 mM HEPES, producing a 215 7 nm particle that
survives purification. b) Polydispersity data for the
same syntheses supporting the observations made
in panel a. c) Layering onto a carboxy-modified latex
core leads to loss of charge using the 25 mM HEPES
20 mM NaCl conditions optimized for liposomal
cores. While the initial PLR layer deposits in a manner
consistent with observations for liposomal systems,
the second anionic layer diverges. Poly(L-glutamate)
(PLE), poly(L-aspartate) (PLD), and dextran sulfate
(DXS) were deposited as second layers in salt, yield-
ing highly charged species. These nanoparticles lost
roughly half their surface charge upon purification,
in contrast to systems where the second layer was
deposited in the absence of any salt. Layering of HA
using 1 mM HEPES still yields consistent results with
liposomal systems. Size and polydispersity data were
acquired by dynamic light scattering, and zeta poten-
tial data was measured using laser Doppler electro-
phoresis. Error bars represent standard deviation of
three technical replicates.
peptides and siRNA, but there is also interest
in working with more challenging materials
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HA also provides HA-coated nanoparticles with a very hydrophilic surface, which likely helps to
mediate some of its resistance to opsonization and monocyte clearance.
We set out to determine if the solution conditions determined for our prior formulation, consisting
of PLD as the outer layer, were compatible with incorporation of HA into an LbL nanoparticle.
Because of the inter and intramolecular forces that complicate working with HA{Suh, 2005 #187,
we hypothesized that the shorter electrostatic screening lengths provided by the salts that were
optimal for siRNA layering would be destabilizing to HA. To assess this, we layered HA at 25 mM
HEPES and 20 mM NaCl, 25 mM HEPES, and 1 mM HEPES (Figure 4.7a-b). Inclusion of NaCl
led to the immediate aggregation of the colloid upon mixing with HA. Interestingly, when using 25
mM HEPES the nanoparticle formed is initially monodisperse and of acceptable size (0.17 0.05
PDI and 189 3 nm z-average diameter), but continues to grow in size over time without becoming
more polydisperse (0.13 0.06 PD! and 276 14 nm z-average diameter). This trend might suggest
continual growth of a thick HA film over time, but the resulting system appears to be unstable
because purification leads to irreversible aggregation as indicated by size and PDI changes in
Figure 4a-b. On the other hand, 1 mM HEPES yielded smaller monodisperse particles (Z-average
diameter of 215 7 nm and PDI of 0.21 0.02) that reduced in size and remained stable after
purification (Z-average diameter of 160 2 nm and PDI of 0.16 0.03). We propose that this trend
suggests that HA is likely more sensitive to electrostatic screening than the polypeptides and
siRNA we tested previously. Even the effects of low ionic strength salt species, like HEPES, alone
may be sufficient to tip the system into an unstable state. We found that dilute HEPES allows for
moderate control of pH for this layer with minimal electrostatic screening, which creates a high
degree of ionization along the HA chain that may promote a stable HA layer and maximize charge-
repulsion between chains to minimize the intermolecular hydrogen bonds8 characteristic of HA.
These results indicate that the solution conditions for LbL nanoparticles are also dependent on
the structure of the polymers being deposited, highlighting how different layers may require spe-
cific solution conditions for a successful synthesis. Along a similar line of inquiry, we also pose the
question of whether the colloidal substrate might impact considerations for optimal solution condi-
tions. To test this, we performed parallel syntheses of bilayered LbL nanoparticles on carboxy-
modified latex (CML) templates (Figure 4.7c). CML/PLR particles were all prepared using 25 mM
HEPES 20 mM NaCl for layering, and purified in water (as optimized above).
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We observe an increase in zeta potential after purification of the CML/PLR particle, a typical
occurrence that can be explained by the removal of excess salts during buffer exchange to deion-
ized water. Surprisingly, we observed a different trend after layering and purifying the second,
anionic layer. A significant loss of surface charge occurred after purification, from ca. -40 mV to ca.
-20 mV. This trend was noted for several terminal layers (e.g., poly(L-glutamate) (PLE), poly(L-
aspartate) (PLD), and dextran sulfate (DXS)) that were deposited in the presence of HEPES/NaCI
and purified with deionized water. The initial charge of the crude products is in line with expected
charge conversion. However, all conditions wherein the layer was deposited in the presence of
salt lose significant surface charge upon purification. Despite the loss of charge, the resulting par-
ticles were monodisperse and of acceptable size (PDI ranging from 0.05 to 0.07 and Z-average
size from 120-130 nm). In contrast, if the second layer is deposited in the absence of salts, the
charge of crude and pure particles remain constant before and after purification.
Interestingly, deposition of HA, using the 1 mM HEPES condition, also provides stable particles
using the CML core, and they do not exhibit a loss of charge upon purification. We also note that
the synthetic solution conditions during LbL may have implications for the fully formed particle.
LbL nanoparticles possess pH-sensitive functionalities, that can mediate charge-shifting and film
swelling. These features of the LbL platform can be used to develop pH-triggered drug release or
cellular uptake26 . We observed that LbL nanoparticles (CML/PLR/HA) prepared at pH 7.4 or pH 6
can initiate swelling characteristics at slightly different pHs (Appendix C Figure 8). While the shift
is modest, it is possible that swelling behavior could be tuned via the synthetic pH.
These intriguing results indicate that the core template may be an important consideration, as it
may alter the ideal solution conditions for LbL synthesis. Further investigation into this phenome-
non should be performed to understand the underlying mechanisms that mediate this discrepancy
between liposomal and CML-core LbL systems, and if those principles extend to other biomedi-
cally relevant substrates like PLGA or mesoporous silica nanoparticles.
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4.3. Conclusions and future work
This work describes a comprehensive and systematic study of the role of solution conditions in the
preparation of LbL-functionalized liposomes for the delivery of siRNA. Our findings demonstrate
important lessons for the continued development of this novel class of therapeutic nanoparticle,
namely through the identification of strategies to independently tailor the degree of polyelectrolyte
ionization and electrostatic screening length using HEPES to control pH and NaCl to control ionic
strength, respectively. We demonstrate that LbL synthesis is tolerant to certain salts but not to oth-
ers, exploring the effects of multivalent, monovalent, and zwitterionic salts. This finding confirms
predictions from prior computational work on the destabilizing nature of larger and more multi-
valent ions on the wrapping of polyelectrolytes around charged spheres. While we demonstrate
that LbL synthesis is relatively tolerant to the presence of monovalent salts like NaCI and tris
hydrochloride, we report that the zwitterionic species HEPES provides outstanding compatibility
with LbL self-assembly. The HEPES buffer provides researchers with an excellent tool for control-
ling pH, and in turn the degree of polymer ionization, for a particular layer deposition step. We
suggest that the compatibility of HEPES with LbL assembly stems from the negligible contribution
of zwitterionic species to electrostatic screening. Meanwhile, the moderate compatibility of LbL
liposomes with NaCl provides the ability to tailor the electrostatic screening length of the solution
to permit more efficient layering of rigid molecules like siRNA. The judicious application of these
conditions ultimately allows for an 8-fold improvement in the weight percent loading of siRNA
in LbL liposomes, from 3.7% to 30%. Notably, the LbL liposomes prepared using the optimized
solution conditions reported here are able to mediate improved gene silencing in human ovarian
cancer cells, both in vitro and in vivo.
Our findings also draw attention to the role of pH in the determination of core-to-polymer mass
ratios that yield stable, layered colloids. Tailoring this condition to maximize the ionization of the
polyelectrolytes and corresponding substrate allow for more efficient mass ratios that call for less
polymer to generate a stable particle. This provides benefits from a materials cost perspective,
but it also has implications for preventing rearrangement of the LbL film. We demonstrate in this
work that polyelectrolytes can compete for incorporation into the LbL film, leading to displacement
of siRNA when the more flexible and charge-dense poly(L-aspartate) is incorporated as the fourth
layer. Shifting pH allows the deposition of PLD to occur using less polymer, which eliminated the
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issue of siRNA displacement on the final layer deposition step.
We extended our studies to analyze the role of salts during the purification process, and deter-
mined that it is beneficial to remove salts from the LbL system during interlayer purification. Using
tangential flow filtration-based methods, we found that purification using salt-containing exchange
buffer led to undesirable increases in particle size and potentially mediates rearrangement or
erosion of the LbL film. This hypothesis is supported by the observation that particles that were
purified in salt required less polymer to achieve charge conversion relative to formulations where
layers are deposited in salt but purified in water. We also report that 3-fold less siRNA incorpora-
tion occurs when LbL liposomes are purified in salt, further suggesting that the film may be erod-
ing or otherwise rearranging during this stage. Using water for the purification allows for improved
encapsulation efficiency and ultimately high weight percent loading of siRNA in the resulting LbL
nanoparticle.
Our study also briefly examines the impact of changing the colloidal substrate for LbL, and we ob-
serve that switching from an anionic liposome to a carboxy-modified latex core has consequences
for LbL synthesis. While the initial PLR layer behaves similarly across CML and liposomes, if the
second layer is deposited in the presence of salts then there is a systematic loss of zeta potential
in the purified LbL CML particle. This observation suggests the need for deeper study into the role
of the colloidal template and how it influences the development of optimal solution conditions for
LbL systems.
Finally, we demonstrated that solution conditions ought to be considered independently for each
polymer being incorporated into the LbL nanoparticle. The polysaccharide hyaluronic acid pro-
vides a breadth of advantages as a terminal layer for the targeted delivery of drugs to cancer, but
also poses considerable challenges during synthesis due to its ability to form inter and intramolec-
ular hydrogen bonds. Deposition of this valuable layer is incompatible with the NaCl and HEPES
conditions that improve siRNA loading, likely because HA must repel other HA molecules from
itself to prevent crosslinking and aggregation of the LbL particle. Consistent with that hypothesis,
we show that by increasing the electrostatic screening length via the removal of NaCl altogether,
we are able to successfully generate thinner films of HA onto LbL liposomes and achieve a stable
colloidal suspension.
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This study demonstrates the importance of carefully optimizing solution conditions for the self-
assembly of LbL nanoparticles, especially for systems designed for drug delivery. Consideration
of the various intermolecular forces and the physical processes that mediate efficient layering can
be used to design solution conditions to optimize the loading of functional biopolymers into this
emerging class of nanocarrier. The work described here offers a useful template for optimization
of similar systems, and aims to promote greater investigation into the role of solution conditions
in the development of these systems.
150
The role of solution conditions in the robust synthesis of layer-by-layer liposomes
4.4. Methods
Chemical and biological reagents: NaCl powder was purchased from (). 1 M Tris-HCI solution
was purchased from (). HEPES, sodium citrate, Na 2HPO 4 and NaH 2 PO4 powders were pur-
chased from MilliporeSigma. 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1-palmitoyl-
2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) (POPG), 1,2-distearoyl-sn-glycero-
3-phospho-(1'-rac-glycerol) (sodium salt) (DSPG), and cholesterol were purchased from Avanti.
Chloroform and methanol were purchased from TCI and Sigma, respectively. Whatman nucle-
pore polycarbonate hydrophilic membranes (400, 200, 100 and 50 nm sizes) were purchased
from GE. All glassware was obtained from Chemglass. 50/15 mL Falcon tubes and 50/5/2 mL
DNA loBind Eppendorf tubes were purchased from VWR. Polysytrene latex microspheres (Fluo-
spheres), locked nucleic acid siRNAs (Silencer Select), 5 M bioreagent grade NaCl solution, and
pre-cast EX 2% agarose E-gels were obtained from Thermo Fisher Scientific. 1 M bioreagent-
grade HEPES was purchased from Fisher Scientific. D02-E100-05-N and C02-E1OO-05-N
tangential flow filtration filters were purchased from Spectrum Labs. Poly(L-arginine hydrochlo-
ride) (9.6 kDa, 38.5 kDa), poly(L-glutamic acid sodium salt) (15 kDa), and poly(L-aspartic acid
sodium salt) (14 kDa) were purchased from Alamanda Polymers. Dextran sulfate sodium salt
(15 kDa) was purchased from MilliporeSigma. Hyaluronic acid (20 kDa) was purchased from
LifeCore. Heparin sulfate was a generous gift from the Sasisekharan Lab. Propargyl-modified
PLD was synthesized according to prior methods{Wang, 2018 #245}{Li, 2017 #244}. Polysty-
rene semi-micro cuvettes for the Malvern Zetasizer were purchased from VWR and DTS1070
folded capillary cells were purchased directly from Malvern. Black 364 well plates for the Wyatt
DLS were purchased directly from the Peterson (1957) Nanotechnology Core Facility.
OVCAR8 and COV362 human ovarian cancer cell lines were gifts from the Bhatia Lab at MIT
and the Elias Lab at Brigham and Women's Hospital, respectively. Tissue culture plasticware
(T75, T25, clear and white 96 well plates), trypsin EDTA, penicillin streptomycin and RPMI 1640
media was purchased from Corning. Fetal bovine serum was purchased from Gibco. Steady-Glo
luciferase expression assay and CellTiter-Fluor viability assay were purchased from Promega.
Preparation of liposomal cores: DSPC, POPG, and cholesterol were dissolved in chloroform and
DSPG was dissolved in a 65:35:8 mixture of chloroform, methanol and deionized water (milli-
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Q). Lipid mixtures composed of 66.7 mol% phospholipid and 33.3% cholesterol were prepared
in round bottom flasks (RBFs) (10 or 50 mL depending on scale), and for DSPG-formulations
methanol was added dropwise until the solution cleared. The lipid solution was evaporated
using a BUCHI RotoVap system under heat (60C, water bath) until completely dry (<15 mBarr).
A Branson sonicator bath was filled with reverse-osmosis water and heated until >70C, at which
point the RBF with the lipid film was partially submerged in the bath and a volume of dH 20 was
added to resuspend the lipid film to a 1 mg lipid/mL solution. The liposome solution was sonicat-
ed for roughly 1 minute and then transferred to an Avestin LiposoFast LF-50 liposome extruder.
The extruder was connected to a Cole-Parmer Polystat Heated Recirculator Bath to maintain
a temperature > 65C. The liposome solution was extruded through successively smaller nucle-
pore membranes until a 50-100 nm liposome was obtained. Generally, this required 1 pass
through a stack of 2-3 400, 200, 100 and 50 nm membranes. Liposomes were characterized for
size and zeta using the techniques outlined below.
Buffer preparation: For the initial PLR layering screen, all buffers were prepared as 200 mM
stock solutions in milli-Q water, and serially diluted to generate 2x strength solutions for each
concentration to be tested. Solution pH was measured using both pH paper and a Hanna
electronic pH-meter. Tris-HCI and sodium citrate were titrated with HCI to obtain pH 7-7.6.
Sodium phosphate was titrated with NaOH to a pH 7-7.6. For the pH-sensitivity experiment in
Supplementary Figure 2, liposomes were diluted in 25 mM HEPES buffer titrated to the desired
pH using either HCI or NaOH. For experiments using the optimized solution conditions, a 50 mM
HEPES 40 mM NaCl solution was prepared in milli-Q water and titrated to pH 7.5.
Layer by layer assembly: Nanoparticles were layered by adding an equal volume of nanopar-
ticle solution (not exceeding 1 mg/mL) to an equal volume of polyelectrolyte solution under
sonication (Branson bath sonicator, room temperature). The mixture was sonicated for roughly
5 seconds. Optimal C:P ratios for each layer were determined prior to the deposition step via a
polyelectrolyte titration using 25-5OuL samples of the nanoparticle solution for each tested C:P
ratio. The test ratios were mixed as above, but only incubated for 5-10 minutes before char-
acterization. If the resulting particle had a zeta potential greater than 30 mV (either positive or
negative) and an appropriate size, it was chosen as the optimal ratio.
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For conditions involving a buffer or salt throughout the entire synthesis, the polyelectrolyte solution
is prepared in 2x strength buffer for the initial layer, and then in 1x strength buffer for subsequent
layers. For conditions that remove the salt during purification steps, the polyelectrolyte solution is
prepared in 2x strength buffer for all deposition steps. Bioreagent-grade NaCl and HEPES were
used for syntheses involving siRNA. DNA loBind tubes are used as the mixing vessels for all
experiments, to prevent nonspecific adsorption of siRNA and other polymers to the plasticware.
The layered particle is allowed to incubate at room temperature for 1 hour and is then purified
using the tangential flow filtration method, as described previously 6 . Briefly, crude nanoparticle
solution is connected to a Spectrum Labs KrosFlo I system using masterflex, Teflon-coated tub-
ing. D02-E100-05-N (batch volume > 5 mL) or C02-E100-05-N (batch volume < 1 mL) 100 kDa
filters were used to purify the particles until 5 volume-equivalents were collected in the permeate.
For cationic layers, the TFF filter was pre-treated with a solution of free polycation (same concen-
tration used for layering) in order to minimize nonspecific adsorption of particles to the membrane
walls. Samples were run at 80 mL/min (size 16 tubing, used with D02-series filters) or 13 mL/min
(size 13 tubing, used with C02-series filters). Once pure, the sample was either concentrated (by
disconnecting the buffer reservoir) or recovered via reversing the direction of the peristaltic pump.
For more complete yields, 1-3 mL of the appropriate buffer was run backwards through the tubing
to recover any remaining particles. This process was repeated until the desired LbL formulation
was obtained. Exchange buffer is chosen to be consistent with the intended synthetic solution
conditions.
Characterization of LbL nanoparticles: Nanoparticles were characterized using dynamic light
scattering. The Wyatt Dyna Pro was used for high throughput experiments shown in Figure 1
and 2 and the Malvern ZS90 Particle Analyzer for all other size measurements reported. Zeta
potential measurements were made using laser Doppler electrophoresis on the Malvern ZS90.
Samples were diluted in milli-Q water for all measurements. Results from the Malvern are
reported using the SD of three measurements.
Determination of siRNA loading and retention (agarose gel and NanoDrop): Agarose gels were
used to determine the complexation state and loading of siRNA. To determine complexation
state, nanoparticles were diluted and 20uL of the diluted particle were added to the wells of a
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pre-cast EX 2% agarose E-gel. To determine loading, the LbL nanoparticles were dissociated
by addition of excess heparin, e.g., the particles were diluted in a solution of 5 mg/mL heparin
and heated (37C) for fifteen minutes. The gel was run using the E-gel system (Thermo Fisher)
for 5 minutes and then visualized using a Typhoon laser scanning imager (GE). To quantify
encapsulation efficiency, permeate fractions were collected during tangential flow filtration of the
siRNA-coated nanoparticles. Fractions were analyzed for siRNA concentration using the Nano-
Drop system (Thermo Fisher), and used to determine total amount of siRNA removed from the
system. The encapsulation efficiency was used in conjunction with the known amount of siRNA
introduced into the system and the yield-adjusted mg of lipid in the system to determine weight
percent loading.
Cell culture and transfection: OVCAR8 and COV362 cells were seeded at a density of 20,000
cells per well in a 96 well plate in complete RPMI 1640 media (10% FBS, 1% pen-strep). Cells
were allowed to adhere to the plate for 24 hours prior to treatment with nanoparticles. Nanopar-
ticles were dosed to provide equivalent siRNA concentrations across conditions (30 nM). After
24 hours, cell viability and luciferase expression were measured using the multiplexed CellTiter-
Fluor and Steady-Glo assay kits according the manufacturer's protocols. Luciferase expression
was normalized to the well viability and then normalized to expression from untreated cells.
In vivo transfection: Female NCR nu/nu mice were purchased from Taconic and subcutaneously
injected with mCherry/Luciferase expressing OVCAR8 cells (1 million cells per flank, 200 uL
injections in 1:1 PBS:MatriGel). Tumors were allowed to establish over the course of one month,
and then randomized into treatment groups. Mice were then injected (tailvein injection, 200 uL
bolus) with nanoparticles to provide a 0.5 mg/kg dose of siRNA against the luciferase gene.
Whole animal imaging was performed using the Xenogen IVIS Imaging System (PerkinElmer)
following an intraperitoneal injection of d-luciferin (200 uL, 15 mg/mL, 10 minute incubation prior
to imaging). These experiments were approved by the Massachusetts Institute of Technology
Committee on Animal Care (CAC).
Calculations and statistics: All statistics were performed using the GraphPad PRISM software,
using the one-way ANOVA test for significance with a Tuker post-hoc test (alpha set to 0.05).
Ionic strengths are calculated as follows:
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a
pH = PKa + 1og10  )
Where I is the ionic strength, summed over n ionizable species in solution, c is the molar concen-
tration of the ith ionized species, and z is the charge number (valency) of the ith species
As there is an inherent relationship for dissociation of acids and bases, Henderson-Hasselbach
was used to calculate the degree of dissociation as follows:
a
pH = pKa + 1g10( -
Where a is the degree of dissociation. Note that for salts, such as NaCl, it is assumed that they
are completely dissociated.
The Debye length K_' (meters) is calculated as follows:
1
K1' Ne 2 21
E EkBT
Where NA is Avogadro's number, e is the elementary charge of an electron, P is the dielectric con-
stant of water (assumed to be 80), co is the permittivity of free space, kB is the Boltzmann constant,
T is the temperature (298K), and I is the ionic strength.
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Chapter 5. Developing theranostic layer-by-layer nanopar-
ticles through clickable terminal layers
Layer-by-layer (LbL) nanoparticles (NPs) are hierarchically organized nanocomposites capable
of incorporating multiple functional materials through sequential deposition steps. While the LbL
process readily integrates charged functional polyelectrolytes, such as siRNA, there are limited
options for materials that are neutral or poorly charged. Here, we describe the covalent attach-
ment of functional biosensing and targeting peptides that would otherwise be incompatible with
LbL assembly, thereby adding new diagnostic capabilities to pre-formed LbL NPs. We report
the preparation of NPs that encapsulate a high weight percentage of siRNA to silence specific
genes, but also carry a biosensing peptide on their surface that is cleaved into a synthetic urinary
biomarker upon exposure to specific metalloproteases overexpressed by tumors. We show this
nanotheranostic is able to mediate simultaneous gene therapy and noninvasive urinary-based
diagnostics in vivo. Importantly, this biosensor reports back on a molecular signature character-
istics to metastatic tumors and associated with poor prognosis - MMP9 protease overexpression.
This work provides a modular nanotheranostic platform to both perturb and characterize tumors
at the molecular level.
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5.1. Introduction
Nanotheranostics refers to multifunctional nanotechnology capable of interweaving diagnostic
and therapeutic utilities1. In addition to bulk tumor imaging, emerging nanotheranostics now aim
to provide molecular and cellular information about the tumor, information that would allow for pa-
tient stratification and treatment personalization. LbL assembly provides a natural route towards
multifunctional nanotheranostics because it introduces functional nanoscale polymer films onto
colloidal substrates, such as drug-loadable and imaging nanoparticles 2. It is no wonder that the
LbL technique has already been extended towards the development of nanotheranostics that
combine imaging with various therapies -5
Nevertheless, the development of more advanced LbL nanotheranostics for the molecular or
cellular characterization of tumors will require more sophisticated approaches. Beyond imaging,
biosensing peptides have been developed that allow for urinary-based detection of molecular sig-
natures of metastatic disease when attached to NPs4,6. These peptides contain cleavage motifs
specific to particular proteases, and when cleaved by the right protease a synthetic biomarker is
released from the NP, which can later be detected in the urine. Such an approach provides both
tumor detection and high-level molecular information about the protease environment, which is
known to correlate with patient prognosis7-9.
Integrating this biosensor peptide technology into the LbL platform would be a significant devel-
opment towards advanced nanotheranostics. The LbL platform would be distinctly capable of
incorporating small molecule drugs10, therapeutic nucleic acids11 , imaging modalities 5, and mo-
lecular probes all within a discrete nanoparticle. The modularity of the approach also lends itself
towards personalization to specific clinical contexts, which could themselves be inferred from the
diagnostic/prognostic functionalities of these nanotheranostic devices.
However, integrating this class of functional peptides into LbL assemblies is not possible through
standard LbL-adsorption techniques, due to a general insufficiency of charged groups on these
peptides. Unfortunately, LbL NPs are not compatible with some of the reaction conditions needed
for typical conjugation chemistries, such as N-hydroxysulfosuccinimide (sulfo-NHS) coupling.
And because many LbL NPs take advantage of facile biopolymer incorporation, such as poly-
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saccharides12 4 and native polypeptides , their complex surface chemistries present additional
challenges for conjugation techniques. To overcome this issue, we describe the optimization of
copper(l)-catalyzed "click" conjugation of functional macromolecules onto pre-formed LbL lipo-
somes. It is worth noting that pre-functionalizing the pPLD polymer prior to LbL assembly could
be another approach towards developing these NPs. We opted against this approach for several
reasons. First, the LbL method works best when layering using an excess of free polypeptide, so
pre-functionalizing the pPLD would lead to significant losses in peptide and excessive materials
costs. Second, it is unclear how the pre-functionalized pPLD would self-assemble onto the LbL
particle. For example, it could layer in a way that buries at least some of the biosensor peptide in
the film, making some peptides inaccessible to protease cleavage. Lastly, pre-functionalization
of the pPLD would limit downstream modularity of the LbL-NP, which could be conjugated to
additional biosensors and molecules depending on the particular biomedical application. Indeed,
we demonstrate this modularity by also exploring a formulation that click-conjugates the cyclic
tumor-targeting peptide iRGD, which has been shown to improve the functionality of this class of
16nanosensor
While click chemistry techniques have been used in the past to build multilayered assemblies on
planar 17-19 and microparticle substrates 20, or to later crosslink hydrogen-bonded assembled LbL
films21-22, limited efforts have been made to introduce this key technique to LbL NPs. By adopting
click-conjugation to modify LbL-NPs, we provide a means to begin introducing functional mac-
romolecules that are otherwise inaccessible via traditional LbL assembly. We demonstrate that
this approach yields stable LbL NPs constructed from liposomal cores, siRNA and polypeptides.
Using a model siRNA, we have shown that the resulting nanoparticles can silence gene expres-
sion in vivo to demonstrate their therapeutic utility, and can detect the MMP9 protease signature
characteristic to a variety of metastatic diseases to demonstrate their diagnostic utility.
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5.2. Results: Covalent attachment of biosensing peptides onto LbL
NPs yields stable colloidal species
We use the biorthogonal copper-catalyzed
azide alkyne cycloaddition to conjugate azide
substrates onto propargyl-modified poly(L-
aspartate) (pPLD) coated LbL-NPs. Because
LbL-NPs are easily aggregated by the pres-
ence of salts23 , this method has the advan-
tage over tradition amide bond formation
reactions of requiring minimal buffering and
higher reactivity at low reagent and catalyst
concentrations, all of which reduce the ionic
strength of reaction medium. The synthetic
bulk conditions for LbL assembly were also
optimized to generate particles in the pres-
ence of low ionic strength, as described in
Chapter 4. While those studies were aimed at
improving siRNA loading into the LbL-NP, we
anticipated that LbL-NPs synthesized in the
presence of salts would have improved com-
patibility with the solution conditions involved
during downstream conjugation reactions.
To produce biosensor LbL NPs, we first syn-
thesized click-compatible LbL-NPs through
the sequential adsorption of poly(L-arginine),
siRNA, poly(L-arginine) (PLR), and propargyl-
modified poly(L-aspartate) (pPLD) onto an
anionic liposomal core. We chose a liposomal
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Figure 5.1. Click-chemistry compatible LbL nanopar-
ticles were formed from liposomal cores, poly-L-
arginine (PLR), siRNA, and propargyl-modified poly-
L-aspartate (pPLD). The anionic liposomal core was
sequentially coated with the charged polyelectrolytes. a)
The steady growth of nanoparticle hydrodynamic diam-
eter was observed during synthesis while maintaining a
low polydispersity index. Z-average size (which is more
sensitive to aggregates) and number average size (which
is more representative of the NP population) are both
included to provide a complete assessment of the NP
size. b) The zeta potential conversion at each stage of the
synthesis corresponds to the successful layering of each
oppositely charged polyelectrolyte. c) Purification kinet-
ics of the siRNA layer were used to determine overall
siRNA loading. Dashed line represents siRNA introduced
into the synthesis. d) Encapsulation efficiency of the
siRNA was determined to be 37.4% and used to calculate
a siRNA to lipid weight percent loading of 41%. Error bars
represent standard deviation of triplicate measurements.
Where error bars are shorter than the height of the data
point symbol, they are omitted.
substrate due to their clinical precedence, ability to encapsulate both hydrophobic and hydro-
philic drugs, tunable surface charge density, and compatibility with extrusion techniques that can
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yield monodisperse particles of specific sizes 24-27 . The PLR coatings were used due to their well-
documented ability to mediate transfection while avoiding nonspecific cytotoxicity2 -29. The PLD
outer layer was chosen to provide a strongly anionic surface that promotes colloidal stability and
repels negatively charged serum proteins. Additionally, approximately 12% of the carboxylic side
chains of the PLD were converted to propargyl groups to yield propargyl-modified PLD (pPLD) to
allow for the downstream click-conjugation with biosensor peptides and other neutral macromol-
ecules (synthetic details available in Appendix D). The nanoparticle size, uniformity and charge
were tracked during the LbL synthesis (Figure 5.1a-b), and the collective data demonstrated the
controlled growth (Z-average diameter of 95 1 nm to 124 3 nm, polydispersity index (PDI) below
0.2 throughout) and sequential charge reversal typical to successful LbL assembly.
The therapeutic capabilities of this nanotheranostic stem from the gene silencing capabilities of
the incorporated siRNA, and the ability for the LbL NP to potently mediate gene silencing depends
in part on the siRNA loading efficiency. We quantified the purification kinetics in order to determine
the encapsulation efficiency of siRNA (Figure 5.1c-d). After siRNA deposition, permeate frac-
tions were collected during tangential flow filtration and analyzed using a UV-spectrophotometer,
indicating an encapsulation efficiency of 37.4%. The weight percent loading of siRNA to lipid was
calculated to be 41 %, and we attribute this high loading to judicious application of salts during LbL
assembly as described in Chapter 4.
Having confirmed that the LbL-NPs possessed good size, charge, and siRNA loading, we used
our modified conjugation conditions to click on various combinations of the MMP9 biosensor
peptide, iRGD targeting peptide, and poly(ethylene glycol) (PEG) pendants (Figure 5.2). We
initially use the PEG pendants in case the biosensor peptides, which are relatively hydrophobic,
might destabilize the colloid. However, size and zeta characterization of the various formulations
indicate the PEG is not necessary for stability (Figure 5.2a-b). As expected with the addition of a
hydrophilic polymer brush layer, inclusion of PEG causes an increase in the hydrodynamic diam-
eter (from 124 3 nm to 184 15 nm for the PEG/Sensor conjugated LbL NP and 175 4 nm for the
PEG/Sensor/iRGD conjugated NP) and a moderate but statistically significant neutralization of
zeta potential (from -50 6 mV to -30 1 mV for PEG/Sensor and -24 1 mV for PEG/SensoriRGD,
p<0.0001 one-way ANOVA with the Dunnett post-hoc test).
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Using our optimized solution conditions,
LbL-NPs tolerated the click conjugation of
the biosensor, iRGD, and PEG, yielding
nanoparticles with mean Z-average hydro-
dynamic diameters ranging from 121 to 184
nm, PDIs ranging from 0.139 to 0.232, and
zeta potentials ranging from -24 to -43 mV.
To confirm the diagnostic utility is preserved
in these NPs, biosensor-functionalized LbL-
NPs were exposed to recombinant MMP9
to test the ability for the protease to cleave
the reporter fragment off of the nanoparticle.
The MMP9-digested particles were pelleted
via centrifugation and the supernatant was
analyzed for the peptide reporter fragment
using enzyme-linked immunosorbent assay
(ELISA) (Figure 5.2c). The results indicated
that the biosensor is still accessible to the
MMP9 protein, providing detectable peptide
signal in the supernatant for both Sensor and
Sensor/iRGD-functionalized LbL NPs.
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Figure 5.2. Click-functionalized LbL NPs remain sta-
ble and exhibit protease-responsive behavior. Various
formulations of LbL NP were generated via covalent at-
tachment of MMP9 biosensing peptide, iRGD targeting
peptide, and PEG. a) The size an uniformity of all the
click-functionalized LbL NP formulations were consistent
with the un-clicked NP. PEGylated formulations exhibit a
larger hydrodynamic diameter, potentially due to the in-
creased hydrophilicity of these NPs. b) The zeta potential
of the clicked LbL NPs remains strong enough to mediate
electrosteric stability for the Sensor and Sensor/iRGD for-
mulations. PEGylation causes a moderate but significant
loss of charge. c) Biosensor LbL NPs were incubated in the
presernce or absence of recombinant MMP9 protease,
and afterwards were pelleted via centrifugation. The su-
pernatant was collected and analyzed for the biomarker
cleavage product using ELISA which indicated elevated
peptide fragment in the MMP9-treated NPs. Error bars
represent standard deviation, and statistical analysis of
panel b uses one-way ANOVA with a Dunnett post-hoc
test and alpha of 0.05.
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5.3. Results: Peptide-functionalized LbL liposomes mediate gene
delivery and urinary based diagnostics in vivo
We then assess the diagnostic capabilities
of the biosensor LbL-NP across models of
colorectal, pancreatic and ovarian cancer.
After each model formed tumors, we sys-
temically injected Sensor/PEG functional-
ized LbL-NPs (Lipo/PLR/siRNA/PLR/pPLD)
to provide a dosage of biosensor peptide
equivalent to 0.03 mg/kg. One hour after in-
jection, the urine from the individual mice was
collected and analyzed using ELISA. Tumor-
free mice were also injected with biosensor
LbL-NP as a control, and their urine was used
to determine baseline peptide reporter frag-
ment (PRF) concentrations in the urine. The
results indicated a broad capability to detect
significantly enriched PRF concentration
in the urine of tumor-bearing mice relative
to tumor-free mice (Figure 5.3a-c). These
results indicate the in vivo diagnostic capa-
bilities of the peptide biosensor are preserved
after conjugation to LbL-NPs. Click conjuga-
tion of these reporter peptides can therefore
facilitate the development of advanced LbL
nanotheranostics capable of sensing molecu-
lar signatures, and potentially characterizing
the tumor microenvironment at the molecular
level all without the need of cumbersome im-
aging infrastructure.
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Figure 5.3. Addition of the biosensing peptide onto
siRNA-loaded LbL liposomes yields a NP capable of
simultaneous tumor detection and gene silencing.
PEG/Sensor functionalized LbL liposomes were systemi-
cally administered to several models of cancer. Analysis
of the urine of the mice one hour after injection indicates
that the theranostic LbL NP yields significantly elevated
levels of the peptide reporter fragment in the urine in
a) pancreatic cancer flank model, b) a metastatic model
of colorectal cancer, and c) a model of ovarian cancer.
Significantly elevated marker levels were detects in the
flank ovarian model, and report levels were elevated in
the metastatic model. d) Theranostic LbL NPs were ad-
ministered to the flank ovarian cancer model to provide
a siRNA dosage of 0.5 mg/kg to silence the model gene
luciferase in vivo. Bioluminescence levels were moni-
tored over three days using an IVIS imaging device. e) All
LbL NPs tested mediated gene silencing but the duration
and intensity of the silencing differed based on the sur-
face chemistry of the NP. Inclusion of the iRGD ligand im-
proved silencing efficacy out to three days. On the other
hand, PEGylation without a targeting ligand causes a
more transient transfection, which by day 3 trends lower
than controls but is not statistically significant (p=0.27).
Error bars represent SEM, and statistical analysis of panels
a and b use students t-tests, while panel c uses a one-way
ANOVA with a Dunnett post-hoc test and alpha of 0.05.
Panel e uses a one-way ANOVA with a Tukey post-hoc
test and alpha of 0.05.
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Having confirmed the diagnostic capabilities of the biosensor LbL-NP, we then demonstrate that
these NPs retain their ability to deliver siRNA in a flank xenograft of ovarian cancer (Figure
5.3e). Biosensor LbL-NPs were prepared using siRNA against the luciferase reporter gene and
click-conjugated with PEG/Sensor or PEG/Sensor/iRGD, and systemically administered to mice
to provide an siRNA dosage of 0.5 mg/kg. Notably, under these conditions, the PEG/Sensor NP
mediated good knockdown after a single dose, decreasing luciferase signal to 51 2% at day 2,
comparable to the 50 9% signal observed from mice treated with the PEG/Sensor/iRGD formula-
tion (Appendix D Figure 2). However, the effects of the PEG/Sensor NP dissipate quickly, lead-
ing to a rise in expression by the third day (88 17% luciferase signal, relative to pre-treatment).
On the other hand, the iRGD NP is able to mediate a consistent and more durable knockdown
- maintaining a decreasing luciferase expression of 50 9% and 46 3% at 2 and 3 days, respec-
tively. We also compare the transfection ability of the non-clicked particle, and find that while it is
able to mediate knockdown of the luciferase gene with a duration similar to the iRGD-formulation,
it is an overall weaker transfection with a peak effect at 3 days with a 68 6% luciferase signal.
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5.4. Results:Click-modification impacts LbL NP interaction with ovar-
ian cancer cells and biodistribution in a metastatic model
To begin to address the potential contribution of iRGD to the in vivo transfection efficiency, we
performed additional in vitro experiments to probe the impact of this ligand on NP-cell binding
(Figure 5.4). Fluorescent biosensor LbL-NPs were generated using 100 nm polystyrene cores
labeled with an infrared dye. These formulations did not involve an siRNA layer, but rather a PLR/
pPLD bilayer that allowed us to probe the impact of the NP surface chemistry on its interaction
with ovarian cancer cells. We explored the impact of Sensor, PEG/Sensor, iRGD/Sensor, and
PEG/iRGD/Sensor conjugation on LbL-NPs using flow cytometry. OVCAR8 cells were incubated
with NPs for 4 or 24 hours prior to analysis via flow cytometry, where shifts in the nanoparticle-
associated fluorescence channel were quantified (Figure 5.4a-b).
PEGylation of the NPs appeared to correlate with increased percentage of cells gated as
nanoparticle-positive at 4 hours, but this effect dissipates by 24 hours. Notably, quantification
of NP-associated fluorescence in the nanoparticle-positive population indicates that PEGylation
depressed NP uptake at both 4 and 24 hours (Figure 5.4c-d). However, this trend was only
statistically significant at 24 hours in the absence of iRGD. Inclusion of the iRGD ligand in general
led to moderate but significant increases in mean NP-associated fluorescence intensity at both 4
and 24 hours, with the most potent trends occurring in the non-PEGylated formulation. Interest-
ingly, inclusion of the sensor appears to improve uptake of NPs compared to un-clicked LbL NP,
though the effect is significantly depressed by 24 hours by inclusion of PEG. Overall, these results
indicate moderate improvement in NP binding to ovarian cancer cells after inclusion of either the
Sensor or iRGD, as well as a negative effect on binding due to PEGylation.
The biodistribution profile of the biosensor LbL-NP was then assessed after intraperitoneal (IP)
administration in an orthotopic model of metastatic ovarian cancer, 72 hours after administration
(Figure 5). We evaluated the IP administration route specifically for its emerging relevance in
the management of ovarian cancer patients in the clinic3032 . The LbL-NPs for this study were
constructed from Cy7-labeled liposomal cores coated with PLR/siRNA/PLR/pPLD, and the NPs
were then further modified via inclusion of the Sensor or Sensor/iRGD. The mice were injected
with dosages equivalent to 0.5mg siRNA/kg, and 72 hours later were sacrificed to determine
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Figure 5.4. Addition of targeting ligands and biosensor peptides improves LbL NP binding to ovarian can-
cer cells. OVCAR8 ovarian cancer cells were incubated with the indicated formulations of LbL NP or unmodified
core substrate and then analyzed using flow cytometry. a) At four hours, LbL NPs have bound to a portion of the
cells. PEGylation appears to increase the fraction of cells identified as nanoparticle positive. b) But by 24 hours,
there is little difference across the formulations in terms of the fraction of cells that are nanoparticle positive. c)
Analysis of the mean nanoparticle-associated fluorescence intensity of the nanoparticle-positive cell population
reveals differences in the amount of NP associated to OVCAR8 cells at 4 hours. All LbL NPs mediate significantly
improved NP-cell binding relative to unmodified core particle. And inclusion of the iRGD peptide significantly
improved uptake over the un-clicked formulation. PEGylation appears to depress uptake, and inclusion of the
biosensing peptide appears to improve it, although these trends are not statistically significant. d) By 24 hours,
these differences are magnified, and the negative influence of PEG on binding affinity becomes apparent with the
significant decrease in RFU with the PEG/Sensor over the Sensor formulation. While it also depresses uptake of the
iRGD formulation, the trend is not significant. Whiskers represent maximum and minimum values, and statistical
analysis was carried out using a one-way ANOVA with Tukey's post-hoc test and an alpha of 0.05.
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Figure 5.5. Theranostic LbL NP biodistribution in a metastatic model of ovarian cancer indicates good
tumor targeting capabilities, especially using intraperitoneal (IP) administration. Mice bearing metastatic
ovarian cancer were treated with either Sensor or iRGD/Sensor-functionalized LbL liposomes (Cy7-labeled lipo-
some/PLR/siRNA/PLR/pPLD). a) Three days following administration of the NPs, the mice were sacrificed and their
liver, spleen, and tumors were isolated for analysis using a fluorescent flatbed scanner (LiCor Odyssey). Tissue
autofluorescence was used to generate a region-of-interest (indicated by the white outline) in which to quan-
tify signal from the Cy7-labeled NPs. b) NP-associated RFU were normalized by the scanned tissue surface area.
Liver and spleen accumulated fewer NPs relative to tumors in all cases. Inclusion of iRGD appears to positively
impact accumulation. Intravenous administration of the NP leads to significant heterogeneity in biodistribution.
Cryohistology was performed on tumor tissue and imaged using a fluorescent slide scanner to detect tissue au-
tofluorescence (psuedocolored magenta) and nanoparticle signal (psuedocolored green). These representative
images show good distribution of LbL liposomes through tumors when administered IP (c-d), but considerably
fewer NPs could be found in tumors from mice treated intravenously with LbL NPs (e). Whiskers represent maxi-
172 mum and minimum values, and statistical analysis was carried out using a one-way ANOVA with Tukey's post-hoc
test and an alpha of 0.05.
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relative nanoparticle levels in the tumor, liver and spleen. The nanoparticle-associated fluores-
cence of the tissues was measured using a LiCor flatbed scanner, and we observed a significant
partitioning of LbL NP into tumor tissue for IP-administered NPs (Figure 5.5a-b, Appendix D
Figure 3). Relative to the NP signal in the tumor, very little was detected in the liver or the spleen
for either Sensor or iRGD/Sensor NPs. Inclusion of the iRGD targeting ligand appears to have a
beneficial effect on tumor accumulation, though the method of quantification used here is based
on tissue surface area, and could be skewed by differences in tumor burden between the two
treatment groups. But based on the qualitative results from the LiCor and histological analyses,
it does appear that the two formulations accumulate in neoplastic tissue preferentially when ad-
ministered IP. We also assessed the ability for the Sensor/iRGD formulation to traffic to the tumor
following a systemic administration, and found that these particles do target tumor tissue but very
heterogeneously, and do not accumulate to the extent observed in the IP-injected mice. Notably,
the IV-administered LbL-NPs do not appear in the liver or spleen by this time, which we propose
may indicate the particle is easily degraded and cleared from these organs. Cryohistology of the
tumors indicates a good distribution of nanoparticles throughout the outer surface of the tumors
for the IP-injected mice (Figure 5.5c-d), but very little NP signal could be found in the tumors from
IV-injected mice (Figure 5.5e). Overall, these results indicate a good tumor-homing ability for
these NPs, especially if administered IP, and that these NPs are likely biodegradable and easily
cleared from filtration organs.
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5.5. Conclusions and future work
Nanotheranostics provide the capability to monitor and characterize tumors and their response to
therapies. This approach has tremendous potential for nanomedicine, as it can be used to identify
patients who may benefit the most from particular treatments. Here, we described a method for
incorporating an advanced diagnostic utility into the LbL nanoparticle platform using click chem-
istry conjugation techniques, specifically by demonstrating a 54 3% knockdown of a model gene
and a sensitive detection of tumor burden in three models of cancer. This approach provides a
highly modular system to which biosensing molecules, antifouling agents, and targeting ligands
can be readily incorporated on top of an already highly-sophisticated drug carrier. The versatility
of the base LbL nanoparticle also provides further layers of modularity in this system, such as the
ability to use different siRNAs for a particular application as well as the option to include drugs or
imaging modalities into the liposomal core. Importantly, this approach provides LbL nanoparticles
the ability to characterize tumors at the molecular level, a functionality which could be employed
to detect changes in specific protease levels in the future. Importantly, this platform demonstrated
an ability to detect various forms of highly metastatic disease, including colorectal, pancreatic and
ovarian cancer. These diseases are so deadly, in part, due to the inability to detect them at early
stages, and thus biosensor-functionalized LbL-NPs may provide a route towards early diagnostic
testing for these challenging malignancies.
Future work on this project aims to incorporate a therapeutic siRNA into the LbL NP design,
specifically siRNA against the transcriptional regulator SMARCE1. This regulator governs the
expression of a host of proteases, and correlates with poor prognosis for patients. Preliminary
findings suggest that loss of SMARCE1 inhibits the metastatic potential of OVCAR8 cells in our
model of metastatic disease, and thus the next steps in this project aim to target SMARCE1 using
the theranostic LbL NP. Of interest is whether the loss of SMARCE1 leads to a decrease in pro-
tease levels, which would logically lead to a loss of biosensor activity. In this way, the theranostic
LbL NP may be able to inform us of the success of siRNA delivery through noninvasive means, a
major advancement in the development of devices that can simultaneously mediate and monitor
a therapy.
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5.6. Methods
Reagents: 1,2-distearoyl-sn-glycero-3-phospho-(l'-rac-glycerol) (sodium salt) (DSPG), 1,2-dio-
leoyl-sn-glycero-3-phosphoethanolamine (DOPE) and cholesterol were purchased from Avanti.
Sulfo-cyanine 3 and 7 NHS esters were purchased from Lumiprobe. Chloroform and methanol
were purchased from TCI and Sigma, respectively. Whatman nuclepore polycarbonate hydrophilic
membranes (400, 200, 100 and 50 nm sizes) were purchased from GE. All glassware was ob-
tained from Chemglass. 50/15 mL Falcon tubes and 50/5/2 mL DNA loBind Eppendorf tubes were
purchased from VWR. Infrared polysytrene latex microspheres (Fluospheres), locked nucleic acid
siRNAs (Silencer Select), and 5 M bioreagent grade NaCl solution were obtained from Thermo
Fisher Scientific. 1 M bioreagent-grade HEPES was purchased from Fisher Scientific. D02-E1 00-
05-N and C02-E100-05-N tangential flow filtration filters were purchased from Spectrum Labs.
Poly(L-arginine hydrochloride) (38.5 kDa) was purchased from Alamanda Polymers. Polystyrene
semi-micro cuvettes for the Malvern Zetasizer were purchased from VWR and DTS1070 folded
capillary cells were purchased directly from Malvern. Black 364 well plates for the Wyatt DLS
were purchased directly from the Peterson (1957) Nanotechnology Core Facility.
OVCAR8 human ovarian cancer cells were obtained from ATCC. Luciferized and mCherry ex-
pressing lines were transfected with Cignal Lenti Reporter Control (Qiagen). Luciferized MC26
murine colorectal cancer cells were a kind gift from Kenneth Tanabe's lab at MGH. And D8-175
pancreatic cancer cells were derived from murine KPC tumors harvested in the lab of Tyler Jacks.
Tissue culture plasticware (T75, T25, clear and white 96 well plates), trypsin EDTA, penicillin
streptomycin, DMEM and RPMI 1640 media were purchased from Corning. Fetal bovine serum
was purchased from Gibco. D-luciferin was purchased from Fisher Scientific.
All peptides were synthesized by CPC Scientific, Inc, with a purity of 90%. In vivo protease sensi-
tive substrates were synthesized to contain a urinary reporter comprised of a protease resistant
D-stereoisomer of Glutamate-Fibrinopeptide B with a fluorophore for urinary detection (Biotin-
eGvndneeGffsarK(FAM)-gGPLGVRGKK(N3), smaller case indicates D-amino acids).
Tumor targeting and penetrating peptides (iRGD) were synthesized and cyclized iRGD: CRGD-
KGPDC.
Polymer synthesis: -benzyl-L-aspartate N-carboxyanhydride (BLD NCA) was prepared as de-
175
Developing theranostic layer-by-layer nanoparticles through clickable terminal layers
scribed previously 33. Briefly, a suspension of -benzyl-L-aspartate (25.0 g, 112 mmol), THF (200
mL), and triphosgene (30.0 g, 100 mmol) was stirred and sparged with a steady stream of argon
under reflux for 2 h. Hexanes (700 mL) were added and the resulting precipitate was collected
by vacuum filtration, washed 4 times with hexanes, dissolved in anhydrous THF (300 mL), and
recrystallized under a layer of hexanes (700 mL). The solids were collected by vacuum filtration,
washed 4 times with hexanes, and dried in vacuo to give white crystals (25.7 g, 103 mmol, 92%).
1H NMR (400 MHz, CDC 3) 6 7.47 - 7.30 (m, 5H), 6.13 (s, 1H), 5.19 (s, 2H), 4.60 (dd, J= 9.5, 2.4
Hz, 1H), 3.09 (dd, J = 17.7, 3.1 Hz, 1H), 2.84 (dd, J = 17.7, 9.6 Hz, 1H)
13C{ 1H} NMR (101 MHz, CDCI) 169.55 (s), 168.31 (s), 151.32 (s), 134.76 (s), 129.03 (s), 128.95
(s), 128.71 (s), 67.98 (s), 53.98 (s), 36.22 (s)
poly(P-benzyl-L-aspartate) (PBLD) was prepared as described previously33. Briefly, to a solution
of BLD NCA (4.99 g, 20.1 mmol) and DMF (50 mL) was added hexylamine (26.5 pL, 0.201 mmol).
The reaction was sparged with a steady stream of argon at RT for 48 h. The polymer was precipi-
tated by addition of water and the resulting precipitate was collected by centrifugation, washed
with water, and dried in vacuo to give a white powder (3.25 g, 15.8 mmol repeat units, 78.8%).
1H NMR (400 MHz, DMSO): 6 8.37 - 7.98 (m, 1 H), 7.51 - 7.08 (m, 5H), 5.21 - 4.92 (m, 2H), 4.74
- 4.48 (m, 1 H), 2.98 - 2.54 (m, 2H).
poly(L-aspartate) (PLD) was prepared as described previously34. Briefly, to a solution of PBLD
(2.42 g, 11.8 mmol repeat units) in trifluoroacetic acid (14.5 mL) was added dropwise 33 wt% HBr
in AcOH (6.0 mL). The reaction was stirred for 1 hour after which diethyl ether was added. The
precipitate was collected by filtration, washed with diethyl ether, and dried in vacuo to yield an off
white powder (1.05 g, 9.12 mmol repeat units, 77.3%).
Poly(propargyl-L-asparate-co-L-aspartate) (pPLD)
PLD (1.05 g, 9.12 mmol) was added to a round bottom flask equipped with a stir bar and DMF (15
mL), water (2 mL), HOBt hydrate (ca. 20% water) (184 mg, 1.09 mmol), and propargylamine (130
pL, 3.19 mmol) were added. EDC (216 mg, 1.09 mmol) was added portion wise with stirring. After
stirring for 24 h, the DMF was removed by extraction with diethyl ether and the pH of the aqueous
phase was adjusted to 7 by addition of saturated sodium bicarbonate solution. The aqueous solu-
tion was dialyzed against saturated sodium chloride followed by deionized water (MWCO 1 kDa,
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regenerated cellulose) and lyophilized to give a white powder (1.06 g). The degree of substitution
was determined to be 12% by the ratio of protons on both sides of the side chain amide group.
Signals from the amide protons, a-proton, and propargyl proton were visible, but dimished due to
deuterium exchange. 1H NMR (400 MHz, D2 0) 6 4.73 - 4.53 (m, 1 H), 3.97 (s, 0.24H), 2.86 - 2.50
(m, 2H). Trace available in Supplemental Figure 1.
Tissue culture: OVCAR8 cells were maintained in RPMI media supplemented with 10% FBS. All
other cell lines were kept in DMEM media supplemented with 10% FBS. All media was supple-
mented with 1 % penicillin streptomycin. All cells were allowed to adhere/grow for 24 hours before
treatment with nanoparticles in a Heracell Incubator (Thermo Fisher) at 37C and 5% C02. All cell
lines were tested for mycoplasma contamination periodically, including immediately upon thaw-
ing, and over time when in culture, using the Lonza MycoAlert kit (Catalog #: LT07-318). Results
were always negative for mycoplasma contamination.
Preparation of liposomes: Cholesterol and DOPE were dissolved in chloroform and DSPG was
dissolved in a 65:35:8 mixture of chloroform, methanol and deionized water (milli-Q). Lipid mix-
tures composed of 66.7 mol% DSPG and 33.3% cholesterol were prepared in round bottom flasks
(RBFs) (10 or 50 mL depending on scale), and for DSPG-formulations methanol was added drop-
wise until the solution cleared. For fluorescent liposomes, the formulation was 61.7% DSPG, 5%
DOPE and 33.3% cholesterol. The lipid solution was evaporated using a BUCHI RotoVap system
under heat (60C, water bath) until completely dry (<15 mBarr). A Branson sonicator bath was
filled with reverse-osmosis water and heated until >70C, at which point the RBF with the lipid film
was partially submerged in the bath and a volume of dH 2 0 was added to resuspend the lipid film
to a 1 mg lipid/mL solution. The liposome solution was sonicated for roughly 1 minute and then
transferred to an Avestin LiposoFast LF-50 liposome extruder. The extruder was connected to a
Cole-Parmer Polystat Heated Recirculator Bath to maintain a temperature > 65C. The liposome
solution was extruded through successively smaller nuclepore membranes until a 50-100 nm
liposome was obtained. Generally, this required 1 pass through a stack of 2-3 400, 200, 100 and
50 nm membranes. Fluorescently labeled liposomes were prepared via standard NHS-coupling of
Sulfo-cyanine NHS ester to DOPE head groups. Liposomes were characterized for size and zeta
using the techniques outlined below.
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Preparation of layer-by-layer nanoparticles: Nanoparticles were layered by adding an equal vol-
ume of nanoparticle solution (not exceeding 1 mg/mL) to an equal volume of polyelectrolyte solu-
tion under sonication (Branson bath sonicator, room temperature). The mixture was sonicated for
roughly 5 seconds. The liposome to polyelectrolyte mass ratios used for each layer were 4:1 for
the first PLR, 1:1 for the siRNA, 3:1 for the second PLR, and 1:1 for the pPLD layer. Polyelectro-
lyte solutions were always prepared in 50 mM HEPES and 40 mM NaCl. DNA loBind tubes are
used as the mixing vessels for all experiments, to prevent nonspecific adsorption of siRNA and
other polymers to the plasticware.
The layered particle is allowed to incubate at room temperature for 1 hour and is then purified
using the tangential flow filtration method, as described previously35 . Briefly, crude nanoparticle
solution is connected to a Spectrum Labs KrosFlo I system using masterflex, Teflon-coated tub-
ing. D02-E100-05-N (batch volume > 5 mL) or C02-E100-05-N (batch volume < 1 mL) 100 kDa
filters were used to purify the particles until 5 volume-equivalents were collected in the permeate.
For cationic layers, the TFF filter was pre-treated with a solution of free polycation (same concen-
tration used for layering) in order to minimize nonspecific adsorption of particles to the membrane
walls. Samples were run at 80 mL/min (size 16 tubing, used with D02-series filters) or 13 mL/min
(size 13 tubing, used with C02-series filters). Once pure, the sample was either concentrated (by
disconnecting the buffer reservoir) or recovered via reversing the direction of the peristaltic pump.
For more complete yields, 1-3 mL of the appropriate buffer was run backwards through the tubing
to recover any remaining particles. This process was repeated until the desired LbL formulation
was obtained. Exchange buffer was always distilled water.
Click-chemistry conjugation onto LbL nanoparticles: To a suspension of nanoparticles (0.1-0.5
mg/mL) was added an equal volume of a freshly made solution consisting of copper(II) sulfate (48
pM), tris(3-hydroxypropyltriazolylmethyl)amine (0.75 mM), sensor peptide (11 pM), iRGD peptide
(7.5 pM), and azido-PEG (12 pM) in deionized water. The solutions were mixed by pipette and a
freshly made solution of sodium ascorbate (3.8 mM) in deionized water equal to the original vol-
ume of nanoparticle suspension was added and mixed by pipette. The reaction vessel was sealed
and incubated in the dark for 12-24 hours, after which the particles were purified by tangential
flow filtration.
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Characterization of nanoparticles: Nanoparticle hydrodynamic size and polydispersity were
measured using dynamic light scattering (Malvern ZS90 Particle Analyzer, A = 633 nm, material/
dispersant RI 1.590/1.330). Zeta potential measurements were also acquired with the Malvern
ZS90, using laser Doppler electrophoresis. Nanoparticle solutions were diluted in milli-Q water
in polystyrene semi-micro cuvettes (VWR) or DTS1070 folded capillary cuvettes (Malvern) to
produce samples for characterization.
In vitro MMP9 cleavage study: NPs were incubated with recombinant proteases (MMP-9: Enzo
Life Sciences) in a final volume of 100 uL in enzyme specific buffers (MMP9 buffer: 50 mM Tris,
150 mM NaCl, 5 mM CaCI2, 1uM ZnCI2, pH 7.5) at 37 0C for 1 hour. Final MMP-9 concentration
was 100 nM. Afterwards, NPs were pelleted using centrifugation (30,000 RCF for 60 minutes)
and the supernatant was collected.
Urinary reporter was detected using an ELISA. Mouse anti-fluorescein (GeneTex) were adsorbed
to 96-well Bactiplates (Thermo) at concentrations of 0.4 pg/mL for 1 h in 1 xPBS. Plates were then
blocked for 1 h with 1 x PBS with 2% (wt/vol) BSA (Sigma). Reporter standards were applied to
blocked plates in two fold serial dilutions in 100 pL volume for 1 h to characterize assay linearity.
To detect reporters, 100 pL of 0.4 pg/mL NeutrAvidin-HRP (Pierce) was applied for 1 h. Bound
HRP was exposed with 50pL of Ultra-TMB (Pierce) for 1-5 min followed by quenching with 50
pL of 1 M HCI. Between each step, plates were washed three times with 1 x PBS with 0.5% (vol/
vol) Tween 20 (Sigma). Absorbance at 450 nm was measured, plotted against known reporter
concentration, and used to generate a linear fit over the assay's linear absorbance region. Results
were normalized relative to NPs that were not exposed to MMP9.
Animal Studies: All animal experiments were approved by the Massachusetts Institute of Technol-
ogy Committee on Animal Care (CAC) and were conducted under the oversight of the Division of
Comparative Medicine (DCM). Pancreatic cancer flank models were established with a subcuta-
neous injection of D5-175 cells to both flanks of Balb/C female mice. Flank ovarian cancer models
were established by subcutaneous injection of a 1:1 mixture of OVCAR8 cells and matrigel into
both flanks of female NCR nude mice. The metastatic model of ovarian cancer was established
via intraperitoneal injection of OVCAR8 cells into female NCR nude mice. The metastatic model
of colorectal cancer was established by direct injection of MC26 cells into the subsplenic capsule
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of Balb/C female mice. After 90 seconds, the spleen was removed to prevent splenic tumors. For
all models, tumor growth was monitored by measuring bioluminescence.
Determination of urinary diagnostic function: Theranostic LbL NPs were injected intravenously via
the tailvein to dose tumor bearing or tumor free mice with 0.03 mg biosensor peptide / kg body
weight. Mice were then held in specialized containers in order to collect urine. One hour after
injection, urine was collected and analyzed via ELISA as described in the MMP9 cleavage study
above.
Determination of in vivo gene silencing: Baseline bioluminescent signal was established for
flank ovarian cancer cell models by injecting 300 uL of 15 mg/mL d-luciferin subcutaneously. Ten
minutes after d-luciferin administration, mice were imaged using an IVIS whole-animal imaging
device (PerkinElmer). After the initial imaging, mice were injected intravenously via the tailvein
to dose 0.5 mg siRNA / kg body weight. Mice were then imaged for bioluminescent signal each
day for three days following the same procedure used to establish the baseline signal. Data was
analyzed using the Livinglmage software to designate regions of interest over the tumors. Each
tumor's luminescent signal was normalized relative to their pre-treatment baseline signal.
Biodistribution study: Metastatic ovarian cancer models were injected intraperitoneally or via the
tailvein with Cy-t labeled theranostic LbL NP to dose 0.5 mg siRNA / kg body weight. After three
days, mice were euthanized and their spleens, livers and tumors were isolated and imaged using
a LiCor Odyssey flatbed fluorescence scanner at both the 700 and 800 nm wavelengths. The
tissue autofluorescence image generated by the 700 nm channel was used to identify regions
of interest for quantitation using FIJI's analyze particle functionality. Fluorescence intensity in
the 800 nm channel was then calculated with regions of interest and normalized by the scanned
surface area.
Cryohistology: Following imaging by the LiCor in the biodistribution study, tissues were embedded
in OCT compound and flash frozen over liquid nitrogen. The cryomolds were maintained at -80C
until they could be sectioned by the Koch Institute's histology core facility. The slides were then
imaged using a Pannoramic Fluorescent Slide Scanner, using the TRITC, and Cy7 channels to
detect tissue autofluorescence and nanoparticle signal, respectively.
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Statistical Analysis: All statistical analysis was performed using GraphPad PRISM 7. For single
comparisons, a student's t-test was used. For multiple comparison testing, one-way or two-way
ANOVA was used in conjuction with the appropriate post-hoc test. Dunnett's test was used when
comparing samples to a shared control group, whereas Tukey's test was used when comparing
all groups. When relevant, normality tests were performed using a Shapiro-Wilk test.
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Chapter 6. Summary and conclusions
Layer-by-layer (LbL) assembly is a flexible and versatile technique for fabricating
multifunctional nanomaterials. It is uniquely capable of integrating the benefits of
traditional colloidal drug carriers with the properties of numerous functional polymers
to create sophisticated nanocomposites. The parameter space available to this
technique is expansive, especially since most colloids of interest (e.g., liposomes,
gold, mesoporous silica and PLGA cores) can be easily modified to become charged
templates for LbL assembly. And beyond the core, there are a tremendous number
of polyelectrolytes suitable for adsorption into LbL films. Other critical properties of
LbL NPs can also be tuned, including polymer molecular weight, core template size,
and synthetic solution conditions. What we are left with is a platform with remarkable
potential and an expansive frontier for continued research.
To harness this potential, we optimized the fabrication process for LbL NPs. First,
we leveraged modern tangential flow filtration (TFF) techniques to develop a higher
throughput synthetic approach. We used TFF to handle the cumbersome interlayer
purification steps required to synthesize diverse LbL NPs. This approach was broadly
compatible with various colloidal templates as small as 40 nm in size, including
liposomes, mesoporous silica, and latex nanoparticles. We fabricated LbL NPs featuring
layers of synthetic polymers, native polypeptides, polysaccharides and nucleic acids.
And importantly, we reported some of the first systematic studies looking at long-term
refrigerated and lyophilized storage of LbL NPs, including the shelf life of LbL-modified
doxorubicin liposomes.
These improvements in scale and production made it feasible for us to study the role
of diverse surface chemistries on nanoparticle interactions with ovarian cancer cells.
Using a library of ten different surface chemistries, we systematically compared LbL
NP binding affinity to ovarian cancer cells. The library spanned the gamut from simple
synthetic polymers (e.g., polyacrylate) to highly complex biopolymers (e.g., heparin
sulfate). LbL nanoparticles terminated with carboxylated layers showed a fascinating
ability to bind preferentially to ovarian cancer cells, a trait not shared with LbL NPs
terminated with sulfated species. Remarkably, this trait was not even shared with the
carboxy-modified latex nanoparticle that served as the template for the LbL library. This
suggests a unique role for the LbL film in mediating this high-affinity interaction. These
trends persisted in a metastatic model of ovarian cancer. We found that administrating
these particles via intraperitoneal injection provided a highly selective trafficking of NPs
to ovarian tumors in vivo.
While overall trends in binding affinity and biodistribution corresponded well with
surface chemistry family (e.g., carboxylated vs sulfated LbL NPs), follow-up studies
with high-performing LbL formulations revealed surprisingly different subcellular
trafficking patterns among carboxylated LbL NPs. Depending on the terminal layer,
these nanoparticles were either readily internalized or exhibited unique surface-bound
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morphologies, even at late time points. Studies into each formulation's engagement with
specific uptake mechanisms also revealed diversity in dependence on key pathways,
including cholesterol and caveolae-mediated uptake.
These unique trafficking patterns could be leveraged to develop nanoparticles capable
of mediating specific functions. We demonstrated this by developing a new kind of
nanotheranostic device that takes advantage of a poly-L-aspartate-based LbL coating.
This theranostic NP needed to deliver siRNA into the cytoplasm of ovarian cancer cells,
and also facilitate interactions with extracellular proteases in order to trigger release
of a urinary biomarker. The poly-L-aspartate coating, with its ability to mediate both
significant internal and external localization in ovarian cancer cells, was a natural choice
for this nanotheranostic. The availability of carboxyl groups also allowed us to modify
the polymer to include click-compatible propargyl groups - thus allowing attachment
of charge-neutral, protease-sensing and tumor-targeting peptides onto the LbL NP's
surface.
The specific biomedical goals of the theranostic NP formulation demanded the
development of a rigorous synthetic strategy. In order to mediate gene silencing, we
needed to reliably form LbL films containing a high content of siRNA. Our LbL NP
also needed to be compatible with ionic strengths used during the click conjugation
of functional peptides to particle surface. To optimize our synthesis, we performed
a systematic study of the role of solution conditions in the fabrication of these
nanoparticles, and obtained some of the most comprehensive experimental data
reported concerning the impact of salts on colloidal LbL assembly. We ultimately
identified an approach that provided robust synthesis of LbL liposomes loaded with
a high weight percentage of siRNA to lipid (on average 30%). This strategy directly
facilitated the preparation of our theranostic LbL liposome that could mediate gene
delivery in a murine model of ovarian cancer, and also detect tumors in pancreatic,
colorectal and ovarian cancer models.
This work begins to map the expansive frontier of layer-by-layer nanotechnology. It lays
the groundwork for scaling up production to probe multiple fundamental parameters
simultaneously. It begins to define the role and importance of solution conditions in
colloidal LbL assembly in a systematic way, and indicates areas where continued
research is needed. It shows how a methodical study using library-based approaches
can identify promising new LbL NP formulations, and how those formulations
can be advanced towards specific innovative biomedical applications, such as
nanotheranostics. The introduction of click-chemistry compatible handles on the surface
of LbL NPs also opens the door for integrating LbL technology with materials that
previously were incompatible with the technique, such as charge-neutral peptides and
macromolecules.
Future work in this area will benefit from continued efforts to streamline, and hopefully
automate, the fabrication of LbL NPs - potentially even the elaboration of good
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manufacturing practice (GMP)-compliant synthetic methods. This will improve the
throughput and scalability of LbL NPs, and thus facilitate more ambitious library-based
biomaterials studies. In this way, more advanced and comprehensive exploration
of key parameters such as surface chemistry, film composition, swelling behavior,
isoelectric point, size, shape, and stimuli-responsive properties can be evaluated.
Continued fundamental studies into the role of solution condition will be vital, not only
for maintaining consistent and reproducible methodologies but also for developing
techniques to tune loading of therapeutic polyelectrolytes and film composition.
Additional studies also are needed to gauge the impact of synthetic solution conditions
on downstream properties, such as nanoparticle stability, shelf life, swelling behavior,
drug release and interactions with biological interfaces. There remains extensive
work and opportunity to explore this exciting frontier in nanotechnology, including
areas involving process engineering, fundamental materials science and applications-
based research. And as this work demonstrates, improving the manufacturing of these
nanomaterials facilitates the design and implementation of systematic studies needed to
unlock the structure-function relationships that govern drug delivery.
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Appendix A Figure 1. Solid-core LbL particles were prepared by coating 100 nm, carboxy-modified latex
particles with three bilayers of polyethylenimine and heparin sulfate (100CML-[PEI/HS] 3). This formulation
was prepared using the TFF-assisted protocol. (a) We tracked the hydrodynamic size using dynamic light scatter-
ing and plotted the particle size distribution on a violin plot to demonstrate controlled growth. Violin plots display
the estimated kernel density of the size or charge distribution, and allow the visualization of population-wide
evolution of LbL nanoparticle characteristics during synthesis. The black squares denote the mean hydrodynamic
size for each layer. (b) The zeta potential reversal at each stage of the layering process confirms successful LbL
assembly. This was tracked with laser Doppler electrophoresis, and the charge distributions were plotted as a
violin plot. The blacks squares denote the mean zeta potential for each layer. (c) The polydispersity index was
measured by dynamic light scattering, and remained small throughout LbL assembly indicating good uniformity.
Error represents SD of three technical replicates. Gray denotes latex core, orange denotes PEI layers, and dark blue
denotes HS layers.
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Appendix A Figure 2. Solid-core LbL particles were prepared by coating 40 nm, carboxy-modified latex
particles with three bilayers of poly(L-lysine) and dextran sulfate (40CML-[PLL/DXS]3 ). This formulation was
prepared using the TFF-assisted protocol to demonstrate compatibility with smaller LbL substrates. (a) We tracked
the hydrodynamic size using dynamic light scattering and plotted the particle size distribution on a violin plot to
demonstrate controlled growth. Violin plots display the estimated kernel density of the size or charge distribution,
and allow the visualization of population-wide evolution of LbL nanoparticle characteristics during synthesis. The
black squares denote the mean hydrodynamic size for each layer. (b) The zeta potential reversal at each stage of
the layering process confirms successful LbL assembly. This was tracked with laser Doppler electrophoresis, and
the charge distributions were plotted as a violin plot. The blacks squares denote the mean zeta potential for each
layer. (c) The polydispersity index was measured by dynamic light scattering, and remained small throughout LbL
assembly indicating good uniformity. Error represents SD of three technical replicates. Gray denotes latex core,
orange denotes PLL layers, and light blue denotes DXS layers.
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Appendix A Figure 3. Mesoporous-core LbL particles were prepared by coating 50 nm, mesoporous silica
nanoparticles with three bilayers of poly(L-arginine) and poly(L-glutamic acid) (50MSN-[PLL/DXS]3). This
formulation was prepared using the TFF-assisted protocol to demonstrate compatibility with a solid, drug-load-
able substrate. (a) We tracked the hydrodynamic size using dynamic light scattering and plotted the particle size
distribution on a violin plot to demonstrate controlled growth. Violin plots display the estimated kernel density of
the size or charge distribution, and allow the visualization of population-wide evolution of LbL nanoparticle char-
acteristics during synthesis. The black squares denote the mean hydrodynamic size for each layer. We observed
improvement in the size distribution during LbL modification which maybe due to the introduction of stronger
electrostatic stabilization thanks to the polymer coating. The initial increase in size at the first layer is thought
to be the generation of a relatively thick "fuzzy" polymer surface, which is then compacted by deposition of the
next layer. (b) The zeta potential reversal at each stage of the layering process confirms successful LbL assembly.
This was tracked with laser Doppler electrophoresis, and the charge distributions were plotted as a violin plot.
The blacks squares denote the mean zeta potential for each layer. The weak charge on the initial MSN substrate
led to relatively broader and less uniform charge distributions for the earlier layers, which eventually gives way
to more uniform, tight charge distribution by layer 4. (c)The polydispersity index was measured by dynamic light
scattering, and decreased throughout LbL assembly indicating improving uniformity. This is consistent with the
observations made in the shape of the size distribution. Error represents SD of three technical replicates. Green
denotes mesoporous silica core, orange denotes PLA layers, and purple denotes PG layers.
192
-
Appendix A
b.a.
N
ECM
C:
2
0
1000 -
100 -
10-
a 0
- & U0~ mm am
E,
0CL
IN
7
150,
100-
50-
0
-50-
-100-
Liposome PLA DXS
Layer
C.
-150
PLA DXS
4 *
N
.I
Liposome PLA DXS PLA
Layer
0.3
0.2.
Polydispersity Index
0.1.
0.0.
0 2 3 4
Layer
Appendix A Figure 4. Hollow-core LbL particles were prepared by coating 70 nm, doxorubicin-loaded Ii-
posomes with two bilayers of poly(L-arginine) and dextran sulfate (Lipo-[PLA/DXS]2 ). This formulation was
prepared using the TFF-assisted protocol to demonstrate compatibility with liposomal substrates, which are im-
portant for drug delivery. This formulation was also used to assess long-term storage options for LbL liposomes(see Main Figure 7). (a) We tracked the hydrodynamic size using dynamic light scattering and plotted the particle
size distribution on a violin plot to demonstrate controlled growth. Violin plots display the estimated kernel den-
sity of the size or charge distribution, and allow the visualization of population-wide evolution of LbL nanoparticle
characteristics during synthesis. The black squares denote the mean hydrodynamic size for each layer. (b) The zeta
potential reversal at each stage of the layering process confirms successful LbL assembly. This was tracked with
laser Doppler electrophoresis, and the charge distributions were plotted as a violin plot.The blacks squares denote
the mean zeta potential for each layer. (c) The polydispersity index was measured by dynamic light scattering,
and remained small throughout LbL assembly indicating good uniformity. Error represents SD of three technical
replicates. Red denotes liposomal core, orange denotes PLA layers, and light blue denotes DXS layers.
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Appendix A Figure 5. This figure displays the size and charge distribution data for the two formulations
featured in the main document; 1 OOCML-[PLL/DXS], and Lipo-[PLL/DXS]4-PLL-HS. (a, c) We tracked the hy-
drodynamic size using dynamic light scattering and plotted the particle size distribution on a violin plot to dem-
onstrate controlled growth. Violin plots display the estimated kernel density of the size or charge distribution,
and allow the visualization of population-wide evolution of LbL nanoparticle characteristics during synthesis. The
black squares denote the mean hydrodynamic size for each layer. (b, d) The zeta potential reversal at each stage
of the layering process confirms successful LbL assembly. This was tracked with laser Doppler electrophoresis, and
the charge distributions were plotted as a violin plot. The blacks squares denote the mean zeta potential for each
layer. For polydispersity index data see the main document. Gray denotes latex core, red denotes liposomal core,
orange denotes PLL layers, light blue denotes DXS layers, and dark blue denotes HS layers.
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Appendix A Figure 6. Cellular viability of SKOV3 cells for 24, 48, and 72 hours following treatment by LbL
nanoparticles indicate that these materials are not nonspecifically toxic. No statistically significant differenc-
es in viability were detected for any formulation, at any of the tested incubation times. Significance was evaluated
using one-way ANOVA with the Dunnet post-test, comparing each formulation to the untreated control group for
each incubation time. Error represents SD of three biological replicates.
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Appendix A Figure 7. The z-average size measurement, which is more sensitive to aggregation, further
indicates that LbL liposomes can be lyophilized and stored at room temperature without loss of colloidal
stability. This requires the use of a cryoprotectant, otherwise large-scale aggregation occurs as indicated above.
Notably, bare liposomal formulations stored with cryoprotectants exhibit statistically significant z-average size in-
creases that were not observed by the number average measurements, indicating the presence of an aggregating
population. This finding supports the observation from the main document that polydispersity index increases for
bare liposomes during long-term storage with cryoprotectants. Error represents SD of three technical replicates.
Red denotes bare liposomes and blue represents LbL liposomes, Lipo-[PLL/DXS] 2-
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Appendix A Figure 8. Further detail of the surface of LbL nanoparticles is provided by the magnification of
the Cryogenic TEM images of LbL nanoparticles. The region indicated by the dashed red line is magnified 200%
in the right panel. (a) LbL-coated carboxy-modified latex (CML-[PLL/DXS],); (b) LbL-coated, doxorubicin-loaded
liposome (Lipo-[PLL/DXS] 4-PLL-HS).
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Appendix A Figure 9. Conventional TEM images of the LbL nanoparticle library, taken after three months
of storage at 4 degrees Celsius in pure water, provide evidence that the morphology of these nanoparticles
are preserved. Specimens were drop-casted from a 10 pg/mL solution onto a mesh copper grid coated with a
continuous carbon film and then imaged on a JEOL 2011 High Contrast Digital TEM (120 kV). The red scale bar
denotes 500 nm in each image. The inset shows a high-magnification view of a single nanoparticle, and the black
scale bar from panel (a) represents 100 nm for all insets.
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Supplemental methods
Synthesis of Heparin-bound Folic acid:
Activation of folic acid was performed according to the protocol as described by Lowe et al.1
Folic acid (FA, 1.0 g) was reacted with 0.5 g of N-hydroxysuccinimide (NHS) in the presence
of 0.5 mL of triethylamine in 25 mL DMSO at 400C with stirring. Subsequently, 0.9 g of N,N'-
Dicyclohexylcarbodiimide (DCC) was added to the solution and the mixture was stirred in the
dark at room temperature overnight. After the reaction, the insoluble byproduct, dicyclohexylurea,
was removed by filtration. After vacuum distillation of the solution to reduce DMSO volume, NHS-
folate was precipitated by addition of lOx volume of acetone/diethylether (30:70). The precipitate
pellet was centrifuged at 10,000 x g for 10 min, and washed three times with acetone/diethylether
(30:70). The pellet was dried for 1h followed by vacuum drying, and stored in the dark at 4C.
Aminated FA was prepared according to the protocol of Huh et al. whereby FA-NHS, ethylenedi-
amine (EDA, 2.0 equivalent of FA-NHS) and pyridine (0.1 equiv.) were allowed to react in DMSO
overnight at room temperature. 2 Excess acetonitrile was added to the reactant solution to precipi-
tate the product and remove excess EDA. The aminated FA was collected by centrifugation and
dried under vacuum.
For conjugation of aminated FA to heparin sulfate, the later (0.05 g) was dissolved in pH 5.5 MES
buffer followed by the addition of NHS and 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)
(1.2 equiv. of the targeted functionalization level (5%) of heparin carboxylic acid). The solution
was allowed to stir for 30 minutes after which aminated FA (at 5% targeted functionalization level
of heparin carboxylic acid group) was dissolved in DMSO, and were added in a drop-wise pattern
to the solution of activated heparin sulfate. After 12h reaction period, the product was dialyzed
through regenerated cellulose membrane (MWCO 2,000 g molV) against deionized water for 16h.
Degree of functionalization of folic acid on heparin sulfate was quantified by UV-Vis spectroscopic
method. Degree of functionalization of folic acid on heparin sulfate was confirmed and quantified
by UV-Vis spectroscopic method considering the folate absorption signal at 363 nm (Figure S10).
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Appendix A Figure 10. Appendix A Figure 10: UV-Visible spectrum of folic acid decorated heparin (after dialysis)
indicating the immobilization of folic acid as evident by the characteristic shoulder of folate at 363 nm.
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Supporting information for Chapter 3: Discovery of ovarian cancer targeting surface
chemistries through a library approach is provided here.
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Appendix B Figure 1. TEM was performed on all nanoparticle formulations to demonstrate the syn-
thesis of uniform LbL-NPs with an approximate diameter of 100 nm. Specimens were drop-casted
from a 10 pg/mL solution onto a mesh copper grid coated with a continuous carbon film and then imaged
on a JEOL 2011 High Contrast Digital TEM (120 kV). The scale bar in the low-magnification image denotes
500 nm and the scale bar for the insets represents 100 nm.
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Appendix B Figure 2. Surface chemistry mediates important differences in nanoparticle uptake and
trafficking, with major differences apparent between sulfated and carboxylated formulations as well
as differences within the surface chemistry families. a) Live cell confocal imaging of JHOS4 ovar-
ian cancer cells demonstrates that carboxylated LbL-NPs bind JHOS4 cells more efficiently than sulfated
formulations. The JHOS4 cells treat the carboxylated formulations differently, sometimes accumulating
particles on the surface in the case of poly-L-glutamate or internalizing them efficiently in the case of
sodium hyaluronate. Inclusion of the folate on the heparin sulfate-coated system provides enhances ac-
cumulation and internalization relative to the corresponding heparin sulfate NP. Nanoparticle signal shown
in green, lysotracker signal shown in red, cell membrane shown in magenta, nuclei shown in blue. Scale
bar in the first micrograph denotes 10 pm for all images. b) Sulfated formulations fail to bind to all cells
after 24 hours, whereas carboxylated systems are more uniformly bound to cancer cells, with the excep-
tion of polyacrylate. Notably, the bare latex core binds to a fewer percentage of cells than the majority of
the carboxylated LbL-NPs. Percentage of nanoparticle positive cells was determined by flow cytometry
following a 24-hour incubation with 20 pM LbL-NP. c) The number of nanoparticles per cell was determined
for four LbL-NP formulations of interest, and demonstrates a 4-fold and 10-fold increase in nanoparticles
bound per cell for poly-L-glutamate and poly-L-aspartate systems relative to sodium hyaluronate-coated
particles. Nanoparticle quantification was performed by lysing a known number of NP-treated cells and
measuring nanoparticle-associated fluorescence using a plate reader. Fluorescence units were converted
to a number of NP using a standard curve of NP prepared in cell lysate from untreated cells. Error bars
represent standard deviation.
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Appendix B Figure 3. COV362 ovarian cancer cells demonstrate consistent subcellular trafficking
patterns for key LbL-NPs. Cells were incubated with 20 pM concentrations of LbL-NPs and imaged live
using a confocal microscope. a) HA-coated NPs were observed mostly internalized by the cell. b) PLE-
coated NPs again demonstrated a fibrous surface coating morphology with limited penetration into the
cell. c) The PLD-coated NPs appeared as punctate signals from within the cells and on the membrane and
cellular projections. d) HF-coated NPs were mostly internalized at this time point, but were less abundant
relative to the carboxylated LbL-NPs. Nanoparticle signal shown in green, lysotracker signal shown in red,
and cell membrane shown in magenta. Scale bar in the first micrograph denotes 10 pm for all images.
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Appendix B Figure 4. Caov3 ovarian cancer cells also process HA and PLD-coated NPs in a manner
consistent with results from other ovarian cancer lines. Cells were incubated with 20 pM concen-
trations of LbL-NPs and imaged live using a confocal microscope. a) HA-coated NPs are internalized
and organized inside or near lysosomes. b) PLD-coated LbL NPs are observed as punctate spots on the
membrane surface as well as co-localized with lysosomes. Nanoparticle signal shown in green, lysotracker
signal shown in red, and cell membrane shown in magenta. Scale bar in the first micrograph denotes 10
pm for both images.
206
Appendix B
a. Dextran sulfate
0U
b. Sodium hyaluronate
e.
C. Poly-L-glutamate
g.
j.
d. POly-L-aspartate
h.
I.
E
0
~0
n. P.
Appendix B Figure 5. LbL-NPs have distinct subcellular fates depending on their terminal coating.
We probed whether nanoparticles associate with caveolae (CAVI positive vesicles, a-d), early endo-
somes (EEA1 positive vesicles, e-h), late endosomes (RAB7 positive vesicles, i-j), lysosomes (LAMP1
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positive vesicles, m-p), and trans golgi (RCAS1 positive vesicles, q-t). Dextran sulfate (DXS), sodium
hyaluronate (HA), poly-L-glutamate (PLE), and poly-L-aspartate (PLD) coated LbL-NPs showed differences
primarily in lysosomal and caveolar association in OVCAR8 cells at 24 hours. Micrographs of OVCAR8
cells were obtained using an Olympus FV1200 confocal microscope following incubation with 20 pM LbL-
NP. Nanoparticle signal shown in green, organelle signal shown in red, nuclei shown in cyan. Scale bar
denotes 10 pm.
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Appendix B Figure 6. LbL-NPs are not associated with the early endosome or in clathrin-coated
vesicles after 24 hours. Confocal microscopy of OVCAR8 cells looked at LbL-NP co-localization with
clathrin-coated vesicles (e-h) and early endosome (Rab5 positive, a-d). Nanoparticle signal shown in green,
vesicle signal shown in red, nuclei shown in cyan. Scale bar denotes 10 pm.
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Appendix B Figure 7. Internalized LbL NPs navigate to the late endosomal-lysosomal compartment
in OVCAR8 cells. Cells were treated with 4 pM LbL NP for 24 hours and then fixed and processed for super
resolution microscopy. LAMP1 and Rab7 proteins are stained to label the lysosomal and late endosomal
compartments, and are shown in red. Wheat germ agglutinin (WGA) was used to stain membranes (includ-
ing outer membrane, some vesicular membranes and the nuclear membrane) and is shown in magenta.
Nanoparticles are shown in green and nuclei in blue. Scale bars denote 10 microns, with the exception of
the scale bar for the detail panels, where they denote 1 micron. All internalized NPs appear to be contained
within this compartment at this time point.
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Appendix B Figure 8. Surface bound LbL-NPs have different degrees of interaction with caveolae
at 24 hours in OVCAR8 cells. Cells were treated with 4 pM LbL NP for 24 hours and then fixed andprocessed for super resolution microscopy. CAV1 proteins are stained to label the caveolar compartment,
and are shown in red. Wheat germ agglutinin (WGA) was used to stain membranes (including outer mem-brane, some vesicular membranes and the nuclear membrane) and is shown in magenta. Nanoparticles
are shown in green and nuclei in blue. Scale bars denote 10 microns, with the exception of the scale barfor the detail panels, where they denote 1 micron. a) Although almost entirely internalized, some faintdextran sulfate-coated NP signal was noted near a caveolar ridge. b) Surface-bound fractions of sodiumhyaluronate-coated NPs also appear to be within caveolae. c) Poly-L-glutamate (PLE)-coated NPs have
surface bound fractions that are not associated with caveolae as indicated by the purple arrow, although
most caveolar regions are enriched with PLE-NPs as indicated by the white arrow. d) In contrast, the con-
siderable fraction of poly-L-aspartate-coated NPs found on the surface are almost always associated with
the caveolar compartment.
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Appendix B Figure 9. By 24 hours, LbL NPs do not appear to co-localize with any early endosomal
compartments. Cells were treated with 4 pM LbL NP for 24 hours and then fixed and processed for super
resolution microscopy. EEA1 and Rab5 proteins are stained to label the early endosomal compartments,
and are shown in red. Wheat germ agglutinin (WGA) was used to stain membranes (including outer mem-
brane, some vesicular membranes and the nuclear membrane) and is shown in magenta. Nanoparticles
are shown in green and nuclei in blue. Scale bars denote 10 microns, with the exception of the scale bar for
the detail panels, where they denote 1 micron.
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Appendix B Figure 10. Carboxylated LbL-NPs can be found near and in between trans golgi stacks,
but not inside them. Cells were treated with 4 pM LbL NP for 24 hours and then fixed and processed for
super resolution microscopy. RCAS1 proteins are stained to label the trans golgi compartment, and are
shown in red. Wheat germ agglutinin (WGA) was used to stain membranes (including outer membrane,
some vesicular membranes and the nuclear membrane) and is shown in magenta. Nanoparticles are shown
in green and nuclei in blue. Scale bars denote 10 microns, with the exception of the scale bar for the detail
panels, where they denote 1 micron. a) Dextran sulfate-coated NPs do not appear in close proximity to the
trans golgi, though this may be a function of overall amount of NP in the cell. b-d) Sodium hyaluronate, poly-
L-glutamate, and poly-L-aspartate-coated NPs are observed near golgi stacks, sometimes in very close
proximity as denoted by the arrows. While provocative, it is unclear the extent to which these NPs may be
engaged with the trans golgi, and should be the focus of future studies.
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Appendix B Figure 11. LbL-NP surface chemistry determines binding affinity towards patient-de-
rived xenograft (PDX) ovarian cancer spheroids. Four LbL formulations were tested for binding affinity to
PDX spheroids, fluorescent latex nanospheres were coated with poly-L-arginine and then either with poly-
aspartic acid, poly-L-glutamic acid, hyaluronic acid or dextran sulfate. Following 24 hour incubation in either
growing or assay media, the PDX spheroids DF83 and DF09 were processed into single cell suspensions
for flow cytometry. Live cells were identified using the PDX cell mCherry signal and nanoparticle positive
populations were identified based on untreated controls. a) Carboxylated LbL nanoparticles show improved
spheroid binding for both cell lines. Percent nanoparticle+ cell populations also confirm that carboxylated
LbL formulations bind to more cells in the spheroids than do dextran sulfate-coated particles. b) Confocal
microscopy z-slices of PDX spheroids following 24 hour incubation with LbL nanoparticles. The confocal
data supports the quantitative results from flow cytometry. Notably, the poly-L-aspartic and poly-L-glutamic
formulations appear to have significant surface accumulations, whereas the hyaluronic acid formulation is
primarily internalized.
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Appendix B Figure 12. Representative images of the biodistribution of the unmodified CML core
particles at 24 hours after either IV or IP-administration. Luciferase signal from tumor cells and infrared
fluorescence from nanoparticles were measured for each organ using an IVIS imaging device. Arrows
denote locations of metastases on organs. The core particle co-localized well with the primary tumor tissue
when administered IP. There is some co-localization with the primary tumor and some intestinal metastasis
following IV administration, but the co-localization is highly heterogeneous and diminished compared to the
results of IP-administration.
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Appendix B Figure 13. PEG-coated nanoparticle biodistribution at 24 hours following IP or IV ad-
ministration indicates improved accumulation in tumor tissue when administered IP. Luciferase
signal from tumor cells and infrared fluorescence from nanoparticles were measured for each organ using
an IVIS imaging device. Arrows denote locations of metastases on organs. Similar to the biodistribution
of the unmodified CML core (Appendix B Figure 12), the IV administration route leads to heterogeneous
co-localization with the primary tumor, though some co-localization with intestine metastatic nodules is
observed. The amount of NP delivered to tumors appears diminished in the IV-administration condition
compared to the IP-administered condition. There is diffuse NP signal throughout the intestine that is not
co-localized to tumor nodules. Notably, diffuse NP signal is detected throughout the liver and spleen for
both IP and IV, in contrast to results from the other nanoparticles shown in the Appendix.
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Appendix B Figure 14. The biodistribution of DXS-coated LbL NPs at 24 hours following IV or IP-
administration follows similar trends between the two administration methods. Luciferase signal
from tumor cells and infrared fluorescence from nanoparticles were measured for each organ using an IVIS
imaging device. Arrows denote locations of metastases on organs. Most of the DXS NP is lost to the liver
following IV administration, but some heterogeneous co-localization with the primary tumor is noted, as well
as co-localization with intestinal metastases. More NP signal is detected from neoplastic tissues following
IP-administration, including in metastases on the other IP organs.
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Appendix B Figure 15. PLE-coated NP biodistribution at 24 hours after either IV or IP-administration
indicate improved NP delivery to tumors when using IP-administration. Luciferase signal from tumor
cells and infrared fluorescence from nanoparticles were measured for each organ using an IVIS imaging
device. Arrows denote locations of metastases on organs. IV-administration of PLE NPs leads to signifi-
cant accumulation in the liver, and reduced but diffuse accumulation in the Spleen. However, NP signal
is detected heterogeneously through the primary tumor mass and some metastatic nodules in the stom-
ach and intestine for IV-administered conditions. Much stronger NP signal is detected from tumors of IP-
administered mice. Very good co-localization of PLE NP with metastases on the intestine are noted in the
IP-administered model.
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Appendix B Figure 16. The biodistribution of PLD-coated LbL NPs at 24 hours after either IV or IP-
administration indicated improved delivery of NP to tumors for IP-routes. Luciferase signal from tumor
cells and infrared fluorescence from nanoparticles were measured for each organ using an IVIS imaging
device. Arrows denote locations of metastases on organs. IV administration of PLD NPs leads to diffuse
signal in the liver and spleen, indicating loss to these filtration organs. However, good co-localization of NP
with the metastatic nodules of the intestine and stomach indicate a good tumor-homing ability. Interestingly,
NP signal from the primary tumor mass is heterogeneous. Despite this, the overall amount of NP signal
from neoplastic tissue is low after IV-administration when compared to the results of IP-administration. IP-
administered PLE NPs appear to be present throughout the primary tumor and in all detectable metastatic
nodules in the other IP organs.
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Appendix B Figure 17. HA-coated LbL NP biodistribution 24 hours after either IP or IV administra-
tion. Luciferase signal from tumor cells and infrared fluorescence from nanoparticles were mea-
sured for each organ using an IVIS imaging device. Arrows denote locations of metastases on organs.
HA NPs have a heterogeneous accumulation in the primary tumor following IV-ad ministration, consistent
with the other NPs tested. The NPs appear to have co-localization with several of the metastatic lesions on
the stomach and intestine as well. However, the majority of the dose appears to be in the liver and spleen.
On the other hand, IP-administration of HA NPs leads to NP signal throughout the primary tumor as well as
the majority of the malignant lesions throughout the other IP organs.
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Appendix B Figure 18. NP biodistribution is strongly impacted by route of administration, and by 24
hours this effect dominates any tumor-targeting contribution from surface chemistry. Infrared fluo-
rescence from nanoparticles were measured for each organ using an IVIS imaging device. a) Retro-orbital
IV administration was compared to IP-administration for poly-L-aspartate (PLD), pol-L-glutamate (PLE),
sodium hyaluronate (HA), dextran sulfate (DXS), poly(ethylene glycol) coated CML core, and unmodified
CML core. In all instances, IV-administration skews NP biodistribution towards the liver and to a lesser ex-
tent the spleen. IP-administration skews NP distribution to neoplastic tissues. b) Quanitification of the IVIS
results shows that LbL NPs, but not unmodified CML core, have a significant and improved accumulation in
the primary tumor relative to PEGylated NPs. c) Quantification of the results from retro-orbital IV injections
indicate that surface chemistry may influence degree of accumulation in the liver spleen and lungs, but not
accumulation in the tumor at this time point. d) A smaller study comparing only LbL NPs was conducted
using a tail-vein injection instead of retro-orbital injection. Interestingly, this approach led to undetectable
PLE NP signal in the tumors, but no significant differences for tumor accumulations observed with the other
formulations. Tail-vein injection also reduced the amount of PLD NP delivered to the lungs. Other than this,
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the distribution to the liver and spleen remained consistent with retro-orbital injection. Error bars represent
SEM, and statistical analysis was done using a two-way ANOVA with a Tukey post-hoc test and an alpha
of 0.5.
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Appendix B Figure 19. Biodistribution of PEGylated CML cores at 48 and 72 hours following IP ad-
ministration indicates a spillover into the liver and spleen compartments. Luciferase signal from tumor
cells and infrared fluorescence from nanoparticles were measured for each organ using an IVIS imaging
device. Arrows denote locations of metastases on organs. PEG NPs appear to have less co-localization
with metastatic lesions at these times. These results may indicate the clearance of the NP from the IP cavity
via the lymphatic system.
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Appendix B Figure 20. DXS-coated LbL NP biodistribution at 48 and 72 hours following IP adminis-
tration indicates continued co-localization with neoplastic tissue. Luciferase signal from tumor cells
and infrared fluorescence from nanoparticles were measured for each organ using an IVIS imaging device.
Arrows denote locations of metastases on organs. Signal from the primary tumor appears dimmer at 72
hours which may imply a clearance pathway, although the lack of NP in the liver or spleen would suggest
the NPs may be captured somewhere between the IP cavity and the lymphatic drainage into the venous
compartment.
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Appendix B Figure 21. PLE-coated LbL NP biodistribution at 48 and 72 hours following IP adminis-
tration indicates continued co-localization with neoplastic tissue. Luciferase signal from tumor cells
and infrared fluorescence from nanoparticles were measured for each organ using an IVIS imaging device.
Arrows denote locations of metastases on organs. Some diffuse NP signal in the intestines and stomach
is not co-localized with detectable lesions, but the majority of signal appears to co-localize with tumor
bioluminescence.
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Appendix B Figure 22. PLD-coated LbL NP biodistribution at 48 and 72 hours following IP admin-
istration indicates continued co-localization with neoplastic tissue. Luciferase signal from tumor
cells and infrared fluorescence from nanoparticles were measured for each organ using an IVIS imaging
device. Arrows denote locations of metastases on organs. PLD-coated NPs co-localize with the tumor
bioluminescence.
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Appendix B Figure 23. HA-coated LbL NP biodistribution at 48 and 72 hours following IP adminis-
tration indicates continued co-localization with neoplastic tissue. Luciferase signal from tumor cells
and infrared fluorescence from nanoparticles were measured for each organ using an IVIS imaging device.
Arrows denote locations of metastases on organs. Some diffuse NP signal in the intestines and stomach
is not co-localized with detectable lesions, but the majority of signal appears to co-localize with tumor
bioluminescence.
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Appendix B Figure 24. Cryohistology of tumor tissue from PLE-NP treated mice indicates how pristine
tissues have more NP signal on the periphery than what is seen on the more heavily processed tissues
discussed in the main text.
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Appendix B Figure 25. Sulfated poly(1-cyclodextrin) (SBC)-coated LbL NPs have an affinity towards
endothelial cells. SBC-NPs are enriched in iPSC endothelial cells at four hours, although the observationis not statistically significant, and the trend dissipates at 24 hours. But for HUVEC cells, the SBC-NPs are
significantly enriched at both 4 and 24-hour time points. Error bars represent SEM and statistical analysis
was performed using two-way ANOVA with a Dunnett's post-hoc test (comparing all results to SBC-NPtreated cells) and alpha of 0.5.
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Endothelial targeting LbL nanoparticles
While SO 3-LbL-NPs were largely unsuccessful at mediating improved uptake in OvCa cells, we
noted an intriguing trend with SBC-coated NPs that indicated improved uptake in endothelial
cells. We first noted this behavior in the context of iPSC-derived endothelial cells. After 4 hour
incubation, all other LbL-NPs had MFR values ranging from 1.1 to 4.4 and no clear correlation
between surface chemistry family was apparent. In contrast, SBC-coated NPs had an MFR of
8.7. The effect does not carry to later time points however, and several formulations accumulate
better in iPSC-derived endothelial cells at 24 hours. However, we also noted that spleen stromal
cells bound SBC-coated NPs more than any other NP both at 4 and 24 hours (MFR of 2.7 and
4.4, respectively). The next best MFR for spleen stroma was fucoidain-coated NP with a MFR of
1.5 at 4 hoursand HA-coated NP with a MFR of 2.0 at 24 hours. Since a significant portion of the
stromal compartment is likely endothelial cells, we followed up on this observation by performing
a similar uptake experiment on HUVEC cells. Notably, HUVECs had a remarkable capacity for
binding all types of nanoparticles almost indiscriminately, but in spite of this we do observe a
preference for SBC-coated NPs (Appendix B Figure 25). SBC-coated NPs have a MFR of 978.5
at 4 hours, relative to the other LbL NPs that range from 2.6 to 389.4. At 24 hours, SBC-coated
NPs retain the highest MFR - 2271.2 - while the rest of the LbL NPs have MFRs ranging from
238.1 to 1977.8. While further study is needed to determine if these differences could lead to
meaningful shifts in nanoparticle targeting, we find the results interesting. If SBC-coated NPs can
exhibit an endothelial-targeting behavior they could have applications for the development of anti-
angiogenesis nanomedicines as well as nanotherapies aimed at treating cardiovascular disease.
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Supplemental methods
Human umbilical vein endothelial cells (HUVECs, Lonza), were a kind gift from the Grifith Lab at
MIT. They were grown using Lonza EGM-2 Endothelial Cell Growth Medium-2 BulletKit. Patient-
derived xenograft (PDX) cell lines were a kind gift from the Brugge Lab at Harvard, and were
grown with a homemade media provided by the lab.
For all experiments, these cells were seeded in 96 well plates according to the methods for the
flow cytometry binding assay described in the main methods section. HUVEC cells were pro-
cessed in the same manner described in the main text.
The PDX cells were processed similarly to the splenocytes described in the main text, with one
small exception: samples of the PDX spheroid suspension were first taken and preserved for
microscopy. Afterwards, the spheroid suspension was pelleted using centrifugation (RCF 300, 5
minutes) and washed. PDX spheroids were incubated in 1x TrypLE Express 30 for 10 minutes.
The suspension was then passed 3x through 70 micron and 40 micron cell strainers and 2x
through a FACS filter cap (BD). The samples were analyzed using a BD LSR2 cytometer, and de-
tected mCherry signal (produced by the PDX cells) and nanoparticle signal in the FITC channel.
For confocal microscopy of the PDX spheroids, the samples isolated prior to flow analysis were
taken and pelleted in FACS tubes (300 RCF, 5 minutes). The cells were resuspended in 300 uL
PBS, and then 100 uL of 16% methanol-free formaldehyde (Pierce) was added. The cells were
fixed at room temperature for 10 minutes, then washed via centrifugation and resuspended in 300
uL of PBS. The spheroid suspension was then added to chambered coverslips and imaged di-
rectly using an Olympus FV1200, as described in the fixed cell imaging methods in the main text.
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Appendix C.
Supporting information for Chapter 4: The role of solution conditions in the robust syn-
thesis of layer-by-layer liposomes is provided here.
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Appendix C Figure 1. The salt screen from Figure 1 was replotted to directly compare the impact
of different salt species on PLR adsorption onto anionic liposomes. The (a) size and (b) zeta are
replotted to demonstrate the impact of salt identity. Salt concentration is not able to completely explain
the aggregation and loss of charge seen with the multivalent species. When the data is replotted based
on each condition's ionic strength (c-d), the data converges somewhat, but it remains apparent that there
is an impact due to valency that is not fully recapitulated by considering ionic strength alone. HEPES is
omitted because a straightforward means to calculate ionic strength of a zwitterion was not found. Size and
polydispersity data were acquired by dynamic light scattering, and zeta potential data was measured using
laser Doppler electrophoresis.
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Appendix C Figure 2. Addition of the third layer, composed of poly(L-arginine), does not lead to loss
of siRNA from the second layer. In fact, as the optimal C:P ratio is achieved (5:1), the PLR layer shields
siRNA from the effects of electrophoresis, which causes partial migration of the siRNA-PLR complexes into
the gel for ratios 10:1 and 8:1. Heparin-degraded particles on the right-hand side of the gel readily release
the entrapped siRNA into the gel.
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Appendix C Figure 3. Agarose gel of the degraded LbL nanoparticle from 4c, showing that layers 3 and 4
were deposited and purified without additional loss of siRNA due to layering. Some loss of siRNA is reflec-
tive of process loss during handling during the additional layering and purification steps.
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Appendix C Figure 4. The size, uniformity and surface charge properties of LbL liposomes prepared
in either deionized water (dH2O), pH 7.5 titrated water (20 pM Na2 HPO4), or 25 mM HEPES 20 mM
NaCI. The HEPES NaCl condition is buffer exchanged to water during the interlayer purification steps. a)
LbL liposomes prepared in the presence of HEPES and NaCl develop thicker layers, producing a steady
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increase in z-average hydrodynamic diameter during the synthesis. Formulations prepared without NaCl
do not exhibit the same steady growth in size. b) Number average size illustrates the same trend. c) All
syntheses generate uniform particles with PDI remaining below 0.025, and d) complete charge conversion
during the addition of different layers. e) In order to achieve these stable syntheses, we note that the C:P
ratio varies significantly with the different bulk conditions. Size and polydispersity data were acquired by
dynamic light scattering, and zeta potential data was measured using laser Doppler electrophoresis. Error
bars represent standard deviation of three technical replicates.
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Appendix C Figure 5. Purification bulk conditions can impact nanoparticle size and charge proper-
ties. a) Use of salts in the exchange buffer increases Z average hydrodynamic diameter, and may indicate
particle bridging or mild aggregation. b) Although C:P ratios were chosen that yielded similar zeta potential
in the crude state, purification in salt led to slight decrease in the magnitude of surface charge during the
purification of anionic layers, which could be indicative of shedding or rearrangement of the LbL film during
purification. Loss of charge could also mediate some of particle aggregation hypothesized in panel a. Size
data were acquired by dynamic light scattering, and zeta potential data was measured using laser Doppler
electrophoresis. Error bars represent standard deviation of three technical replicates.
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Silencing COV362 in vitro
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Appendix C Figure 6. Easier to transfect cell lines like COV362 do not exhibit significantly improved
knockdown with bulk condition-optimized formulations. COV362 cells were treated with 30 nM siRNA
using nanoparticles generated from either pH 7.5 titrated water or the optimized HEPES/NaCI method,
and knockdown of the luciferase reporter gene was assayed after 24 hours. Error bars represent the SD of
triplicates. All statistical tests were performed using one-way ANOVA (alpha = 0.05), with the Tukey post-
test, on PRISM graphing software.
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Appendix C Figure 7. Results from siRNA delivery using LbL liposomes prepared using the opti-
mized HEPES/NaCI bulk conditions described in Figures 3 and 4. Subcutaneous flank xenografts of
luciferized OVCAR8 cells were treated with 0.5 mg/kg siLuciferase and evaluated periodically for silencing
of the reporter gene. These data represent silencing 3 days after injection, and show significant downregu-
lation of the luciferase gene relative to untreated mice. All statistical tests were performed using one-way
ANOVA (alpha = 0.05), with the Tukey post-test, on PRISM graphing software.
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Appendix C Figure 8. LbL nanoparticles (CML/PLR/HA) were synthesized at different pHs and then
stimulated to induce swelling via exposure to different pH solutions. a) Nanoparticle prepared at pH
7.4 exhibit swelling behavior at pH 3.5 and 11.5, whereas particles prepared at pH 6 only begin exhibit-
ing a similar degree of swelling at pH 3. b) Both nanoparticles exhibit similar changes in ionization state
thoughout this pH range, with the HA-coated particle losing its charge rapidly as the system is protonated
at acidic pH.
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Appendix D.
Supporting information for Chapter 5: Developing theranostic layer-by-layer nanopar-
ticles through clickable terminal layers is provided here.
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Appendix D Figure 1. NMR trace of propargyl-modified poly-L-aspartate. Peaks: 4.7 is residual solvent, 4.5 is
alpha hydrogen, 4.0/3.0 is from propargyl amine, and 2.5-3.0 is side chain. Small peaks are either from solvent
initiator or residual salt from the reaction
247
--i- ---- __jjv
Appendix D
150%-
C
41-1
0~
0
I-
100%.
50%.
AOL-
In vivo transfection
at 2 days
I
'0
*+
I~4
Appendix D Figure 2. In vivo transfection of flank ovarian cancer model, two days after injection with ther-
anostic LbL NPs. Un-clicked LbL NPs mediate transfection but it is variable at this time point. Meanwhile, both
PEG/Sensor and PEG/Sensor/iRGD functionalized LbL NPs mediate transfections, knocking down roughly 50% of
luciferase expression on average. The results are statistically significant when compared to the control condition.
Statistical analysis was performed with a one-way ANOVA with a Tukey post-hoc test and alpha of 0.05.
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Appendix D Figure 3. Spleens, livers, and
tumors from mice treated with Cy7-labeled
theranostic LbL NP. White outlines denote
the region of interest as defined by tissue au-
tofluorescence in the 700 nm channel. Green
signal corresponds to fluorescence from LbL
liposomes in the 800 nm channel.
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